PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32500793-0	2020	Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.	nimesulide	12-22	solute carrier family 6 member 19	Homo sapiens	50-55
33129925-5	2021	Immunocytochemistry showed that ASS and iNOS were increased in ASCs expressing neurofilament medium polypeptide (NeFM), a neuronal marker, by VPA and NIM synergistically.	nimesulide	150-153	argininosuccinate synthase 1	Rattus norvegicus	32-35
33129925-5	2021	Immunocytochemistry showed that ASS and iNOS were increased in ASCs expressing neurofilament medium polypeptide (NeFM), a neuronal marker, by VPA and NIM synergistically.	nimesulide	150-153	nitric oxide synthase 2	Rattus norvegicus	40-44
33129925-5	2021	Immunocytochemistry showed that ASS and iNOS were increased in ASCs expressing neurofilament medium polypeptide (NeFM), a neuronal marker, by VPA and NIM synergistically.	nimesulide	150-153	neurofilament medium chain	Rattus norvegicus	79-111
33129925-5	2021	Immunocytochemistry showed that ASS and iNOS were increased in ASCs expressing neurofilament medium polypeptide (NeFM), a neuronal marker, by VPA and NIM synergistically.	nimesulide	150-153	neurofilament medium chain	Rattus norvegicus	113-117
32500793-7	2020	As a serendipity occurrence, nimesulide was shown to abolish the transport function of B0AT1.	nimesulide	29-39	solute carrier family 6 member 19	Homo sapiens	87-92
32632112-1	2020	Nimesulide is an inhibitor of COX-2 with antioxidant and anti-inflammatory effects.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	30-35
31913347-0	2020	Nimesulide increases the aldehyde oxidase activity of humans and rats.	nimesulide	0-10	aldehyde oxidase 1	Homo sapiens	25-41
31913347-4	2020	Thus, we speculated that NIM could induce AOX.	nimesulide	25-28	acyl-CoA oxidase 1	Rattus norvegicus	42-45
31913347-5	2020	In this study, we investigated the potential induction of AOX activity by NIM using methotrexate as the probe substrate.	nimesulide	74-77	acyl-CoA oxidase 1	Rattus norvegicus	58-61
31913347-10	2020	Collectively, our results demonstrate for the first time that NIM can increase the AOX activity of humans and rats, and may raise concerns regarding the risk of drug interactions between NIM and AOX substrates in clinical practice.	nimesulide	62-65	aldehyde oxidase 1	Homo sapiens	83-86
31913347-10	2020	Collectively, our results demonstrate for the first time that NIM can increase the AOX activity of humans and rats, and may raise concerns regarding the risk of drug interactions between NIM and AOX substrates in clinical practice.	nimesulide	62-65	acyl-CoA oxidase 1	Rattus norvegicus	195-198
31411575-4	2019	Nimesulide is a cyclooxygenase-2 inhibitor, which has also been reported to exert a significant antioxidant effect.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	16-32
30477960-3	2020	Nimesulide, which is a specific cyclooxygenase-2 inhibitor drug, have antioxidant, antiinflammatory, analgesics and antipyretic effects.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	32-48
30477960-10	2020	RESULTS: Total glutathione (tGSH) and cyclooxygenase-1 (COX-1) levels were increased in the NIM-50 and NIM-100 groups compared to IR group.	nimesulide	92-95	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	38-54
30477960-10	2020	RESULTS: Total glutathione (tGSH) and cyclooxygenase-1 (COX-1) levels were increased in the NIM-50 and NIM-100 groups compared to IR group.	nimesulide	92-95	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	56-61
31435854-7	2019	Similar results were found after treatment with nimesulide and indomethacin, inhibitors of the PGE2-producing enzymes cyclooxygenase 1 and 2.	nimesulide	48-58	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	118-140
31480608-3	2019	Nimesulide (N), the selective COX-2 inhibitor, inhibits growth and proliferation of various types of cancer cells by COX-2 dependent and independent mechanisms.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	30-35
31480608-3	2019	Nimesulide (N), the selective COX-2 inhibitor, inhibits growth and proliferation of various types of cancer cells by COX-2 dependent and independent mechanisms.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	117-122
31480608-3	2019	Nimesulide (N), the selective COX-2 inhibitor, inhibits growth and proliferation of various types of cancer cells by COX-2 dependent and independent mechanisms.	nimesulide	0-1	prostaglandin-endoperoxide synthase 2	Homo sapiens	30-35
31480608-3	2019	Nimesulide (N), the selective COX-2 inhibitor, inhibits growth and proliferation of various types of cancer cells by COX-2 dependent and independent mechanisms.	nimesulide	0-1	prostaglandin-endoperoxide synthase 2	Homo sapiens	117-122
31632570-9	2019	The results revealed that NIM markedly improved pancreatic histological injury and decreased the levels of serum amylase, lipase, TNF-alpha, IL-1beta and IL-6 in a dose-dependent after NIM treatment.	nimesulide	26-29	lipase, endothelial	Mus musculus	122-128
31632570-9	2019	The results revealed that NIM markedly improved pancreatic histological injury and decreased the levels of serum amylase, lipase, TNF-alpha, IL-1beta and IL-6 in a dose-dependent after NIM treatment.	nimesulide	26-29	tumor necrosis factor	Mus musculus	130-139
31632570-9	2019	The results revealed that NIM markedly improved pancreatic histological injury and decreased the levels of serum amylase, lipase, TNF-alpha, IL-1beta and IL-6 in a dose-dependent after NIM treatment.	nimesulide	26-29	interleukin 1 beta	Mus musculus	141-149
31632570-9	2019	The results revealed that NIM markedly improved pancreatic histological injury and decreased the levels of serum amylase, lipase, TNF-alpha, IL-1beta and IL-6 in a dose-dependent after NIM treatment.	nimesulide	26-29	interleukin 6	Mus musculus	154-158
31632570-12	2019	The expression levels of TNF-alpha, IL-1beta and IL-6 proteins were downregulated following NIM treatment.	nimesulide	92-95	tumor necrosis factor	Mus musculus	25-34
31632570-12	2019	The expression levels of TNF-alpha, IL-1beta and IL-6 proteins were downregulated following NIM treatment.	nimesulide	92-95	interleukin 1 beta	Mus musculus	36-44
31632570-12	2019	The expression levels of TNF-alpha, IL-1beta and IL-6 proteins were downregulated following NIM treatment.	nimesulide	92-95	interleukin 6	Mus musculus	49-53
31632570-13	2019	More, NIM inhibited the expression of COX2 in lung tissues.	nimesulide	6-9	cytochrome c oxidase II, mitochondrial	Mus musculus	38-42
31095963-6	2019	However, if administered at termination of convulsions, the NSAID ibuprofen, the selective COX 2 inhibitor nimesulide and the PLA2 inhibitor quinacrine were partially effective in reducing brain inflammatory markers.	nimesulide	107-117	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	91-96
31075744-3	2019	Thus, numerous works have been developed to modify the nimesulide skeleton aiming to develop new and more potent and selective COX-2 inhibitors as well as potential anticancer agents.	nimesulide	55-65	prostaglandin-endoperoxide synthase 2	Homo sapiens	127-132
30689999-0	2019	The relatively selective cyclooxygenase-2 inhibitor nimesulide: What"s going on?	nimesulide	52-62	prostaglandin-endoperoxide synthase 2	Homo sapiens	25-41
30689999-1	2019	Nimesulide is a relatively selective cyclooxygenase (COX)-2 inhibitor, non-steroidal anti-inflammatory drug; it has been discovered in 1971 and firstly commercialized in Italy in 1985.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-59
30689999-2	2019	There is much evidence that the pharmacological profile of nimesulide is peculiar and not shared with the other COX-2 selective inhibitors, suggesting that other molecular mechanisms besides inhibition of COX-2 derived prostaglandins are involved.	nimesulide	59-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	205-210
30689999-3	2019	Similarly, experimental data suggest that the gastrointestinal safety of nimesulide cannot be ascribed only to a COX-1 sparing effect.	nimesulide	73-83	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	113-118
30689999-5	2019	Early data demonstrated a central role for cyclic AMP (cAMP) in the anti-inflammatory effect of nimesulide; more recently, we have shown the involvement of the pathway ecto-5"-nucleotidase/adenosine A2A receptor.	nimesulide	96-106	5'-nucleotidase ecto	Homo sapiens	168-188
30689999-5	2019	Early data demonstrated a central role for cyclic AMP (cAMP) in the anti-inflammatory effect of nimesulide; more recently, we have shown the involvement of the pathway ecto-5"-nucleotidase/adenosine A2A receptor.	nimesulide	96-106	adenosine A2a receptor	Homo sapiens	189-211
29728874-10	2019	The results obtained by in vitro cell line study, histopathological and biochemical data concluded that nimesulide, a preferential COX-2 inhibitor, has anticancer activity, which is by first reducing the formation of reactive oxygen species and second by inhibiting the PGE2 effect via Wnt signaling pathway (cell invasion, angiogenesis, and cell proliferation).	nimesulide	104-114	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	131-136
30677025-8	2019	From studies using spontaneous reporting databases (n = 6), rates of reported hepatotoxicity were significantly higher in patients using nimesulide, compared with those treated with other NSAIDs [pooled ROR 3.99, 95% CI 2.86-5.57].	nimesulide	137-147	RAR related orphan receptor A	Homo sapiens	203-208
29952221-10	2018	Iloprost and nimesulide reduced hyperoxia-induced increases in MPO and some cytokines (IL-1beta and TNF-alpha) but not others (IL-6 and KC/Gro).	nimesulide	13-23	myeloperoxidase	Mus musculus	63-66
30367827-5	2018	We found that clonazepam, flunitrazepam, flutamide, nilutamide, nimesulide, and nimetazepam were substantially reduced by recombinant AOX1 and HLC, whereas azelnidipine, nifedipine, and nimodipine were slightly reduced and metronidazole and tolcapone were not reduced.	nimesulide	64-74	aldehyde oxidase 1	Homo sapiens	134-138
29952221-10	2018	Iloprost and nimesulide reduced hyperoxia-induced increases in MPO and some cytokines (IL-1beta and TNF-alpha) but not others (IL-6 and KC/Gro).	nimesulide	13-23	interleukin 1 beta	Mus musculus	87-95
29952221-10	2018	Iloprost and nimesulide reduced hyperoxia-induced increases in MPO and some cytokines (IL-1beta and TNF-alpha) but not others (IL-6 and KC/Gro).	nimesulide	13-23	tumor necrosis factor	Mus musculus	100-109
29952221-10	2018	Iloprost and nimesulide reduced hyperoxia-induced increases in MPO and some cytokines (IL-1beta and TNF-alpha) but not others (IL-6 and KC/Gro).	nimesulide	13-23	chemokine (C-X-C motif) ligand 1	Mus musculus	139-142
29884288-0	2018	Retraction notice to "Graphene quantum dots decorated CdS doped graphene oxide sheets in dual action mode: as initiator and platform for designing of nimesulide imprinted polymer " [BIOS 89P1 (2017) 627-635].	nimesulide	150-160	CDP-diacylglycerol synthase 1	Homo sapiens	54-57
29498006-5	2018	Interestingly, nimesulide, a preferential COX-2 inhibitor, further potentiated the MPTP-induced cell death of human neuroblastoma cells.	nimesulide	15-25	prostaglandin-endoperoxide synthase 2	Homo sapiens	42-47
29498006-6	2018	Treatment of nimesulide with MPTP further potentiated expressions of p62, ATG-5, beclin-1, LC3 autophagic proteins.	nimesulide	13-23	nucleoporin 62	Homo sapiens	69-72
29498006-6	2018	Treatment of nimesulide with MPTP further potentiated expressions of p62, ATG-5, beclin-1, LC3 autophagic proteins.	nimesulide	13-23	autophagy related 5	Homo sapiens	74-79
29498006-6	2018	Treatment of nimesulide with MPTP further potentiated expressions of p62, ATG-5, beclin-1, LC3 autophagic proteins.	nimesulide	13-23	beclin 1	Homo sapiens	81-89
29498006-6	2018	Treatment of nimesulide with MPTP further potentiated expressions of p62, ATG-5, beclin-1, LC3 autophagic proteins.	nimesulide	13-23	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	91-94
29498006-7	2018	Furthermore, nimesulide with MPTP increased apoptotic protein cleaved caspase-3 and also induced expression of p53 gene.	nimesulide	13-23	caspase 3	Homo sapiens	70-79
29498006-7	2018	Furthermore, nimesulide with MPTP increased apoptotic protein cleaved caspase-3 and also induced expression of p53 gene.	nimesulide	13-23	tumor protein p53	Homo sapiens	111-114
29934349-4	2018	Bath application of the selective phospholipase A2 (PLA2) inhibitor arachidonyl trifluoromethyl ketone (AACOCF3) or the cyclooxygenase 2 (Cox-2) inhibitor nimesulide prevented t-LTP at sensory synapses onto spino-parabrachial neurons.	nimesulide	155-165	prostaglandin-endoperoxide synthase 2	Mus musculus	120-136
29934349-4	2018	Bath application of the selective phospholipase A2 (PLA2) inhibitor arachidonyl trifluoromethyl ketone (AACOCF3) or the cyclooxygenase 2 (Cox-2) inhibitor nimesulide prevented t-LTP at sensory synapses onto spino-parabrachial neurons.	nimesulide	155-165	prostaglandin-endoperoxide synthase 2	Mus musculus	138-143
29094308-0	2018	Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway.	nimesulide	52-62	NFE2 like bZIP transcription factor 2	Rattus norvegicus	110-114
30002494-5	2018	The decrease in occludin was blocked by the COX-2 specific inhibitor nimesulide treatment during abstinence from Meth.	nimesulide	69-79	occludin	Rattus norvegicus	16-24
30002494-5	2018	The decrease in occludin was blocked by the COX-2 specific inhibitor nimesulide treatment during abstinence from Meth.	nimesulide	69-79	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	44-49
29896263-0	2018	Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN.	nimesulide	0-10	phosphatase and tensin homolog	Homo sapiens	110-114
29896263-3	2018	Nimesulide, a selective COX-2 inhibitor, can induce cell apoptosis, resulting in an anti-cancer effect.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29
29896263-10	2018	Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2).	nimesulide	40-50	BCL2 associated X, apoptosis regulator	Homo sapiens	97-120
29896263-10	2018	Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2).	nimesulide	40-50	BCL2 apoptosis regulator	Homo sapiens	122-127
29896263-10	2018	Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2).	nimesulide	40-50	caspase 3	Homo sapiens	183-196
29896263-10	2018	Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2).	nimesulide	40-50	BCL2 apoptosis regulator	Homo sapiens	221-226
29896263-10	2018	Western blot analysis demonstrated that nimesulide increased expression of cleaved caspase-3 and apoptosis regulator Bax (Bcl-2 associated protein X), and decreased the expression of pro-caspase-3 and apoptosis regulator Bcl-2 (B-cell lymphoma 2).	nimesulide	40-50	BCL2 apoptosis regulator	Homo sapiens	228-245
29896263-11	2018	Furthermore, nimesulide enhanced expression of phosphatase and tensin homolog (PTEN), and decreased the expression level of COX-2 and vascular endothelial growth factor.	nimesulide	13-23	phosphatase and tensin homolog	Homo sapiens	79-83
29896263-11	2018	Furthermore, nimesulide enhanced expression of phosphatase and tensin homolog (PTEN), and decreased the expression level of COX-2 and vascular endothelial growth factor.	nimesulide	13-23	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	124-129
29896263-11	2018	Furthermore, nimesulide enhanced expression of phosphatase and tensin homolog (PTEN), and decreased the expression level of COX-2 and vascular endothelial growth factor.	nimesulide	13-23	vascular endothelial growth factor A	Homo sapiens	134-168
29896263-12	2018	In summary, the results of the present study demonstrated that nimesulide could induce apoptosis and inhibit growth of PANC-1 cells by enhancing the expression of PTEN, which indicates the potential of nimesulide to prevent tumor angiogenesis.	nimesulide	63-73	phosphatase and tensin homolog	Homo sapiens	163-167
29896263-12	2018	In summary, the results of the present study demonstrated that nimesulide could induce apoptosis and inhibit growth of PANC-1 cells by enhancing the expression of PTEN, which indicates the potential of nimesulide to prevent tumor angiogenesis.	nimesulide	202-212	phosphatase and tensin homolog	Homo sapiens	163-167
29094308-0	2018	Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway.	nimesulide	52-62	heme oxygenase 1	Rattus norvegicus	115-119
29094308-0	2018	Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway.	nimesulide	52-62	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	120-125
29300762-7	2018	Results revealed that nimesulide (3), a non-steroidal anti-inflammatory drug, possesses a good anti-glycation activity in in-vitro BSA-MG and BSA-glucose glycation models with IC50 values of 330.56 +- 2.90, and 145.46 +- 16.35 muM, respectively.	nimesulide	22-32	latexin	Homo sapiens	227-230
28583427-10	2017	Nimesulide was the only COX-2 inhibitors that attenuated PTZ-induced seizures.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	24-29
28856805-10	2017	Furthermore, in vivo inhibition of COX2 with Nimesulide rescues hypomyelination and behavioral impairment.	nimesulide	45-55	prostaglandin-endoperoxide synthase 2	Homo sapiens	35-39
28583427-11	2017	This effect coincided with an increase of IL-10 levels in the cerebral cortex and hippocampus, constituting circumstantial evidence that IL-10 increase may be involved in the anticonvulsant effect of nimesulide.	nimesulide	200-210	interleukin 10	Mus musculus	42-47
28583427-11	2017	This effect coincided with an increase of IL-10 levels in the cerebral cortex and hippocampus, constituting circumstantial evidence that IL-10 increase may be involved in the anticonvulsant effect of nimesulide.	nimesulide	200-210	interleukin 10	Mus musculus	137-142
28202577-5	2017	In sandwich-cultured rat hepatocytes, NIM and 4"-hydroxynimesulide (M1) reduced the biliary excretion index of d8-taurocholic acid (d8-TCA) and 5 (and 6)-carboxy-2",7"-dichlorofluorescein in a concentration-dependent manner, indicating the inhibition of the efflux transporters bile salt export pump and multidrug resistance-associated protein 2, respectively.	nimesulide	38-41	ATP binding cassette subfamily C member 2	Rattus norvegicus	304-345
28666860-1	2017	Since nimesulide, a nonsteroidal anti-inflammatory drug, is known to be a selective inhibitor of cyclooxygenase-2 and shows activity against cancer cells, there has been much interest in developing related molecules with enhanced anticancer properties.	nimesulide	6-16	prostaglandin-endoperoxide synthase 2	Homo sapiens	97-113
28392690-4	2017	In this study, hydrophobic nimesulide was conjugated to HA of two different molecular weights (360 kDa as HA with high molecular weight [HAH] and 43kDa as HA with low molecular weight [HAL]) to improve its tumor-targeting ability and hydrophilicity.	nimesulide	27-37	histidine ammonia-lyase	Homo sapiens	185-188
28392690-7	2017	In the in vitro cytotoxic test, HA-nimesulide conjugate displayed >46% cell killing ability at a nimesulide concentration of 400 microM in HT-29 cells, whereas exiguous cytotoxic effects were observed on HCT-15 cells, indicating that HA-nimesulide causes cell death in CD44-overexpressing HT-29 cells.	nimesulide	35-45	CD44 molecule (Indian blood group)	Homo sapiens	272-276
28392690-9	2017	These results indicated that HA-nimesulide with improved selectivity through HA/CD44 receptor interactions has the potential to enhance the therapeutic efficacy and safety of nimesulide for cancer treatment.	nimesulide	32-42	CD44 molecule (Indian blood group)	Homo sapiens	80-84
29209105-4	2017	Thirty minutes after oral administration, nimesulide, 10 mg/Kg, decreased the GCRP release induced by an inflammatory soup, while the other NSAIDs were ineffective at this point in time.	nimesulide	42-52	RUN domain containing 3A	Rattus norvegicus	78-82
28240227-3	2017	Phosphorylation of the EGF receptor (EGFR) was inhibited even more effective in the presence of indomethacin and nimesulide than in the presence of genistein.	nimesulide	113-123	epidermal growth factor receptor	Homo sapiens	23-35
28240227-3	2017	Phosphorylation of the EGF receptor (EGFR) was inhibited even more effective in the presence of indomethacin and nimesulide than in the presence of genistein.	nimesulide	113-123	epidermal growth factor receptor	Homo sapiens	37-41
27007742-2	2017	The major purpose of this research was to develop a novel poly(ethyleneglycol)-block-poly(epsilon-caprolactone) (PEG-b-PCL) nano-sized particles encapsulated with nimesulide (NMS), a selective COX-2 inhibitor, and to evaluate its anticancer activity against MCF-7 breast cancer cells.	nimesulide	163-173	PHD finger protein 1	Homo sapiens	119-122
27007742-2	2017	The major purpose of this research was to develop a novel poly(ethyleneglycol)-block-poly(epsilon-caprolactone) (PEG-b-PCL) nano-sized particles encapsulated with nimesulide (NMS), a selective COX-2 inhibitor, and to evaluate its anticancer activity against MCF-7 breast cancer cells.	nimesulide	163-173	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	193-198
29209105-5	2017	Two hours after oral nimesulide (5 and 10 mg/Kg) and ketoprofen (10 mg/Kg), but not of etoricoxib, a significant decrease in the CGRP release was observed.	nimesulide	21-31	calcitonin-related polypeptide alpha	Rattus norvegicus	129-133
29209105-7	2017	The reduction of CGRP release from rat trigeminal ganglia after nimesulide and ketoprofen may help to explain the mechanism of action of NSAIDs in migraine.	nimesulide	64-74	calcitonin-related polypeptide alpha	Rattus norvegicus	17-21
29209105-8	2017	Since at 30 minutes only nimesulide was effective in reducing CGRP release, these results suggest that this NSAID may exert a particularly rapid effect in patients with migraine.	nimesulide	25-35	calcitonin related polypeptide alpha	Homo sapiens	62-66
27431935-0	2016	Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor gamma.	nimesulide	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	170-218
27224271-6	2016	Inhibition of cycloxygenase-2 with nimesulide abolished the potentiating effect of gamma-terpinene on interleukin-10 production.	nimesulide	35-45	interleukin 10	Mus musculus	102-116
27224271-7	2016	Moreover, nimesulide treatment also abrogated the inhibitory effect of gamma-terpinene on interleukin-1beta and interleukin-6.	nimesulide	10-20	interleukin 1 beta	Mus musculus	90-107
27224271-7	2016	Moreover, nimesulide treatment also abrogated the inhibitory effect of gamma-terpinene on interleukin-1beta and interleukin-6.	nimesulide	10-20	interleukin 6	Mus musculus	112-125
27431935-2	2016	The aim of this study was to examine how the COX-2 selective inhibitor nimesulide suppresses NAFLD in a murine model of high-fat diet (HFD)-induced obesity.	nimesulide	71-81	cytochrome c oxidase II, mitochondrial	Mus musculus	45-50
27177092-8	2016	None of the cytokine or LPS explant incubations affected the potency or maximum cholinergic contraction in vitro, and subsequent COX-2 blockade with nimesulide revealed a significant but similar decrease in potency of ACh-evoked contraction in control, LPS and cytokine-incubated muscle strips.	nimesulide	149-159	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	129-134
27325447-0	2016	Isomeric iodinated analogs of nimesulide: Synthesis, physicochemical characterization, cyclooxygenase-2 inhibitory activity, and transport across Caco-2 cells.	nimesulide	30-40	prostaglandin-endoperoxide synthase 2	Homo sapiens	87-103
27325447-1	2016	Isomeric iodinated derivatives of nimesulide, with an iodine substituent on the phenoxy ring, were prepared with the aim of identifying potential candidate compounds for the development of imaging agents targeting cyclooxygenase-2 (COX-2) in the brain.	nimesulide	34-44	prostaglandin-endoperoxide synthase 2	Homo sapiens	214-230
27325447-6	2016	The para-iodo-substituted analog of nimesulide appears to be an attractive candidate for the development of radioiodine-labeled tracers for in vivo brain imaging of COX-2 levels.	nimesulide	36-46	prostaglandin-endoperoxide synthase 2	Homo sapiens	165-170
27452436-3	2016	We sought to investigate the importance of COX-2 on mouse pregnancy inoculated with Gram-negative bacteria Lipopolysaccharide (LPS) by treating with a selective COX-2 inhibitor (nimesulide).	nimesulide	178-188	cytochrome c oxidase II, mitochondrial	Mus musculus	43-48
27452436-3	2016	We sought to investigate the importance of COX-2 on mouse pregnancy inoculated with Gram-negative bacteria Lipopolysaccharide (LPS) by treating with a selective COX-2 inhibitor (nimesulide).	nimesulide	178-188	cytochrome c oxidase II, mitochondrial	Mus musculus	161-166
27188793-0	2016	Adenosine signalling mediates the anti-inflammatory effects of the COX-2 inhibitor nimesulide.	nimesulide	83-93	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	67-72
27188793-3	2016	We evaluated whether CD73/adenosine/A2A signalling pathway is involved in nimesulide anti-inflammatory effect, in vivo and in vitro.	nimesulide	74-84	5' nucleotidase, ecto	Rattus norvegicus	21-25
27188793-9	2016	Furthermore, we found increased activity of 5"-nucleotidase/CD73 in paws and plasma of nimesulide treated rats, 4h following oedema induction.	nimesulide	87-97	5' nucleotidase, ecto	Rattus norvegicus	44-59
27188793-9	2016	Furthermore, we found increased activity of 5"-nucleotidase/CD73 in paws and plasma of nimesulide treated rats, 4h following oedema induction.	nimesulide	87-97	5' nucleotidase, ecto	Rattus norvegicus	60-64
27188793-11	2016	Furthermore, nimesulide increased CD73 activity in J774 macrophages while it did not inhibit nitrite accumulation by lipopolysaccharide-activated SiRNA CD73 silenced J774 macrophages.	nimesulide	13-23	5' nucleotidase, ecto	Rattus norvegicus	34-38
27188793-12	2016	Our data demonstrate that the anti-inflammatory effect of nimesulide in part is mediated by CD73-derived adenosine acting on A2A receptors.	nimesulide	58-68	5' nucleotidase, ecto	Rattus norvegicus	92-96
26455657-0	2015	Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.	nimesulide	28-38	prostaglandin-endoperoxide synthase 2	Homo sapiens	81-86
25579384-9	2016	Otherwise, the non-steroidal anti-inflammatory drugs nimesulide, acetylsalicylic acid, ibuprofen, and diclofenac sodium decreased the extracellular glutamate and glutamine levels, downregulated GS and AChE activities, and restored ACh levels in Pro-treated astrocytes.	nimesulide	53-63	acetylcholinesterase	Rattus norvegicus	201-205
26455657-0	2015	Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.	nimesulide	28-38	prostaglandin-endoperoxide synthase 2	Homo sapiens	133-138
26455657-1	2015	Nimesulide analogs bearing a methoxy substituent either at the ortho-, meta- or para-position on the phenyl ring, were designed, synthesized, and evaluated for potential as radioligands for brain cyclooxygenase-2 (COX-2) imaging.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	196-212
26455657-1	2015	Nimesulide analogs bearing a methoxy substituent either at the ortho-, meta- or para-position on the phenyl ring, were designed, synthesized, and evaluated for potential as radioligands for brain cyclooxygenase-2 (COX-2) imaging.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	214-219
26455657-4	2015	In vitro inhibition studies using a colorimetric COX (ovine) inhibitor-screening assay demonstrated that the para-methoxy substituted analog retains the inhibition ability and selectivity observed for parent nimesulide toward COX-2 enzyme, whereas the meta- and ortho-methoxy substituents detrimentally affected COX-2-inhibition activity, which was further supported by molecular docking studies.	nimesulide	208-218	prostaglandin-endoperoxide synthase 2	Homo sapiens	226-231
25892078-9	2015	The selective COX-2 inhibitor nimesulide was used in ESTG rats to examine the association between p-ERK, CGRP and COX-2.	nimesulide	30-40	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-19
26144697-6	2015	RESULTS: Compared with the nimesulide group, YLSPS significantly decreased the activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and the content of bilirubin in the serum.	nimesulide	27-37	glutamic pyruvic transaminase, soluble	Mus musculus	93-117
26144697-6	2015	RESULTS: Compared with the nimesulide group, YLSPS significantly decreased the activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and the content of bilirubin in the serum.	nimesulide	27-37	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	125-151
26455241-1	2015	BACKGROUND: The present study was designed to determine the effects of cyclooxygenase-2 (COX-2) inhibitor-nimesulide on platelet activating factor (PAF) and arachidonic acid (AA)-induced platelet aggregation during myocardial infarction (Ml) and ischaemia in rabbits.	nimesulide	106-116	prostaglandin G/H synthase 2	Oryctolagus cuniculus	71-87
26455241-1	2015	BACKGROUND: The present study was designed to determine the effects of cyclooxygenase-2 (COX-2) inhibitor-nimesulide on platelet activating factor (PAF) and arachidonic acid (AA)-induced platelet aggregation during myocardial infarction (Ml) and ischaemia in rabbits.	nimesulide	106-116	prostaglandin G/H synthase 2	Oryctolagus cuniculus	89-94
25724470-9	2015	Nimesulide downregulated the phosphorylation levels of JAK2 and STAT3, and JAK2 inhibition by AG490 significantly augmented both nimesulide-induced apoptosis and the downregulation of COX-2 and survivin (P<0.05).	nimesulide	129-139	Janus kinase 2	Homo sapiens	75-79
25250798-2	2015	CONTEXT: Nimesulide is a selective inhibitor of the enzyme cyclooxygenase 2.	nimesulide	9-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	59-75
25846103-5	2015	Chronic treatment with nimesulide or NS-398 (5 mg/kg/day) for 3 weeks lowered high blood pressure and cardiac hypertrophy with decreased expression levels of cardiac hypertrophy markers [atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)], Ang type 1 receptor, urotensin II, and urotensin II receptor in 2K1C rats.	nimesulide	23-33	natriuretic peptide B	Rattus norvegicus	221-246
25846103-5	2015	Chronic treatment with nimesulide or NS-398 (5 mg/kg/day) for 3 weeks lowered high blood pressure and cardiac hypertrophy with decreased expression levels of cardiac hypertrophy markers [atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)], Ang type 1 receptor, urotensin II, and urotensin II receptor in 2K1C rats.	nimesulide	23-33	natriuretic peptide B	Rattus norvegicus	248-251
25846103-5	2015	Chronic treatment with nimesulide or NS-398 (5 mg/kg/day) for 3 weeks lowered high blood pressure and cardiac hypertrophy with decreased expression levels of cardiac hypertrophy markers [atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)], Ang type 1 receptor, urotensin II, and urotensin II receptor in 2K1C rats.	nimesulide	23-33	urotensin 2	Rattus norvegicus	276-288
25846103-5	2015	Chronic treatment with nimesulide or NS-398 (5 mg/kg/day) for 3 weeks lowered high blood pressure and cardiac hypertrophy with decreased expression levels of cardiac hypertrophy markers [atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)], Ang type 1 receptor, urotensin II, and urotensin II receptor in 2K1C rats.	nimesulide	23-33	urotensin 2 receptor	Rattus norvegicus	294-315
25846103-6	2015	Plasma level of ANP was markedly increased and plasma levels of Ang II and aldosterone were decreased by treatment with nimesulide or NS-398.	nimesulide	120-130	angiotensinogen	Rattus norvegicus	64-70
25724470-0	2015	Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway.	nimesulide	0-10	Janus kinase 2	Homo sapiens	87-91
25724470-0	2015	Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway.	nimesulide	0-10	signal transducer and activator of transcription 3	Homo sapiens	92-97
25724470-8	2015	Nimesulide also induced apoptosis, which was accompanied by a significant decrease in the expression of COX-2 and survivin and an increase in caspase-3 expression.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	104-109
25724470-8	2015	Nimesulide also induced apoptosis, which was accompanied by a significant decrease in the expression of COX-2 and survivin and an increase in caspase-3 expression.	nimesulide	0-10	caspase 3	Homo sapiens	142-151
25724470-9	2015	Nimesulide downregulated the phosphorylation levels of JAK2 and STAT3, and JAK2 inhibition by AG490 significantly augmented both nimesulide-induced apoptosis and the downregulation of COX-2 and survivin (P<0.05).	nimesulide	0-10	Janus kinase 2	Homo sapiens	55-59
25724470-9	2015	Nimesulide downregulated the phosphorylation levels of JAK2 and STAT3, and JAK2 inhibition by AG490 significantly augmented both nimesulide-induced apoptosis and the downregulation of COX-2 and survivin (P<0.05).	nimesulide	0-10	signal transducer and activator of transcription 3	Homo sapiens	64-69
25724470-9	2015	Nimesulide downregulated the phosphorylation levels of JAK2 and STAT3, and JAK2 inhibition by AG490 significantly augmented both nimesulide-induced apoptosis and the downregulation of COX-2 and survivin (P<0.05).	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	184-189
25724470-10	2015	In vivo, nimesulide inhibited the growth of Eca-109 tumors and the expression of p-JAK2 and p-STAT3.	nimesulide	9-19	Janus kinase 2	Homo sapiens	83-87
25724470-10	2015	In vivo, nimesulide inhibited the growth of Eca-109 tumors and the expression of p-JAK2 and p-STAT3.	nimesulide	9-19	signal transducer and activator of transcription 3	Homo sapiens	94-99
25724470-11	2015	Thus, nimesulide downregulates COX-2 and survivin expression and upregulates caspase-3 expression in Eca-109 cells, by inactivating the JAK2/STAT3 pathway.	nimesulide	6-16	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	31-36
25724470-11	2015	Thus, nimesulide downregulates COX-2 and survivin expression and upregulates caspase-3 expression in Eca-109 cells, by inactivating the JAK2/STAT3 pathway.	nimesulide	6-16	caspase 3	Homo sapiens	77-86
25724470-11	2015	Thus, nimesulide downregulates COX-2 and survivin expression and upregulates caspase-3 expression in Eca-109 cells, by inactivating the JAK2/STAT3 pathway.	nimesulide	6-16	Janus kinase 2	Homo sapiens	136-140
25724470-11	2015	Thus, nimesulide downregulates COX-2 and survivin expression and upregulates caspase-3 expression in Eca-109 cells, by inactivating the JAK2/STAT3 pathway.	nimesulide	6-16	signal transducer and activator of transcription 3	Homo sapiens	141-146
25375820-1	2014	Nimesulide is a COX-2 inhibitor used for symptomatic relief of rheumatoid arthritis.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	16-21
26124563-6	2015	The present in silico study has been performed to find out the relative efficacy of three different NSAIDs (Piroxicam, Aspirin and Nimesulide) in preventing neurodegeneration in CI, with respect to their inhibitory potential on COXs, AQ-4 and ASIC-1a.	nimesulide	131-141	aquaporin 4	Homo sapiens	234-238
25637769-6	2015	Pre-exposure of PZ-DHA ester was more effective in reducing tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and cyclooxygenase-2 (COX-2) protein levels compared to DHA and nimesulide.	nimesulide	186-196	prostaglandin-endoperoxide synthase 2	Homo sapiens	144-149
25483152-6	2015	Specific inhibition of COX-2 activity by nimesulide further confirmed that miR-26b was able to regulate the cell proliferation and metastasis of the human tongue squamous cell carcinoma cells through a COX-2-dependent mechanism.	nimesulide	41-51	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	23-28
25483152-6	2015	Specific inhibition of COX-2 activity by nimesulide further confirmed that miR-26b was able to regulate the cell proliferation and metastasis of the human tongue squamous cell carcinoma cells through a COX-2-dependent mechanism.	nimesulide	41-51	microRNA 26b	Homo sapiens	75-82
25375820-10	2014	Combination of nimesulide and leflunomide significantly improved symptomatic (analgesia and joint stiffness) and arthritic disease progression (radiological, pathological and Myeloperoxidase enzyme activity) in collagen induced arthritis animal model.	nimesulide	15-25	myeloperoxidase	Mus musculus	175-190
24621649-0	2014	Effects of nimesulide, a selective COX-2 inhibitor, on cardiovascular function in 2 rat models of diabetes.	nimesulide	11-21	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	35-40
24948067-1	2014	BACKGROUND: Nimesulide is a pharmacological agent and selective COX-2 inhibitor.	nimesulide	12-22	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	64-69
24948067-3	2014	The purpose of this study was to investigate the effect of nimesulide on oxidant/antioxidant, DNA mutation and COX-1/COX-2 activities in rat liver tissue with induced ischemia/reperfusion (I/R).	nimesulide	59-69	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	111-116
24621649-2	2014	We investigated whether nimesulide (selective COX-2 inhibitor) alters cardiovascular responses to adrenaline in 2 rat models of diabetes.	nimesulide	24-34	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	46-51
24215890-0	2013	Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.	nimesulide	39-49	phosphodiesterase 4B	Homo sapiens	103-108
24704252-0	2014	Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter.	nimesulide	0-10	solute carrier family 6 member 19	Rattus norvegicus	31-36
24704252-0	2014	Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter.	nimesulide	0-10	solute carrier family 6 member 19	Rattus norvegicus	38-45
24704252-6	2014	Among the tested compounds, only the anti-inflammatory drug nimesulide exerted potent inhibition on B0AT1.	nimesulide	60-70	solute carrier family 6 member 19	Rattus norvegicus	100-105
24704252-13	2014	Molecular docking of nimesulide suggested that this drug is able to bind B0AT1 in an external dedicated binding site and that its binding produces a steric hindrance effect of the protein translocation path abolishing the transporter activity.	nimesulide	21-31	solute carrier family 6 member 19	Rattus norvegicus	73-78
24675150-9	2014	Nimesulide (3mg/kg), a COX-2 inhibitor, completely reversed the inhibitory action of L-694,247, whereas 1-[[4,5-bis (4-methoxyphenyl)-2-thiazolyl]carbonyl]-4-methylpiperazine hydrochloride (FR122047) (3mg/kg), a COX-1 inhibitor, partially blocked this action.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28
24440378-1	2014	Nimesulide, a COX-2 preferential inhibitor with a favorable gastric and cardiovascular safety profile, was responsible for some cases of acute liver failure attributed to the nitrobenzene ring.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
24372551-11	2014	Chronic treatment with selective COX-2 inhibitors, celecoxib or nimesulide, significantly ameliorated arterial inflammation, steatohepatitis and hyperlipidaemia in EC-AMPK mice, without altering their blood pressure or clotting.	nimesulide	64-74	cytochrome c oxidase II, mitochondrial	Mus musculus	33-38
24215890-1	2013	A new class of 1,2,3-triazol derivatives derived from nimesulide was designed as potential inhibitors of PDE4B.	nimesulide	54-64	phosphodiesterase 4B	Homo sapiens	105-110
24298452-1	2013	AIM: Nimesulide, a preferential COX-2 inhibitor has 20 times more selectivity towards COX-2 than that of COX-1.	nimesulide	5-15	cytochrome c oxidase II, mitochondrial	Mus musculus	32-37
22994526-1	2013	Nimesulide is a non-steroidal anti-inflammatory drug that acts through selective inhibition of COX-2 enzyme.	nimesulide	0-10	cytochrome c oxidase subunit II	Oryctolagus cuniculus	95-100
24298452-1	2013	AIM: Nimesulide, a preferential COX-2 inhibitor has 20 times more selectivity towards COX-2 than that of COX-1.	nimesulide	5-15	cytochrome c oxidase II, mitochondrial	Mus musculus	86-91
24298452-1	2013	AIM: Nimesulide, a preferential COX-2 inhibitor has 20 times more selectivity towards COX-2 than that of COX-1.	nimesulide	5-15	cytochrome c oxidase I, mitochondrial	Mus musculus	105-110
23117109-6	2013	Activation of these pathways by tryptamine releases cyclooxygenase (COX) products since indomethacin (non-selective inhibitor of COX-1/2) and nimesulide (selective COX-2 inhibitor) reduced the vasoconstriction.	nimesulide	142-152	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	164-169
23587942-7	2013	Nimesulide, a COX-2 inhibitor, increased the dendritic processes of COX-2-expressing cells as well as expression of both COX-2 and alpha-SMA.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19
23587942-7	2013	Nimesulide, a COX-2 inhibitor, increased the dendritic processes of COX-2-expressing cells as well as expression of both COX-2 and alpha-SMA.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	68-73
23587942-7	2013	Nimesulide, a COX-2 inhibitor, increased the dendritic processes of COX-2-expressing cells as well as expression of both COX-2 and alpha-SMA.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	68-73
23587942-7	2013	Nimesulide, a COX-2 inhibitor, increased the dendritic processes of COX-2-expressing cells as well as expression of both COX-2 and alpha-SMA.	nimesulide	0-10	actin gamma 2, smooth muscle	Rattus norvegicus	131-140
23401306-10	2013	Upon occurrence of an inflammatory stress, the inhibitory potential of trovafloxacin, nimesulide, and nefazodone on the efflux activity of MRP2 was noticeably revealed, while the telithromycin and nefazodone-induced inhibition of MDR1 was clearly attenuated.	nimesulide	86-96	ATP binding cassette subfamily C member 2	Homo sapiens	139-143
23401306-10	2013	Upon occurrence of an inflammatory stress, the inhibitory potential of trovafloxacin, nimesulide, and nefazodone on the efflux activity of MRP2 was noticeably revealed, while the telithromycin and nefazodone-induced inhibition of MDR1 was clearly attenuated.	nimesulide	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	230-234
23042097-6	2013	Furthermore, inhibition of COX2 by nimesulide reduced HIF-2alpha-induced colon tumor formation.	nimesulide	35-45	prostaglandin-endoperoxide synthase 2	Mus musculus	27-31
23042097-6	2013	Furthermore, inhibition of COX2 by nimesulide reduced HIF-2alpha-induced colon tumor formation.	nimesulide	35-45	endothelial PAS domain protein 1	Mus musculus	54-64
23042097-7	2013	Interestingly, the levels of prostaglandin E(2) (PGE(2)), the downstream effector of COX2, remained elevated in normal and tumor tissues of the nimesulide-treated Vhl(DeltaIE)/Apc(min/+) mice.	nimesulide	144-154	prostaglandin-endoperoxide synthase 2	Mus musculus	85-89
23042097-7	2013	Interestingly, the levels of prostaglandin E(2) (PGE(2)), the downstream effector of COX2, remained elevated in normal and tumor tissues of the nimesulide-treated Vhl(DeltaIE)/Apc(min/+) mice.	nimesulide	144-154	von Hippel-Lindau tumor suppressor	Mus musculus	163-166
23377804-11	2013	Treatment with allopurinol and nimesulide significantly decreased the MDA and MPO levels whereas increased the SOD and CAT levels when compared I/R group in both non-diabetic and diabetic rats.	nimesulide	31-41	myeloperoxidase	Rattus norvegicus	78-81
23377804-11	2013	Treatment with allopurinol and nimesulide significantly decreased the MDA and MPO levels whereas increased the SOD and CAT levels when compared I/R group in both non-diabetic and diabetic rats.	nimesulide	31-41	catalase	Rattus norvegicus	119-122
23526055-2	2013	Given that curcumin can desensitize transient receptor potential A1, a nociceptor seemingly also mediating the analgesic effect of acetaminophen, as well as inhibiting and downregulating the expression of cyclo-oxygenase 2, the selective target of nimesulide, a nonsteroidal anti-inflammatory agent, we carried out a pilot comparative study of the acute pain-relieving properties of these three agents.	nimesulide	248-258	prostaglandin-endoperoxide synthase 2	Homo sapiens	205-222
23973990-6	2013	Nimesulide, a preferential COX-2 inhibitor, down-regulated IDO1 mRNA/protein and attenuated kynurenine synthesis, suggesting that overall IDO inhibition resulted both from reduced IDO1 gene transcription and from inhibited IDO1 catalytic activity.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-32
23973990-6	2013	Nimesulide, a preferential COX-2 inhibitor, down-regulated IDO1 mRNA/protein and attenuated kynurenine synthesis, suggesting that overall IDO inhibition resulted both from reduced IDO1 gene transcription and from inhibited IDO1 catalytic activity.	nimesulide	0-10	indoleamine 2,3-dioxygenase 1	Homo sapiens	59-63
23973990-6	2013	Nimesulide, a preferential COX-2 inhibitor, down-regulated IDO1 mRNA/protein and attenuated kynurenine synthesis, suggesting that overall IDO inhibition resulted both from reduced IDO1 gene transcription and from inhibited IDO1 catalytic activity.	nimesulide	0-10	indoleamine 2,3-dioxygenase 1	Homo sapiens	59-62
23973990-6	2013	Nimesulide, a preferential COX-2 inhibitor, down-regulated IDO1 mRNA/protein and attenuated kynurenine synthesis, suggesting that overall IDO inhibition resulted both from reduced IDO1 gene transcription and from inhibited IDO1 catalytic activity.	nimesulide	0-10	indoleamine 2,3-dioxygenase 1	Homo sapiens	180-184
23973990-6	2013	Nimesulide, a preferential COX-2 inhibitor, down-regulated IDO1 mRNA/protein and attenuated kynurenine synthesis, suggesting that overall IDO inhibition resulted both from reduced IDO1 gene transcription and from inhibited IDO1 catalytic activity.	nimesulide	0-10	indoleamine 2,3-dioxygenase 1	Homo sapiens	180-184
23973990-7	2013	From a functional standpoint, IFN-g-challenged HL-60 cells promoted the in vitro conversion of allogeneic CD4+CD25- T cells into bona fide CD4+CD25+FoxP3+ regulatory T cells, an effect that was significantly reduced by treatment of IFN-gamma-activated HL-60 cells with nimesulide.	nimesulide	269-279	interferon gamma	Homo sapiens	30-35
23645839-7	2013	In addition, treatment with nimesulide, a COX-2 selective inhibitor, dramatically suppresses xenograft tumor formation and inhibits in vivo progression of human leukemia cells.	nimesulide	28-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	42-47
23031659-8	2013	COX-2 inhibitors were well tolerated in the majority of the patients [nimesulide: 91.9%; meloxicam: 90.2%; rofecoxib: 94.9%; and celecoxib: 94.9%)].	nimesulide	70-80	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5
23412109-4	2013	Nimesulide, a selective COX-2 inhibitor, was given to mice for five consecutive days before irradiation.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	24-29
23179355-4	2013	Treatment with the non-selective cyclooxygenase (COX) inhibitor ketoprofen and the COX-2 selective inhibitor nimesulide attenuated the increase in extracellular glutamate in the hippocampus evoked by repeated MDMA exposure (10 mg/kg, i.p., every 2 h); no attenuation was observed in rats treated with the COX-1 selective inhibitor piroxicam.	nimesulide	109-119	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	83-88
23179355-4	2013	Treatment with the non-selective cyclooxygenase (COX) inhibitor ketoprofen and the COX-2 selective inhibitor nimesulide attenuated the increase in extracellular glutamate in the hippocampus evoked by repeated MDMA exposure (10 mg/kg, i.p., every 2 h); no attenuation was observed in rats treated with the COX-1 selective inhibitor piroxicam.	nimesulide	109-119	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	305-310
23287776-2	2013	In this context, the binding of nimesulide to human serum albumin (HSA), in IL media, was studied.	nimesulide	32-42	albumin	Homo sapiens	52-65
23429763-4	2013	While nimesulide and paracetamol, as in previous experiments, decreased the percentage of cultured DRG neurons showing translocation of PKCe caused by 100 nM thrombin or 1 muM bradykinin in a dose-dependent manner, the other NSAIDs tested did not have a significant effect.	nimesulide	6-16	protein kinase C, epsilon	Rattus norvegicus	136-140
23429763-4	2013	While nimesulide and paracetamol, as in previous experiments, decreased the percentage of cultured DRG neurons showing translocation of PKCe caused by 100 nM thrombin or 1 muM bradykinin in a dose-dependent manner, the other NSAIDs tested did not have a significant effect.	nimesulide	6-16	coagulation factor II	Rattus norvegicus	158-166
22940226-3	2012	The present study demonstrated that, guggulipid and nimesulide (preferentially selective COX-2 inhibitor) treatment of rat astrocytoma cells, C6 for 24 h significantly decreased MPTP (400 muM) induced nitrative and oxidative stress and intracellular calcium ion (Ca(2+)) level.	nimesulide	52-62	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	89-94
22940226-4	2012	Guggulipid and nimesulide also deactivated MPTP-induced P-p38 MAPK (Phosphorylated p38 mitogen-activated protein kinase) and down regulated expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and CHOP (C/EBP, homologous protein 10).	nimesulide	15-25	mitogen activated protein kinase 14	Rattus norvegicus	83-119
22940226-5	2012	At transcriptional level of inflammatory cytokine genes, guggulipid and nimesulide down regulated MPTP-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) mRNA expressions with up regulations in interleukin-6 (IL-6) and interleukin-1alpha (IL-1alpha) mRNA expressions.	nimesulide	72-82	tumor necrosis factor	Rattus norvegicus	140-149
22940226-4	2012	Guggulipid and nimesulide also deactivated MPTP-induced P-p38 MAPK (Phosphorylated p38 mitogen-activated protein kinase) and down regulated expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and CHOP (C/EBP, homologous protein 10).	nimesulide	15-25	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	155-171
22940226-5	2012	At transcriptional level of inflammatory cytokine genes, guggulipid and nimesulide down regulated MPTP-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) mRNA expressions with up regulations in interleukin-6 (IL-6) and interleukin-1alpha (IL-1alpha) mRNA expressions.	nimesulide	72-82	interleukin 1 beta	Rattus norvegicus	155-172
22940226-4	2012	Guggulipid and nimesulide also deactivated MPTP-induced P-p38 MAPK (Phosphorylated p38 mitogen-activated protein kinase) and down regulated expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and CHOP (C/EBP, homologous protein 10).	nimesulide	15-25	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	173-178
22940226-5	2012	At transcriptional level of inflammatory cytokine genes, guggulipid and nimesulide down regulated MPTP-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) mRNA expressions with up regulations in interleukin-6 (IL-6) and interleukin-1alpha (IL-1alpha) mRNA expressions.	nimesulide	72-82	interleukin 1 beta	Rattus norvegicus	174-182
22940226-4	2012	Guggulipid and nimesulide also deactivated MPTP-induced P-p38 MAPK (Phosphorylated p38 mitogen-activated protein kinase) and down regulated expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and CHOP (C/EBP, homologous protein 10).	nimesulide	15-25	nitric oxide synthase 2	Rattus norvegicus	181-212
22940226-5	2012	At transcriptional level of inflammatory cytokine genes, guggulipid and nimesulide down regulated MPTP-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) mRNA expressions with up regulations in interleukin-6 (IL-6) and interleukin-1alpha (IL-1alpha) mRNA expressions.	nimesulide	72-82	interleukin 6	Rattus norvegicus	224-237
22940226-5	2012	At transcriptional level of inflammatory cytokine genes, guggulipid and nimesulide down regulated MPTP-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) mRNA expressions with up regulations in interleukin-6 (IL-6) and interleukin-1alpha (IL-1alpha) mRNA expressions.	nimesulide	72-82	interleukin 6	Rattus norvegicus	239-243
22940226-4	2012	Guggulipid and nimesulide also deactivated MPTP-induced P-p38 MAPK (Phosphorylated p38 mitogen-activated protein kinase) and down regulated expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and CHOP (C/EBP, homologous protein 10).	nimesulide	15-25	nitric oxide synthase 2	Rattus norvegicus	214-218
22940226-5	2012	At transcriptional level of inflammatory cytokine genes, guggulipid and nimesulide down regulated MPTP-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) mRNA expressions with up regulations in interleukin-6 (IL-6) and interleukin-1alpha (IL-1alpha) mRNA expressions.	nimesulide	72-82	interleukin 1 alpha	Rattus norvegicus	249-267
22940226-5	2012	At transcriptional level of inflammatory cytokine genes, guggulipid and nimesulide down regulated MPTP-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) mRNA expressions with up regulations in interleukin-6 (IL-6) and interleukin-1alpha (IL-1alpha) mRNA expressions.	nimesulide	72-82	interleukin 1 alpha	Rattus norvegicus	269-278
22940226-4	2012	Guggulipid and nimesulide also deactivated MPTP-induced P-p38 MAPK (Phosphorylated p38 mitogen-activated protein kinase) and down regulated expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and CHOP (C/EBP, homologous protein 10).	nimesulide	15-25	DNA-damage inducible transcript 3	Rattus norvegicus	224-228
22940226-4	2012	Guggulipid and nimesulide also deactivated MPTP-induced P-p38 MAPK (Phosphorylated p38 mitogen-activated protein kinase) and down regulated expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and CHOP (C/EBP, homologous protein 10).	nimesulide	15-25	DNA-damage inducible transcript 3	Rattus norvegicus	230-258
22849544-2	2012	The lead molecule of these compounds was nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), a cyclooxygenase (COX) inhibitor acting on both COX-1 and 2 isoforms, with some selectivity for COX-2.	nimesulide	41-51	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	141-152
22849544-2	2012	The lead molecule of these compounds was nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), a cyclooxygenase (COX) inhibitor acting on both COX-1 and 2 isoforms, with some selectivity for COX-2.	nimesulide	41-51	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	189-194
23291066-1	2012	OBJECTIVE: This study was designed to evaluate the inhibitory effect of nimesulide in combination with oxaliplatin on tumor growth, expression of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin, and lymphatic metastasis in lung cancer xenograft in nude mice, and to discuss the possible synergistic effect of nimesulide in combination with oxaliplatin.	nimesulide	72-82	cytochrome c oxidase II, mitochondrial	Mus musculus	146-151
23291066-1	2012	OBJECTIVE: This study was designed to evaluate the inhibitory effect of nimesulide in combination with oxaliplatin on tumor growth, expression of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin, and lymphatic metastasis in lung cancer xenograft in nude mice, and to discuss the possible synergistic effect of nimesulide in combination with oxaliplatin.	nimesulide	72-82	vascular endothelial growth factor C	Mus musculus	153-159
23291066-1	2012	OBJECTIVE: This study was designed to evaluate the inhibitory effect of nimesulide in combination with oxaliplatin on tumor growth, expression of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin, and lymphatic metastasis in lung cancer xenograft in nude mice, and to discuss the possible synergistic effect of nimesulide in combination with oxaliplatin.	nimesulide	72-82	catenin (cadherin associated protein), beta 1	Mus musculus	183-195
23291066-8	2012	Immunohistochemical and RT-PCR analysis showed that compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide group were significantly reduced (all P < 0.05).	nimesulide	167-177	cytochrome c oxidase II, mitochondrial	Mus musculus	110-115
23112421-0	2012	Nimesulide inhibits the proliferation of HepG2 by up-regulation of Smad4.	nimesulide	0-10	SMAD family member 4	Homo sapiens	67-72
23291066-8	2012	Immunohistochemical and RT-PCR analysis showed that compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide group were significantly reduced (all P < 0.05).	nimesulide	167-177	vascular endothelial growth factor C	Mus musculus	117-123
23291066-8	2012	Immunohistochemical and RT-PCR analysis showed that compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide group were significantly reduced (all P < 0.05).	nimesulide	167-177	FMS-like tyrosine kinase 4	Mus musculus	125-132
23291066-8	2012	Immunohistochemical and RT-PCR analysis showed that compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide group were significantly reduced (all P < 0.05).	nimesulide	167-177	baculoviral IAP repeat-containing 5	Mus musculus	134-142
23291066-8	2012	Immunohistochemical and RT-PCR analysis showed that compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide group were significantly reduced (all P < 0.05).	nimesulide	167-177	catenin (cadherin associated protein), beta 1	Mus musculus	147-159
23291066-10	2012	Compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide + oxaliplatin group were significantly reduced (all P < 0.05).	nimesulide	115-125	cytochrome c oxidase II, mitochondrial	Mus musculus	58-63
23291066-10	2012	Compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide + oxaliplatin group were significantly reduced (all P < 0.05).	nimesulide	115-125	vascular endothelial growth factor C	Mus musculus	65-71
23291066-10	2012	Compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide + oxaliplatin group were significantly reduced (all P < 0.05).	nimesulide	115-125	FMS-like tyrosine kinase 4	Mus musculus	73-80
23291066-10	2012	Compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide + oxaliplatin group were significantly reduced (all P < 0.05).	nimesulide	115-125	baculoviral IAP repeat-containing 5	Mus musculus	82-90
23291066-10	2012	Compared with the control group, the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin of the nimesulide + oxaliplatin group were significantly reduced (all P < 0.05).	nimesulide	115-125	catenin (cadherin associated protein), beta 1	Mus musculus	95-107
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	nimesulide	18-28	cytochrome c oxidase II, mitochondrial	Mus musculus	175-180
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	nimesulide	18-28	vascular endothelial growth factor C	Mus musculus	182-188
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	nimesulide	18-28	FMS-like tyrosine kinase 4	Mus musculus	190-197
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	nimesulide	18-28	baculoviral IAP repeat-containing 5	Mus musculus	199-207
23291066-11	2012	CONCLUSIONS: Both nimesulide alone or in combination with oxaliplatin can significantly inhibit the growth of lung cancer xenografts in nude mice and the expression levels of COX-2, VEGF-C, VEGFR-3, survivin and beta-catenin.	nimesulide	18-28	catenin (cadherin associated protein), beta 1	Mus musculus	212-224
22656329-7	2012	Apoptosis induced by nimesulide might be related to caspase-3 activation.	nimesulide	21-31	caspase 3	Homo sapiens	52-61
22213194-1	2012	JCC76 is a novel nimesulide analog that selectively inhibits the human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer cell proliferation and tumor progression.	nimesulide	17-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-105
22213194-1	2012	JCC76 is a novel nimesulide analog that selectively inhibits the human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer cell proliferation and tumor progression.	nimesulide	17-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
23112421-2	2012	This study was designed to investigate the effect of selective Cyclooxygenase-2 (COX-2) inhibitor, nimesulide, on the expression of Smad4 in human hepatocellular carcinoma HepG2.	nimesulide	99-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	63-79
23112421-2	2012	This study was designed to investigate the effect of selective Cyclooxygenase-2 (COX-2) inhibitor, nimesulide, on the expression of Smad4 in human hepatocellular carcinoma HepG2.	nimesulide	99-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	81-86
23112421-2	2012	This study was designed to investigate the effect of selective Cyclooxygenase-2 (COX-2) inhibitor, nimesulide, on the expression of Smad4 in human hepatocellular carcinoma HepG2.	nimesulide	99-109	SMAD family member 4	Homo sapiens	132-137
23112421-5	2012	RESULTS: The result showed that nimesulide inhibited the proliferation of HepG2 cell in a concentrations-dependent manner, and promoted the karyopyknosis and fragmentation of HepG2 cell nucleus, induced its apoptosis, the number of fluorescence labeling of Smad4 in Nimesulide group was higher than control group (P<0.05).	nimesulide	32-42	SMAD family member 4	Homo sapiens	257-262
23112421-6	2012	CONCLUSIONS: Nimesulide inhibits the proliferation and promotes apoptosis of HepG2 by up-regulation of Smad4 in HepG2.	nimesulide	13-23	SMAD family member 4	Homo sapiens	103-108
22107987-1	2012	We investigated the protective effects of two non-steroid anti-inflammatory drugs, indomethacin (COX-1 and COX-2 inhibitors) and nimesulide (specific COX-2 inhibitor) on the hepatic injury induced by lipopolysaccharide in d-galactosamine sensitized (Gal/LPS) mice.	nimesulide	129-139	cytochrome c oxidase II, mitochondrial	Mus musculus	150-155
22245539-7	2012	In conclusion, NSAIDs with the greatest cytoprotective effect (nimesulide, celecoxib and meloxicam) may exert their effect mainly through the blockade of cyclooxygenase-2 (COX-2) activity.	nimesulide	63-73	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	154-170
22245539-7	2012	In conclusion, NSAIDs with the greatest cytoprotective effect (nimesulide, celecoxib and meloxicam) may exert their effect mainly through the blockade of cyclooxygenase-2 (COX-2) activity.	nimesulide	63-73	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	172-177
22287609-4	2012	Our second study aimed to block LPS-induced increases in PGE(2) with a PGHS-2 inhibitor (nimesulide) and determine lung inflammation and surfactant protein mRNA expression.	nimesulide	89-99	prostaglandin G/H synthase 2	Ovis aries	71-77
22287609-10	2012	Nimesulide inhibited LPS-induced increases in PGE(2) and decreased fetal lung IL-1beta and IL-8 mRNA (P <= 0.002) without altering lung inflammatory cell infiltration.	nimesulide	0-10	interleukin-1 beta	Ovis aries	78-86
22287609-10	2012	Nimesulide inhibited LPS-induced increases in PGE(2) and decreased fetal lung IL-1beta and IL-8 mRNA (P <= 0.002) without altering lung inflammatory cell infiltration.	nimesulide	0-10	interleukin-8	Ovis aries	91-95
22287609-11	2012	Nimesulide decreased surfactant protein (SP)-A (P = 0.05), -B (P = 0.05), and -D (P = 0.0015) but increased SP-C mRNA (P = 0.023).	nimesulide	0-10	pulmonary surfactant-associated protein A	Ovis aries	21-46
22287609-11	2012	Nimesulide decreased surfactant protein (SP)-A (P = 0.05), -B (P = 0.05), and -D (P = 0.0015) but increased SP-C mRNA (P = 0.023).	nimesulide	0-10	pulmonary surfactant-associated protein C	Ovis aries	108-112
22980656-0	2012	[Downregulation of HSP70 gene expression and apoptosis in human hepatocellular carcinoma SMMC-7721 cells induced by nimesulide in vitro].	nimesulide	116-126	heat shock protein family A (Hsp70) member 4	Homo sapiens	19-24
22980656-8	2012	Moreover,  nimesulide promoted the cleavage of caspase-9 and PARP and inhibited the mRNA and protein expression of HSP70.	nimesulide	11-21	caspase 9	Homo sapiens	47-56
22980656-8	2012	Moreover,  nimesulide promoted the cleavage of caspase-9 and PARP and inhibited the mRNA and protein expression of HSP70.	nimesulide	11-21	poly(ADP-ribose) polymerase 1	Homo sapiens	61-65
22980656-8	2012	Moreover,  nimesulide promoted the cleavage of caspase-9 and PARP and inhibited the mRNA and protein expression of HSP70.	nimesulide	11-21	heat shock protein family A (Hsp70) member 4	Homo sapiens	115-120
22980656-10	2012	CONCLUSION: Nimesulide could inhibit cell growth and induce apoptosis in human hepatocellular carcinoma SMMC-7721 cells via the downregulation of HSP70.	nimesulide	12-22	heat shock protein family A (Hsp70) member 4	Homo sapiens	146-151
22554045-2	2012	We hypothesized that the COX-2 inhibitor nimesulide and the thromboxane A(2) receptor antagonist daltroban would attenuate HPV.	nimesulide	41-51	cytochrome c oxidase subunit II	Sus scrofa	25-30
22451531-1	2012	Nimesulide is a selective COX-2 inhibitor that is as effective as the classical non-acidic nonsteroidal anti-inflammatory drugs in the relief of various pain and inflammatory conditions, but is better tolerated with lower incidences of adverse effects than other drugs.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	26-31
22435708-1	2012	We previously developed a series of anticancer agents based on cyclooxygenase-2 (COX-2) inhibitor nimesulide as a lead compound.	nimesulide	98-108	prostaglandin-endoperoxide synthase 2	Homo sapiens	63-79
22435708-1	2012	We previously developed a series of anticancer agents based on cyclooxygenase-2 (COX-2) inhibitor nimesulide as a lead compound.	nimesulide	98-108	prostaglandin-endoperoxide synthase 2	Homo sapiens	81-86
22453101-1	2012	BACKGROUND: The objective of this study was to evaluate the efficacy of Nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, on the growth of hypopharyngeal carcinoma cells (FaDu) in vitro, and investigate its potential mechanism.	nimesulide	72-82	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-112
22453101-1	2012	BACKGROUND: The objective of this study was to evaluate the efficacy of Nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, on the growth of hypopharyngeal carcinoma cells (FaDu) in vitro, and investigate its potential mechanism.	nimesulide	72-82	prostaglandin-endoperoxide synthase 2	Homo sapiens	114-119
22453101-9	2012	The percentage of apoptosis in FaDu cells were markedly increased after Nimesulide-treatment for 6 h, 12 h and 24 h. Nimesulide down-regulated the Survivin and COX-2 expressions at mRNA and protein levels in FaDu cells.	nimesulide	72-82	prostaglandin-endoperoxide synthase 2	Homo sapiens	160-165
22453101-9	2012	The percentage of apoptosis in FaDu cells were markedly increased after Nimesulide-treatment for 6 h, 12 h and 24 h. Nimesulide down-regulated the Survivin and COX-2 expressions at mRNA and protein levels in FaDu cells.	nimesulide	117-127	prostaglandin-endoperoxide synthase 2	Homo sapiens	160-165
22107987-5	2012	Our results showed marked reduction of hepatic necrosis, serum ALT, and tissue TBARS levels in both indomethacin- and nimesulide-pre-treated mice when compared with Gal/LPS-treated mice.	nimesulide	118-128	glutamic pyruvic transaminase, soluble	Mus musculus	63-66
22228706-1	2012	We hypothesized that acute pharmacological blockade of cyclooxygenase-2 (COX-2) using nimesulide (Nime) would prevent maladaptive changes in left ventricular (LV) structure and function secondary to abdominal aortic coarctation-induced pressure overload (PO).	nimesulide	86-96	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	55-71
22119125-0	2012	From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.	nimesulide	21-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	5-10
22119125-1	2012	Cyclooxygenase-2 (COX-2) inhibitor nimesulide inhibits the proliferation of various types of cancer cells mainly via COX-2 independent mechanisms, which makes it a good lead compound for anti-cancer drug development.	nimesulide	35-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
22119125-1	2012	Cyclooxygenase-2 (COX-2) inhibitor nimesulide inhibits the proliferation of various types of cancer cells mainly via COX-2 independent mechanisms, which makes it a good lead compound for anti-cancer drug development.	nimesulide	35-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	18-23
22119125-1	2012	Cyclooxygenase-2 (COX-2) inhibitor nimesulide inhibits the proliferation of various types of cancer cells mainly via COX-2 independent mechanisms, which makes it a good lead compound for anti-cancer drug development.	nimesulide	35-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	117-122
22228706-1	2012	We hypothesized that acute pharmacological blockade of cyclooxygenase-2 (COX-2) using nimesulide (Nime) would prevent maladaptive changes in left ventricular (LV) structure and function secondary to abdominal aortic coarctation-induced pressure overload (PO).	nimesulide	86-96	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	73-78
22228706-1	2012	We hypothesized that acute pharmacological blockade of cyclooxygenase-2 (COX-2) using nimesulide (Nime) would prevent maladaptive changes in left ventricular (LV) structure and function secondary to abdominal aortic coarctation-induced pressure overload (PO).	nimesulide	98-102	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	55-71
22228706-1	2012	We hypothesized that acute pharmacological blockade of cyclooxygenase-2 (COX-2) using nimesulide (Nime) would prevent maladaptive changes in left ventricular (LV) structure and function secondary to abdominal aortic coarctation-induced pressure overload (PO).	nimesulide	98-102	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	73-78
22228706-8	2012	In summary, acute COX-2 inhibition with nimesulide attenuated the maladaptive changes in the LV after PO.	nimesulide	40-50	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	18-23
21920740-0	2011	Novel 1-alkynyl substituted 1,2-dihydroquinoline derivatives from nimesulide (and their 2-oxo analogues): a new strategy to identify inhibitors of PDE4B.	nimesulide	66-76	phosphodiesterase 4B	Homo sapiens	147-152
22509279-6	2012	Nimesulide reduced mitochondrial activity, depolarized mitochondria and caused membrane permeability transition (MPT) followed by release of apoptotic proteins (AIF; apoptosis inducing factor, EndoG; endonuclease G, and Cyto c; cytochrome c).	nimesulide	0-10	endonuclease G	Rattus norvegicus	193-198
22509279-6	2012	Nimesulide reduced mitochondrial activity, depolarized mitochondria and caused membrane permeability transition (MPT) followed by release of apoptotic proteins (AIF; apoptosis inducing factor, EndoG; endonuclease G, and Cyto c; cytochrome c).	nimesulide	0-10	endonuclease G	Rattus norvegicus	200-214
21873451-10	2011	In addition, treatment with the COX-2-selective inhibitor nimesulide potentiated the degree of airway fibrosis following repeated allergen challenge.	nimesulide	58-68	prostaglandin-endoperoxide synthase 2	Mus musculus	32-37
21920740-1	2011	A number of novel 1-(3-arylprop-2-ynyl) substituted 1,2-dihydroquinoline derivatives related to nimesulide and their 2-oxo analogues have been designed as potential inhibitors of PDE4.	nimesulide	96-106	phosphodiesterase 4A	Homo sapiens	179-183
21807508-0	2011	Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76.	nimesulide	64-74	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	48-53
21807508-1	2011	JCC76 is a derivative of cyclooxygenase-2(COX-2) selective inhibitor nimesulide and exhibits potent anti-breast cancer activity.	nimesulide	69-79	prostaglandin-endoperoxide synthase 2	Homo sapiens	25-41
21807508-1	2011	JCC76 is a derivative of cyclooxygenase-2(COX-2) selective inhibitor nimesulide and exhibits potent anti-breast cancer activity.	nimesulide	69-79	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	42-47
20803081-3	2011	METHODS: Human CRC cell lines with varying COX-2 expression levels were treated with Indo and Nim.	nimesulide	94-97	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-48
21458568-0	2011	In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells.	nimesulide	61-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	34-50
21461920-0	2011	Guggulipid and nimesulide differentially regulated inflammatory genes mRNA expressions via inhibition of NF-kB and CHOP activation in LPS-stimulated rat astrocytoma cells, C6.	nimesulide	15-25	nuclear factor kappa B subunit 1	Rattus norvegicus	105-110
21461920-0	2011	Guggulipid and nimesulide differentially regulated inflammatory genes mRNA expressions via inhibition of NF-kB and CHOP activation in LPS-stimulated rat astrocytoma cells, C6.	nimesulide	15-25	DNA-damage inducible transcript 3	Rattus norvegicus	115-119
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	nimesulide	15-25	nitric oxide synthase 2	Rattus norvegicus	66-70
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	nimesulide	15-25	nuclear factor kappa B subunit 1	Rattus norvegicus	72-77
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	nimesulide	15-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	83-88
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	nimesulide	15-25	interleukin 6	Rattus norvegicus	191-195
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	nimesulide	15-25	interleukin 1 alpha	Rattus norvegicus	197-206
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	nimesulide	15-25	interleukin 1 beta	Rattus norvegicus	208-216
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	nimesulide	15-25	prostaglandin E synthase	Mus musculus	222-229
21866634-1	2011	OBJECTIVE: To investigate the effect of a cyclooxygenase-2 inhibitor nimesulide on learning and memory function of rats after traumatic brain injury (TBI).	nimesulide	69-79	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	42-58
21866634-10	2011	A significantly decreased peak of COX-2 protein expression was observed in nimesulide treated group when compare with that of TBI (P < 0.05).	nimesulide	75-85	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	34-39
21491446-1	2011	Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) and a COX-2 inhibitor.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	66-71
21349729-0	2011	Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.	nimesulide	34-44	prostaglandin-endoperoxide synthase 2	Homo sapiens	92-110
21349729-0	2011	Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.	nimesulide	34-44	arachidonate 5-lipoxygenase	Homo sapiens	115-129
21349729-2	2011	In the present study, a variety of new nimesulide derivatives were synthesized through incorporation of a 5-LOX pharmacophore into nimesulide followed with some structural modifications, which were then characterized for dual enzyme inhibitors for these two types of enzymes.	nimesulide	39-49	arachidonate 5-lipoxygenase	Homo sapiens	106-111
21349729-2	2011	In the present study, a variety of new nimesulide derivatives were synthesized through incorporation of a 5-LOX pharmacophore into nimesulide followed with some structural modifications, which were then characterized for dual enzyme inhibitors for these two types of enzymes.	nimesulide	131-141	arachidonate 5-lipoxygenase	Homo sapiens	106-111
21862873-3	2011	In this study, we investigated the effect of three COX-2 inhibitors (nimesulide, NS-398 and celecoxib) on cell proliferation of leukemic and lymphoblastic cells expressing COX-2 at high (U937, Jurkat, Hel and Raji) and very low (K562) protein levels.	nimesulide	69-79	prostaglandin-endoperoxide synthase 2	Homo sapiens	172-177
21542630-1	2011	Dual target inhibitors against COX-2 and LTA(4)H were designed by adding functional groups from a marketed COX-2 inhibitor, Nimesulide, to an existing LTA(4)H inhibitor 1-(2-(4-phenoxyphenoxy) ethyl) pyrrolidine.	nimesulide	124-134	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	31-36
21542630-1	2011	Dual target inhibitors against COX-2 and LTA(4)H were designed by adding functional groups from a marketed COX-2 inhibitor, Nimesulide, to an existing LTA(4)H inhibitor 1-(2-(4-phenoxyphenoxy) ethyl) pyrrolidine.	nimesulide	124-134	leukotriene A4 hydrolase	Homo sapiens	41-48
21542630-1	2011	Dual target inhibitors against COX-2 and LTA(4)H were designed by adding functional groups from a marketed COX-2 inhibitor, Nimesulide, to an existing LTA(4)H inhibitor 1-(2-(4-phenoxyphenoxy) ethyl) pyrrolidine.	nimesulide	124-134	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	107-112
21079976-5	2011	Semi-quantitative RT-PCR analysis showed that the depigmentation effect of mefenamic acid and nimesulide might be due to the inhibition of tyrosinase gene transcription.	nimesulide	94-104	tyrosinase	Mus musculus	139-149
21448017-2	2011	The purpose of the present study was to investigate whether nimesulide (Nimesulida, Medley S.A., Campinas, SP, Brazil), a preferential cyclooxygenase-2 inhibitor, can hinder alveolar bone healing, in rats.	nimesulide	60-70	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	135-151
21448017-6	2011	CONCLUSION: Short-term treatment with nimesulide, although its capacity to inhibit preferentially the enzyme cyclooxygenase-2, does not interfere with alveolar bone healing in rats.	nimesulide	38-48	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	109-125
21882652-0	2011	Effect of caffeine, norfloxacin and nimesulide on heartbeat and VEGF expression of zebrafish larvae.	nimesulide	36-46	vascular endothelial growth factor Aa	Danio rerio	64-68
21882652-4	2011	Three drugs, caffeine, norfloxacin and nimesulide, were used for this study to see the effect mainly the hatching rate of eggs, heart beat rate and the vascular endothelial growth factor (VEGF) expression of the larvae.	nimesulide	39-49	vascular endothelial growth factor Aa	Danio rerio	152-186
20803081-0	2011	mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway.	nimesulide	47-57	mechanistic target of rapamycin kinase	Homo sapiens	0-4
20803081-0	2011	mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway.	nimesulide	47-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	109-114
20803081-2	2011	Here, we analyzed the effect of indomethacin (Indo, a nonselective COX-2 inhibitor) and nimesulide (Nim, a selective COX-2 inhibitor) on mTOR signaling in CRC cells in vitro and in vivo to determine the dependence of this effect on COX-2.	nimesulide	88-98	mechanistic target of rapamycin kinase	Homo sapiens	137-141
20803081-2	2011	Here, we analyzed the effect of indomethacin (Indo, a nonselective COX-2 inhibitor) and nimesulide (Nim, a selective COX-2 inhibitor) on mTOR signaling in CRC cells in vitro and in vivo to determine the dependence of this effect on COX-2.	nimesulide	100-103	mechanistic target of rapamycin kinase	Homo sapiens	137-141
20735790-3	2011	We assessed the influence of subchronic (21 days) and acute administration of nimesulide, a preferential cyclooxygenase-2 (COX-2) inhibitor, on mean blood pressure (MAP), renal blood flow (RBF), glomerular filtration rate (GFR) and urinary output (U(v)) in adult rats that were prenatally undernourished.	nimesulide	78-88	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	105-121
20735790-3	2011	We assessed the influence of subchronic (21 days) and acute administration of nimesulide, a preferential cyclooxygenase-2 (COX-2) inhibitor, on mean blood pressure (MAP), renal blood flow (RBF), glomerular filtration rate (GFR) and urinary output (U(v)) in adult rats that were prenatally undernourished.	nimesulide	78-88	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	123-128
20735790-7	2011	These findings demonstrate that prenatal nutritional programming differentially modulates adult renovascular responses to nimesulide in the cortex and medulla, which may exacerbate the deleterious effects of COX-2 inhibition in the kidney.	nimesulide	122-132	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	208-213
20803081-9	2011	Additionally, Indo and Nim could reduce the mTOR signaling activity after COX-2 silencing in CRC cells.	nimesulide	23-26	mechanistic target of rapamycin kinase	Homo sapiens	44-48
20803081-9	2011	Additionally, Indo and Nim could reduce the mTOR signaling activity after COX-2 silencing in CRC cells.	nimesulide	23-26	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
20803081-10	2011	CONCLUSIONS: mTOR signaling is involved in Indo- and Nim-mediated suppression of CRC growth via a COX-2 independent pathway.	nimesulide	53-56	mechanistic target of rapamycin kinase	Homo sapiens	13-17
20803081-10	2011	CONCLUSIONS: mTOR signaling is involved in Indo- and Nim-mediated suppression of CRC growth via a COX-2 independent pathway.	nimesulide	53-56	prostaglandin-endoperoxide synthase 2	Homo sapiens	98-103
19782545-5	2011	By contrast, an equipotent therapeutic dose of nimesulide reduced renal COX-1 expression within the first 24h of treatment.	nimesulide	47-57	cytochrome c oxidase I, mitochondrial	Mus musculus	72-77
21980345-0	2011	Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.	nimesulide	60-70	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	34-39
21811393-0	2011	Nimesulide inhibits protein kinase C epsilon and substance P in sensory neurons - comparison with paracetamol.	nimesulide	0-10	protein kinase C, epsilon	Rattus norvegicus	20-44
21811393-8	2011	The present results suggest that PKCe might be a target for the effect of nimesulide and paracetamol, while inhibition of SP synthesis and release is clearly more relevant for nimesulide than for paracetamol mechanism of action.	nimesulide	74-84	protein kinase C, epsilon	Rattus norvegicus	33-37
29913996-0	2010	The attenuation of pain behaviour and serum interleukin-6 concentration by nimesulide in a rat model of neuropathic pain.	nimesulide	75-85	interleukin 6	Rattus norvegicus	44-57
21159610-6	2010	Combining ligand activation of PPARbeta/delta with dietary nimesulide resulted in a further decrease of tumor multiplicity (58%) in wild-type mice but not in Pparbeta/delta-null mice.	nimesulide	59-69	peroxisome proliferator activator receptor delta	Mus musculus	158-166
21159610-8	2010	Increased levels and activity of PPARbeta/delta by nimesulide were also observed.	nimesulide	51-61	peroxisome proliferator activator receptor delta	Mus musculus	33-41
20939553-8	2010	We demonstrate here that the reduced nimesulide, M1, undergoes a facile oxidation with activated neutrophils or with MPO in the presence of H(2)O(2) or HOCl to produce a variety of reactive as well as stable metabolites.	nimesulide	37-47	myeloperoxidase	Homo sapiens	117-120
20939553-10	2010	Other metabolites, for example, M6, M8, and M9, were unique to the myeloperoxidase, because of their mode of formation from activation of the amino group of reduced nimesulide.	nimesulide	165-175	myeloperoxidase	Homo sapiens	67-82
20939553-13	2010	In summary, our results demonstrate that a known nimesulide metabolite could be bioactivated by MPO through a pathway distinct from HLM-mediated pathways and that the generation of reactive species by the MPO-mediated bioactivation pathway at the site of inflammation may contribute to the toxicity associated with nimesulide.	nimesulide	49-59	myeloperoxidase	Homo sapiens	96-99
20939553-13	2010	In summary, our results demonstrate that a known nimesulide metabolite could be bioactivated by MPO through a pathway distinct from HLM-mediated pathways and that the generation of reactive species by the MPO-mediated bioactivation pathway at the site of inflammation may contribute to the toxicity associated with nimesulide.	nimesulide	49-59	oxysterol binding protein 2	Homo sapiens	132-135
20939553-13	2010	In summary, our results demonstrate that a known nimesulide metabolite could be bioactivated by MPO through a pathway distinct from HLM-mediated pathways and that the generation of reactive species by the MPO-mediated bioactivation pathway at the site of inflammation may contribute to the toxicity associated with nimesulide.	nimesulide	49-59	myeloperoxidase	Homo sapiens	205-208
20939553-13	2010	In summary, our results demonstrate that a known nimesulide metabolite could be bioactivated by MPO through a pathway distinct from HLM-mediated pathways and that the generation of reactive species by the MPO-mediated bioactivation pathway at the site of inflammation may contribute to the toxicity associated with nimesulide.	nimesulide	315-325	myeloperoxidase	Homo sapiens	96-99
20939553-13	2010	In summary, our results demonstrate that a known nimesulide metabolite could be bioactivated by MPO through a pathway distinct from HLM-mediated pathways and that the generation of reactive species by the MPO-mediated bioactivation pathway at the site of inflammation may contribute to the toxicity associated with nimesulide.	nimesulide	315-325	myeloperoxidase	Homo sapiens	205-208
20542113-0	2010	COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.	nimesulide	16-26	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-5
20542113-1	2010	Cyclooxygenase-2 (COX-2) inhibitor nimesulide derivatives compounds A and B decreased aromatase activity in breast cancer cells via a novel mechanism different to aromatase inhibitors (AIs), and were defined as "aromatase suppressors".	nimesulide	35-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
20542113-1	2010	Cyclooxygenase-2 (COX-2) inhibitor nimesulide derivatives compounds A and B decreased aromatase activity in breast cancer cells via a novel mechanism different to aromatase inhibitors (AIs), and were defined as "aromatase suppressors".	nimesulide	35-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	18-23
29913996-19	2010	Conclusions It appears that nimesulide was able to reduce pain behaviour due to nerve inflammation and a parallel decrease in the serum IL-6 concentration was observed.	nimesulide	28-38	interleukin 6	Rattus norvegicus	136-140
20654654-7	2010	or nimesulide (5mg/kg) blocked behavioural changes induced by LPS in the FTS, TST, open field and light-dark box test.	nimesulide	3-13	AKT interacting protein	Mus musculus	73-76
20939553-0	2010	Neutrophil- and myeloperoxidase-mediated metabolism of reduced nimesulide: evidence for bioactivation.	nimesulide	63-73	myeloperoxidase	Homo sapiens	16-31
20702753-7	2010	Although AEA is hydrolyzed primarily by fatty acid amide hydrolase (FAAH), ex vivo autoradiography revealed that COX-2 inhibition by nimesulide redirected [(3)H]AEA substrate from COX-2 to FAAH in the cortex, hippocampus, thalamus, and periaqueductal gray.	nimesulide	133-143	fatty acid amide hydrolase	Mus musculus	51-66
20702753-7	2010	Although AEA is hydrolyzed primarily by fatty acid amide hydrolase (FAAH), ex vivo autoradiography revealed that COX-2 inhibition by nimesulide redirected [(3)H]AEA substrate from COX-2 to FAAH in the cortex, hippocampus, thalamus, and periaqueductal gray.	nimesulide	133-143	fatty acid amide hydrolase	Mus musculus	68-72
20702753-7	2010	Although AEA is hydrolyzed primarily by fatty acid amide hydrolase (FAAH), ex vivo autoradiography revealed that COX-2 inhibition by nimesulide redirected [(3)H]AEA substrate from COX-2 to FAAH in the cortex, hippocampus, thalamus, and periaqueductal gray.	nimesulide	133-143	prostaglandin-endoperoxide synthase 2	Mus musculus	113-118
20702753-7	2010	Although AEA is hydrolyzed primarily by fatty acid amide hydrolase (FAAH), ex vivo autoradiography revealed that COX-2 inhibition by nimesulide redirected [(3)H]AEA substrate from COX-2 to FAAH in the cortex, hippocampus, thalamus, and periaqueductal gray.	nimesulide	133-143	prostaglandin-endoperoxide synthase 2	Mus musculus	180-185
20702753-7	2010	Although AEA is hydrolyzed primarily by fatty acid amide hydrolase (FAAH), ex vivo autoradiography revealed that COX-2 inhibition by nimesulide redirected [(3)H]AEA substrate from COX-2 to FAAH in the cortex, hippocampus, thalamus, and periaqueductal gray.	nimesulide	133-143	fatty acid amide hydrolase	Mus musculus	189-193
29913996-9	2010	Nimesulide, a highly selective cox-2 inhibitor, effectively reduces hyperalgesia due to peripherally administration of inflammatory agents like formalin.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	31-36
21030939-3	2010	Nimesulide is the only NSAID related to the arylsulfonamide class and is a "COX-2 preferential NSAIDs", because despite having a prevalent effect on COX-2, has a balanced action on both cyclooxygenase.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	76-81
20457212-1	2010	Nimesulide (selective cyclooxygenase-2 inhibitor) is a nonsteroidal anti-inflammatory drug for the symptomatic treatment of painful conditions like osteoarthritis, spondilitis and primary dysmenorrhoea.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	22-38
20665602-5	2010	The results showed that after the endothelial cells were incubated with 250 muM of hydrogen peroxide for 12 h, apoptosis increased, which was antagonized by the cyclooxygenase-2 inhibitor nimesulide or the nonselective cyclooxygenase inhibitor aspirin, but not by the cyclooxygenase-1 inhibitor piroxicam.	nimesulide	188-198	prostaglandin-endoperoxide synthase 2	Homo sapiens	161-177
20665602-5	2010	The results showed that after the endothelial cells were incubated with 250 muM of hydrogen peroxide for 12 h, apoptosis increased, which was antagonized by the cyclooxygenase-2 inhibitor nimesulide or the nonselective cyclooxygenase inhibitor aspirin, but not by the cyclooxygenase-1 inhibitor piroxicam.	nimesulide	188-198	prostaglandin-endoperoxide synthase 1	Homo sapiens	268-284
20665602-6	2010	The expression of GRP78 was induced in endothelial cells after exposure to hydrogen peroxide for 12 h. The overexpression of GRP78 was inhibited by nimesulide and aspirin, but not by piroxicam.	nimesulide	148-158	heat shock protein family A (Hsp70) member 5	Homo sapiens	18-23
20665602-6	2010	The expression of GRP78 was induced in endothelial cells after exposure to hydrogen peroxide for 12 h. The overexpression of GRP78 was inhibited by nimesulide and aspirin, but not by piroxicam.	nimesulide	148-158	heat shock protein family A (Hsp70) member 5	Homo sapiens	125-130
21176579-1	2010	OBJECTIVE: To investigate the effects of Nimesulide, a selective Cox-2 inhibitor, on the apoptosis, invasion and migration of hypopharyngeal carcinoma cell line (FaDu).	nimesulide	41-51	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	65-70
21176579-6	2010	The mRNA and protein expressions of Cox-2, MMP-9 and caspase-3 in response to Nimesulide were examined by RT-PCR and Western blot, respectively.	nimesulide	78-88	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	36-41
21176579-6	2010	The mRNA and protein expressions of Cox-2, MMP-9 and caspase-3 in response to Nimesulide were examined by RT-PCR and Western blot, respectively.	nimesulide	78-88	matrix metallopeptidase 9	Homo sapiens	43-48
21176579-6	2010	The mRNA and protein expressions of Cox-2, MMP-9 and caspase-3 in response to Nimesulide were examined by RT-PCR and Western blot, respectively.	nimesulide	78-88	caspase 3	Homo sapiens	53-62
21176579-11	2010	Nimesulide decreased the expressions of Cox-2 and MMP-9, whereas increased expression the of Caspase-3.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	40-45
21176579-11	2010	Nimesulide decreased the expressions of Cox-2 and MMP-9, whereas increased expression the of Caspase-3.	nimesulide	0-10	matrix metallopeptidase 9	Homo sapiens	50-55
21176579-11	2010	Nimesulide decreased the expressions of Cox-2 and MMP-9, whereas increased expression the of Caspase-3.	nimesulide	0-10	caspase 3	Homo sapiens	93-102
20404772-3	2010	Nimesulide, a selective inhibitor of COX-2 that causes the breakdown of proinflammatory 2-series prostaglandins (PG2), adversely affected the growth of B16-F10 melanoma cells through the induction of differentiation.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	37-42
20404772-3	2010	Nimesulide, a selective inhibitor of COX-2 that causes the breakdown of proinflammatory 2-series prostaglandins (PG2), adversely affected the growth of B16-F10 melanoma cells through the induction of differentiation.	nimesulide	0-10	delta like non-canonical Notch ligand 1	Mus musculus	113-116
21030939-3	2010	Nimesulide is the only NSAID related to the arylsulfonamide class and is a "COX-2 preferential NSAIDs", because despite having a prevalent effect on COX-2, has a balanced action on both cyclooxygenase.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	149-154
21030939-6	2010	From the standpoint of safety, nimesulide arises NSAIDs with lower risk of upper gastrointestinal bleeding thanks to its preferential activity on COX-2.	nimesulide	31-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	146-151
20445154-8	2010	Pretreatment with nimesulide (10 mg iv, n = 6), a specific inhibitor of PGHS-2, significantly reduced the HPA axis response to NMDA.	nimesulide	18-28	prostaglandin G/H synthase 2	Ovis aries	72-78
20405857-0	2010	Nimesulide-induced electrophile stress activates Nrf2 in human hepatocytes and mice but is not sufficient to induce hepatotoxicity in Nrf2-deficient mice.	nimesulide	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	49-53
20882760-2	2010	The present study evaluated the neuroprotective effect of nimesulide, a preferential COX-2-inhibitor against 1-methyl-4-phenyl-1,2,3,6-tertahydropyridine (MPTP)-model of Parkinson"s disease.	nimesulide	58-68	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	85-90
20590570-4	2010	Here, the effect of the COX-2 inhibitor nimesulide, which does not inhibit fatty acid amide hydrolase, on spinal nociceptive processing was determined.	nimesulide	40-50	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	24-29
20590570-11	2010	CONCLUSIONS AND IMPLICATIONS: Although the inhibitory effects of COX-2 blockade on spinal neuronal responses by nimesulide were dependent on CB(1) receptors, we did not detect a concomitant elevation in anandamide or 2-AG.	nimesulide	112-122	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	65-70
20004922-4	2010	The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).	nimesulide	183-193	cytochrome c oxidase subunit II	Canis lupus familiaris	48-53
20004922-4	2010	The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).	nimesulide	183-193	cytochrome c oxidase subunit I	Canis lupus familiaris	61-66
20405857-3	2010	Also, we explored whether nimesulide can activate the transcription factor Nrf2 that would protect from drug-induced hepatocyte injury.	nimesulide	26-36	nuclear factor, erythroid derived 2, like 2	Mus musculus	75-79
20405857-5	2010	Although exposure of hepatocytes to nimesulide was not associated with increased net levels of superoxide anion, nimesulide (100 microM, 24 h) caused nuclear translocation of Nrf2 in a sulfaphenazole-sensitive manner, indicating a role of electrophilic metabolites.	nimesulide	113-123	nuclear factor, erythroid derived 2, like 2	Mus musculus	175-179
20405857-7	2010	Similarly, exposure of wild-type C57BL/6x129 Sv mice to nimesulide (100 mg/kg/day, po, for 5 days) was associated with nuclear translocation of immunoreactive Nrf2 in a small number of hepatocytes and induced >2-fold the expression levels of the Nrf2-target gene Nqo1 in wild-type but not Nrf2-null mice.	nimesulide	56-66	nuclear factor, erythroid derived 2, like 2	Mus musculus	159-163
20405857-7	2010	Similarly, exposure of wild-type C57BL/6x129 Sv mice to nimesulide (100 mg/kg/day, po, for 5 days) was associated with nuclear translocation of immunoreactive Nrf2 in a small number of hepatocytes and induced >2-fold the expression levels of the Nrf2-target gene Nqo1 in wild-type but not Nrf2-null mice.	nimesulide	56-66	nuclear factor, erythroid derived 2, like 2	Mus musculus	249-253
20405857-7	2010	Similarly, exposure of wild-type C57BL/6x129 Sv mice to nimesulide (100 mg/kg/day, po, for 5 days) was associated with nuclear translocation of immunoreactive Nrf2 in a small number of hepatocytes and induced >2-fold the expression levels of the Nrf2-target gene Nqo1 in wild-type but not Nrf2-null mice.	nimesulide	56-66	NAD(P)H dehydrogenase, quinone 1	Mus musculus	266-270
20405857-7	2010	Similarly, exposure of wild-type C57BL/6x129 Sv mice to nimesulide (100 mg/kg/day, po, for 5 days) was associated with nuclear translocation of immunoreactive Nrf2 in a small number of hepatocytes and induced >2-fold the expression levels of the Nrf2-target gene Nqo1 in wild-type but not Nrf2-null mice.	nimesulide	56-66	nuclear factor, erythroid derived 2, like 2	Mus musculus	249-253
20405857-9	2010	In conclusion, these data indicate that nimesulide is bioactivated by CYP2C to a protein-reactive electrophilic intermediate that activates the Nrf2 pathway even at nontoxic exposure levels.	nimesulide	40-50	cytochrome P450, family 2, subfamily c, polypeptide 29	Mus musculus	70-75
20405857-9	2010	In conclusion, these data indicate that nimesulide is bioactivated by CYP2C to a protein-reactive electrophilic intermediate that activates the Nrf2 pathway even at nontoxic exposure levels.	nimesulide	40-50	nuclear factor, erythroid derived 2, like 2	Mus musculus	144-148
20136845-0	2010	The COX-2 inhibitors, meloxicam and nimesulide, suppress neurogenesis in the adult mouse brain.	nimesulide	36-46	cytochrome c oxidase II, mitochondrial	Mus musculus	4-9
20091905-3	2010	This study was undertaken to determine if incorporation of nimesulide (NM), a selective cyclooxygenase (COX)-2 inhibitor, could reduce the extent and tenacity of intraabdominal adhesion formation associated with SIS implantation.	nimesulide	59-69	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	88-110
20091905-3	2010	This study was undertaken to determine if incorporation of nimesulide (NM), a selective cyclooxygenase (COX)-2 inhibitor, could reduce the extent and tenacity of intraabdominal adhesion formation associated with SIS implantation.	nimesulide	71-73	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	88-110
20230693-4	2010	RESULTS: Nimesulide (1 micromol/L) caused gammadeltaT cells to express more of perforin and granzyme B (62.8% and 72.7%, respectively) than the control group (51.4% and 60.9%, respectively) (P<0.05).	nimesulide	9-19	granzyme B	Homo sapiens	92-102
20230693-5	2010	Likewise, nimesulide (1 micromol/L) enabled gammadeltaT cells to secret more of IFN-gamma and TNF-alpha (262.3 ng/L and 177.5 ng/L, respectively) than the control group (196.1 ng/L and 158.5 ng/L, respectively) (P<0.05).	nimesulide	10-20	interferon gamma	Homo sapiens	80-89
20230693-5	2010	Likewise, nimesulide (1 micromol/L) enabled gammadeltaT cells to secret more of IFN-gamma and TNF-alpha (262.3 ng/L and 177.5 ng/L, respectively) than the control group (196.1 ng/L and 158.5 ng/L, respectively) (P<0.05).	nimesulide	10-20	tumor necrosis factor	Homo sapiens	94-103
20230693-8	2010	CONCLUSION: Nimesulide made gammadeltaT cells to express more perforin and granzyme B and to secret more IFN-gamma and TNF-alpha into the supernatant, leading to higher killing rate of SGC-7901 and BCG-823 gastric cancer cells.	nimesulide	12-22	granzyme B	Homo sapiens	75-85
20230693-8	2010	CONCLUSION: Nimesulide made gammadeltaT cells to express more perforin and granzyme B and to secret more IFN-gamma and TNF-alpha into the supernatant, leading to higher killing rate of SGC-7901 and BCG-823 gastric cancer cells.	nimesulide	12-22	interferon gamma	Homo sapiens	105-114
20230693-8	2010	CONCLUSION: Nimesulide made gammadeltaT cells to express more perforin and granzyme B and to secret more IFN-gamma and TNF-alpha into the supernatant, leading to higher killing rate of SGC-7901 and BCG-823 gastric cancer cells.	nimesulide	12-22	tumor necrosis factor	Homo sapiens	119-128
24778826-3	2010	Based on the Biopharmaceutical Classification System (BCS), Nimesulide is considered a BCS 2 drug (poorly soluble and highly permeable).	nimesulide	60-70	PR/SET domain 5	Homo sapiens	87-92
20014174-9	2010	Our results show a notable increase (325%, 2002-2007) of the "stronger cyclooxygenase 2 inhibitor group" (nimesulide and meloxicam).	nimesulide	106-116	prostaglandin-endoperoxide synthase 2	Homo sapiens	71-87
20018235-5	2010	Both guggulipid and nimesulide significantly attenuated nitrite release, ROS generation and also down regulated expressions of COX-2, GFAP and TNF-alpha.	nimesulide	20-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	127-132
20018235-5	2010	Both guggulipid and nimesulide significantly attenuated nitrite release, ROS generation and also down regulated expressions of COX-2, GFAP and TNF-alpha.	nimesulide	20-30	glial fibrillary acidic protein	Rattus norvegicus	134-138
20018235-5	2010	Both guggulipid and nimesulide significantly attenuated nitrite release, ROS generation and also down regulated expressions of COX-2, GFAP and TNF-alpha.	nimesulide	20-30	tumor necrosis factor	Rattus norvegicus	143-152
20043093-8	2010	To examine whether this experimental system is useful for screening of the candidate agents for cancer preventive effect, nimesulide, a selective COX2 inhibitor, was tested in the present model.	nimesulide	122-132	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	146-150
20043093-10	2010	Treatment of Hras128 rats with nimesulide caused a significant decrease in the levels of mRNA expression of cyclin D1 and COX2 in the tumor.	nimesulide	31-41	cyclin D1	Rattus norvegicus	108-117
20043093-10	2010	Treatment of Hras128 rats with nimesulide caused a significant decrease in the levels of mRNA expression of cyclin D1 and COX2 in the tumor.	nimesulide	31-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	122-126
19786061-0	2010	Interaction of nimesulide, a cyclooxygenase-2 inhibitor, with cisplatin in normotensive and spontaneously hypertensive rats.	nimesulide	15-25	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	29-45
19786061-1	2010	We investigated the effect of administration of nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, on cisplatin (CP)-induced nephrotoxicity in rats.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	72-88
19786061-1	2010	We investigated the effect of administration of nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, on cisplatin (CP)-induced nephrotoxicity in rats.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	90-95
19894761-4	2009	As a test, we examined the effects of three competitive inhibitors (nimesulide, flurbiprofen, and diclofenac) on the proportions and stability of the two radicals in PGHS-2 pretreated with peroxide.	nimesulide	68-78	prostaglandin-endoperoxide synthase 2	Homo sapiens	166-172
19748995-5	2010	After 22 weeks, cohorts of both mouse lines were divided into four experimental groups: (1) control, (2) topical application of the PPARbeta/delta ligand GW0742, (3) dietary administration of the COX-2 inhibitor nimesulide, or (4) both GW0742 and nimesulide.	nimesulide	212-222	prostaglandin-endoperoxide synthase 2	Mus musculus	196-201
19748995-7	2010	Interestingly, the combined treatment of GW0742 and nimesulide increased the efficacy of the decrease in papilloma multiplicity for 6 weeks in wild-type mice, but this effect was not found at later time points and was not found in similarly treated Pparbeta/delta-null mice.	nimesulide	52-62	peroxisome proliferator activator receptor delta	Mus musculus	249-257
22272001-2	2009	Both compounds did not alter the expression of cytochrome P450 (CYP) 2E1, the enzyme that plays a major role in the activation of DEN to genotoxic products; however, nimesulide induced the expression of CYP1A1.	nimesulide	166-176	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	203-209
19854050-0	2009	Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.	nimesulide	37-47	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	21-26
19854050-0	2009	Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.	nimesulide	37-47	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	68-77
19854050-1	2009	A series of COX-2 selective inhibitor nimesulide derivatives were synthesized.	nimesulide	38-48	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	12-17
19791801-0	2009	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.	nimesulide	22-32	prostaglandin-endoperoxide synthase 1	Homo sapiens	118-140
19791801-3	2009	In the present study, we report the synthesis and the pharmacological evaluation of pyridine analogues of nimesulide, a COX-2 preferential inhibitor.	nimesulide	106-116	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	120-125
19950766-2	2009	Nimesulide is a selective cyclooxygenase-2 inhibitor, whose adverse effects on the liver range from acute hepatitis to more serious conditions, involving the development of acute liver failure and fatal outcome.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	26-42
19360361-0	2009	Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29
19638440-4	2009	Nimesulide significantly decreased nitrotyrosine in plasma (p < .0001), frontal gray IL1beta (p = .03), and heart IL1beta (p = .02).	nimesulide	0-10	interleukin 1 beta	Canis lupus familiaris	88-95
19638440-4	2009	Nimesulide significantly decreased nitrotyrosine in plasma (p < .0001), frontal gray IL1beta (p = .03), and heart IL1beta (p = .02).	nimesulide	0-10	interleukin 1 beta	Canis lupus familiaris	117-124
19428334-0	2009	A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.	nimesulide	18-28	prostaglandin-endoperoxide synthase 2	Homo sapiens	2-7
19428334-0	2009	A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.	nimesulide	18-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
19428334-0	2009	A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.	nimesulide	18-28	cytochrome c, somatic	Homo sapiens	113-125
19428334-2	2009	The cyclooxygenase-2 (COX-2) inhibitor nimesulide shows anti-cancer effect in different type of cancers.	nimesulide	39-49	prostaglandin-endoperoxide synthase 2	Homo sapiens	4-20
19428334-2	2009	The cyclooxygenase-2 (COX-2) inhibitor nimesulide shows anti-cancer effect in different type of cancers.	nimesulide	39-49	prostaglandin-endoperoxide synthase 2	Homo sapiens	22-27
19524064-5	2009	The retinal vasodilator responses to BK were significantly attenuated by treatment with either indomethacin, a non-selective COX inhibitor, or nimesulide, a selective COX-2 inhibitor, but not with SC-560, a selective COX-1 inhibitor.	nimesulide	143-153	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	167-172
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	73-83	BH3 interacting domain death agonist	Homo sapiens	167-170
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	73-83	caspase 8	Homo sapiens	152-161
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	234-244	caspase 8	Homo sapiens	37-46
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	234-244	caspase 9	Homo sapiens	130-139
19360361-0	2009	Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3.	nimesulide	0-10	caspase 8	Homo sapiens	149-158
19360361-0	2009	Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3.	nimesulide	0-10	caspase 3	Homo sapiens	163-172
19360361-3	2009	The combined nimesulide-radiation treatment increased apoptosis, induced the cleavage of caspase-3, caspase-9, and poly(ADP-ribose) polymerase (PARP), activated caspase-8, and induced cleavage of Bid.	nimesulide	13-23	caspase 3	Homo sapiens	89-98
19360361-3	2009	The combined nimesulide-radiation treatment increased apoptosis, induced the cleavage of caspase-3, caspase-9, and poly(ADP-ribose) polymerase (PARP), activated caspase-8, and induced cleavage of Bid.	nimesulide	13-23	caspase 9	Homo sapiens	100-109
19360361-3	2009	The combined nimesulide-radiation treatment increased apoptosis, induced the cleavage of caspase-3, caspase-9, and poly(ADP-ribose) polymerase (PARP), activated caspase-8, and induced cleavage of Bid.	nimesulide	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	115-142
19360361-3	2009	The combined nimesulide-radiation treatment increased apoptosis, induced the cleavage of caspase-3, caspase-9, and poly(ADP-ribose) polymerase (PARP), activated caspase-8, and induced cleavage of Bid.	nimesulide	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	144-148
19360361-3	2009	The combined nimesulide-radiation treatment increased apoptosis, induced the cleavage of caspase-3, caspase-9, and poly(ADP-ribose) polymerase (PARP), activated caspase-8, and induced cleavage of Bid.	nimesulide	13-23	caspase 8	Homo sapiens	161-170
19360361-3	2009	The combined nimesulide-radiation treatment increased apoptosis, induced the cleavage of caspase-3, caspase-9, and poly(ADP-ribose) polymerase (PARP), activated caspase-8, and induced cleavage of Bid.	nimesulide	13-23	BH3 interacting domain death agonist	Homo sapiens	196-199
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	73-83	caspase 8	Homo sapiens	37-46
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	73-83	caspase 9	Homo sapiens	130-139
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	73-83	caspase 3	Homo sapiens	141-150
19360361-5	2009	In addition, z-IETD-fmk, a selective caspase-8 inhibitor, suppressed the nimesulide- and radiation-induced cleavage activation of caspase-9, caspase-3, caspase-8, and Bid, and suppressed the concomitant apoptosis, indicating that the nimesulide-induced increase in radiosensitivity was initiated by caspase-8.	nimesulide	73-83	caspase 8	Homo sapiens	152-161
19152549-3	2009	We compared the effects of acetylsalicylic acid, ibuprofen, nabumetone and nimesulide on COX-1 and COX-2 pathways in healthy volunteers in an ex vivo set-up using single oral doses commonly used to treat acute pain.	nimesulide	75-85	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	89-94
19046800-0	2009	Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms.	nimesulide	0-10	interferon gamma	Homo sapiens	20-29
19046800-0	2009	Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms.	nimesulide	0-10	CD274 molecule	Homo sapiens	38-65
19046800-0	2009	Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	111-116
19046800-4	2009	In the present study, we examined the effects of nimesulide, a selective COX-2 inhibitor, on PD-L1 surface expression in breast cancer cells by flow cytometry.	nimesulide	49-59	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	73-78
19046800-4	2009	In the present study, we examined the effects of nimesulide, a selective COX-2 inhibitor, on PD-L1 surface expression in breast cancer cells by flow cytometry.	nimesulide	49-59	CD274 molecule	Homo sapiens	93-98
19046800-5	2009	We demonstrated that nimesulide was able to inhibit IFN-gamma-induced PD-L1 surface expression in breast cancer cells.	nimesulide	21-31	interferon gamma	Homo sapiens	52-61
19046800-5	2009	We demonstrated that nimesulide was able to inhibit IFN-gamma-induced PD-L1 surface expression in breast cancer cells.	nimesulide	21-31	CD274 molecule	Homo sapiens	70-75
19152549-10	2009	Nimesulide caused almost complete suppression of COX-2 activity and a partial reduction of COX-1 activity.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	49-54
19152549-10	2009	Nimesulide caused almost complete suppression of COX-2 activity and a partial reduction of COX-1 activity.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	91-96
19152549-11	2009	This confirms the relative COX-2 selectivity of nimesulide.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-32
19440670-0	2009	The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells.	nimesulide	31-41	prostaglandin-endoperoxide synthase 2	Homo sapiens	4-20
19152549-3	2009	We compared the effects of acetylsalicylic acid, ibuprofen, nabumetone and nimesulide on COX-1 and COX-2 pathways in healthy volunteers in an ex vivo set-up using single oral doses commonly used to treat acute pain.	nimesulide	75-85	prostaglandin-endoperoxide synthase 2	Homo sapiens	99-104
19793025-4	2009	The expression of MDR1 mRNA was increased by diclofenac, fenbufen, indomethacin, and nimesulide and the tended to be increased by meloxicam, mepirizole, and sulindac.	nimesulide	85-95	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
19099228-0	2008	Four-week administration of nimesulide, a cyclooxygenase-2 inhibitor, improves endothelial dysfunction in the hindlimb vasculature of streptozotocin-induced diabetic rats.	nimesulide	28-38	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	42-58
20214021-0	2009	Suppression of constitutively expressed cyclooxygenase-2 in the epididymis of mice by nimesulide decreases sperm motility.	nimesulide	86-96	prostaglandin-endoperoxide synthase 2	Mus musculus	40-56
20214021-3	2009	The present study aims at localizing COX-2 in the epididymis and analyzing the effects of the preferential COX-2 inhibitor nimesulide.	nimesulide	123-133	prostaglandin-endoperoxide synthase 2	Mus musculus	107-112
20214021-6	2009	Nimesulide administration induced a significant reduction in both COX-2 staining intensity and protein activity, followed by an initial decline in total prostaglandin levels but a reversible increase upon sustained COX-2 suppression.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	66-71
20214021-6	2009	Nimesulide administration induced a significant reduction in both COX-2 staining intensity and protein activity, followed by an initial decline in total prostaglandin levels but a reversible increase upon sustained COX-2 suppression.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	215-220
19235548-1	2009	Mechanism of interaction of six cox-2 inhibitors--celecoxib, valdecoxib, etoricoxib, parecoxib sodium, meloxicam and nimesulide--with bovine serum albumin (BSA) was studied using fluorescence spectroscopic technique.	nimesulide	117-127	albumin	Homo sapiens	141-154
19099228-1	2008	The aim of this study was to examine the effect of chronic administration of nimesulide, a cyclooxygenase-2 inhibitor, on endothelial dysfunction in streptozotocin-induced diabetic rats.	nimesulide	77-87	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	91-107
19099228-4	2008	The third group received the selective COX-2 inhibitor, nimesulide (20 mg/kg/day), orally by gavage for 4 weeks while the second group received only drinking water and served as diabetic control.	nimesulide	56-66	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	39-44
19099228-11	2008	In conclusion, chronic administration of the selective COX-2 inhibitor, nimesulide improved endothelial dysfunction in the hindlimb vasculature of streptozotocin induced diabetic rats.	nimesulide	72-82	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	55-60
18329216-1	2008	Nimesulide, a Cox-2 inhibitor anti-inflammatory drug, is a light sensitive compound and its biological activity is decreased upon photodegradation.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
18848576-4	2008	While the catalytic activity of COX-2 was observed to increase in the senescence process, we found that among three selective COX-2 inhibitors studied, only NS-398 inhibited the senescence whereas celecoxib and nimesulide accelerated the senescence.	nimesulide	211-221	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
18806603-4	2008	To determine the effects of COX-2 inhibition on infarct size after E2 treatment, New Zealand white rabbits were anesthetized and administered the COX-2 inhibitor nimesulide (5 mg/kg) or vehicle intravenously 30 minutes before an intravenous injection of E2.	nimesulide	162-172	cytochrome c oxidase subunit II	Oryctolagus cuniculus	146-151
19356094-0	2008	Allosteric modulation of SULT2A1 by celecoxib and nimesulide: computational analyses.	nimesulide	50-60	sulfotransferase family 2A member 1	Homo sapiens	25-32
18581209-5	2008	RESULTS: The chronic exposure of Caco-2 to indomethacin heptyl ester (indo HE) (0.4 muM) or nimesulide (10 muM) (selective COX-2 inhibitors) and naproxen (6 muM) (non selective inhibitor COX-1/COX-2) significantly decreased the expression and activity of P-gp.	nimesulide	92-102	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	123-128
18450957-10	2008	Nimesulide reduced PGHS-2 mRNA and increased PGHS-2 protein, while not altering PGHS-1 mRNA or protein in most brain regions, suggesting an effect of the inhibitor on PGHS-2 turnover and relative specificity for PGHS-2 in vivo.	nimesulide	0-10	prostaglandin G/H synthase 2	Ovis aries	19-25
18450957-10	2008	Nimesulide reduced PGHS-2 mRNA and increased PGHS-2 protein, while not altering PGHS-1 mRNA or protein in most brain regions, suggesting an effect of the inhibitor on PGHS-2 turnover and relative specificity for PGHS-2 in vivo.	nimesulide	0-10	prostaglandin G/H synthase 2	Ovis aries	45-51
18450957-10	2008	Nimesulide reduced PGHS-2 mRNA and increased PGHS-2 protein, while not altering PGHS-1 mRNA or protein in most brain regions, suggesting an effect of the inhibitor on PGHS-2 turnover and relative specificity for PGHS-2 in vivo.	nimesulide	0-10	prostaglandin G/H synthase 2	Ovis aries	45-51
18450957-10	2008	Nimesulide reduced PGHS-2 mRNA and increased PGHS-2 protein, while not altering PGHS-1 mRNA or protein in most brain regions, suggesting an effect of the inhibitor on PGHS-2 turnover and relative specificity for PGHS-2 in vivo.	nimesulide	0-10	prostaglandin G/H synthase 2	Ovis aries	45-51
18534634-11	2008	The finding that PPARalpha antagonism blocked the inhibitory effects of nimesulide and URB597 suggests that PPARalpha contributes to their antinociceptive effects in the carrageenan model of inflammatory hyperalgesia.	nimesulide	72-82	peroxisome proliferator activated receptor alpha	Homo sapiens	17-26
18534634-11	2008	The finding that PPARalpha antagonism blocked the inhibitory effects of nimesulide and URB597 suggests that PPARalpha contributes to their antinociceptive effects in the carrageenan model of inflammatory hyperalgesia.	nimesulide	72-82	peroxisome proliferator activated receptor alpha	Homo sapiens	108-117
18515226-1	2008	The purpose of this study was to compare the topical anti-inflammatory effects of the nonselective cyclooxygenase (COX) inhibitor, ketorolac, with the selective COX-2 inhibitor, nimesulide, in an animal model of dry eye in albino rabbits.	nimesulide	178-188	cytochrome c oxidase subunit II	Oryctolagus cuniculus	161-166
18515226-6	2008	The use of selective COX-2 inhibitor, nimesulide, is preferred to avoid local and systemic side effects which may occur with the use of the nonselective COX inhibitor, ketorolac.	nimesulide	38-48	cytochrome c oxidase subunit II	Oryctolagus cuniculus	21-26
18481165-6	2008	Administration of nimesulide, a highly specific COX-2 inhibitor, significantly reduced PGE-2 levels in vulnerable regions but, rather than being neuroprotective, precipitated encephalopathy and exacerbated neuronal cell death due to TD.	nimesulide	18-28	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	48-53
18380483-3	2008	The cyclooxygenase-2 (COX-2) inhibitor nimesulide shows anticancer effects in several cancer cell lines via COX-2-dependent and -independent mechanisms.	nimesulide	39-49	prostaglandin-endoperoxide synthase 2	Homo sapiens	4-20
18407349-5	2008	Our results show that selective COX2 inhibitor (Nimesulide) inhibits decidualization while COX1 inhibitor (SC560) does not affect decidualization.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Mus musculus	32-36
18380483-3	2008	The cyclooxygenase-2 (COX-2) inhibitor nimesulide shows anticancer effects in several cancer cell lines via COX-2-dependent and -independent mechanisms.	nimesulide	39-49	prostaglandin-endoperoxide synthase 2	Homo sapiens	22-27
18380483-3	2008	The cyclooxygenase-2 (COX-2) inhibitor nimesulide shows anticancer effects in several cancer cell lines via COX-2-dependent and -independent mechanisms.	nimesulide	39-49	prostaglandin-endoperoxide synthase 2	Homo sapiens	108-113
18439837-1	2008	Nimesulide is a preferential inhibitor of cyclooxygenase-2 (COX-2) and it is one of the most prescribed non-steroidal anti-inflammatory drugs (NSAID) worldwide.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	42-58
18439837-1	2008	Nimesulide is a preferential inhibitor of cyclooxygenase-2 (COX-2) and it is one of the most prescribed non-steroidal anti-inflammatory drugs (NSAID) worldwide.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	60-65
18266822-12	2008	Nimesulide also decreased ornithine decarboxylase expression and the nuclear accumulation of nuclear factor kappa B transcriptionally active protein complexes.	nimesulide	0-10	ornithine decarboxylase, structural 1	Mus musculus	26-49
18271519-2	2008	Previously, the COX-2 selective inhibitor nimesulide and analogs decreased aromatase expression and enzyme activity independent of COX-2 inhibition.	nimesulide	42-52	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	16-21
18079364-5	2008	Nimesulide, a preferential COX-2 inhibitor, protected rats with TNBS-induced colitis (TNBS-colitis) against the down-regulation of hepatic CYP3A2.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	27-32
18079364-5	2008	Nimesulide, a preferential COX-2 inhibitor, protected rats with TNBS-induced colitis (TNBS-colitis) against the down-regulation of hepatic CYP3A2.	nimesulide	0-10	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	139-145
18266822-0	2008	Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.	nimesulide	27-37	prostaglandin-endoperoxide synthase 2	Mus musculus	0-16
17604186-0	2007	Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.	nimesulide	26-36	cytochrome c oxidase II, mitochondrial	Mus musculus	53-58
18256803-0	2008	Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors.	nimesulide	11-21	prostaglandin-endoperoxide synthase 2	Mus musculus	25-41
17893232-6	2008	Inhibition of COX2 by nimesulide attenuated colon cancer and ligand activation of PPARbeta/delta by GW0742 had inhibitory effects.	nimesulide	22-32	prostaglandin-endoperoxide synthase 2	Mus musculus	14-18
18333314-6	2008	This data suggests that gastrointestinal side effects of classic NSAIDs cannot be related to the COX-1 inhibition alone and also suggest that nimesulide is an atypical NSAID, which is different from both non-selective and selective COX-2 inhibitors.	nimesulide	142-152	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	97-102
18197933-6	2008	Both aspirin (5-20 mmol/L) and Nimesulide (0.1-0.8 mmol/L) inhibited EC-9706 cell line proliferation and suppressed its COX-2 mRNA expression dose-dependently.	nimesulide	31-41	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-125
18488158-0	2008	Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.	nimesulide	51-61	prostaglandin-endoperoxide synthase 2	Homo sapiens	23-39
18488158-3	2008	This study was designed to investigate whether nimesulide, a COX-2 selective inhibitor, could suppress tumor growth in implanted ovarian carcinoma mice and to explore the molecular mechanisms.	nimesulide	47-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	61-66
23392785-6	2007	Results from clinical studies in these patient groups show that NSAIDs such as nimesulide, with its preferential inhibitory activity on the COX-2 isoform and the lack of a topical effect, do not influence the evolution of IBD in patients requiring NSAID treatment for concomitant arthritic complaints.	nimesulide	79-89	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	140-145
23392786-5	2007	The NSAID nimesulide, along with its preferential activity on COX-2 and a short half-life that correlates with a rapid onset of analgesic action, acts also through a variety of COX-independent pathways that contributes to its potent antiinflammatory and analgesic activity.	nimesulide	10-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	62-67
23392786-6	2007	The pathways affected by nimesulide include inhibition of tumour necrosis factor alpha (TNF-alpha) release, histamine release, reactive oxygen species production and chondrocyte death.	nimesulide	25-35	tumor necrosis factor	Homo sapiens	88-97
18178179-3	2008	Pre-treatment with COX-2 inhibitors such as indomethacin, nimesulide, and celecoxib is known to aggravate kainic acid (KA)-induced seizure activity.	nimesulide	58-68	cytochrome c oxidase II, mitochondrial	Mus musculus	19-24
18509974-4	2008	The expressions of VEGF-C mRNA and protein were detected by reverse transcription polymerase chain reaction (RT-PCR) and Western blot in MDA-MB-231 cell lines by the treatment of selective COX-2 inhibitor Nimesulide at different doses.	nimesulide	205-215	vascular endothelial growth factor C	Homo sapiens	19-25
18509974-4	2008	The expressions of VEGF-C mRNA and protein were detected by reverse transcription polymerase chain reaction (RT-PCR) and Western blot in MDA-MB-231 cell lines by the treatment of selective COX-2 inhibitor Nimesulide at different doses.	nimesulide	205-215	prostaglandin-endoperoxide synthase 2	Homo sapiens	189-194
18509974-10	2008	Nimesulide could down-regulate the expressions of VEGF-C mRNA and protein in a does-dependent manner, while PGE2 could up-regulate the expressions.	nimesulide	0-10	vascular endothelial growth factor C	Homo sapiens	50-56
18090373-9	2008	The COX-1 and COX-2 inhibitor aspirin (10(-6)-10(-5) mol/L) and the COX-2 inhibitor nimesulide (10(-6) mol/L) induced leftward shifts of the concentration-response curve for vasopressin in gastroepiploic artery.	nimesulide	84-94	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	68-73
18090373-9	2008	The COX-1 and COX-2 inhibitor aspirin (10(-6)-10(-5) mol/L) and the COX-2 inhibitor nimesulide (10(-6) mol/L) induced leftward shifts of the concentration-response curve for vasopressin in gastroepiploic artery.	nimesulide	84-94	arginine vasopressin	Homo sapiens	174-185
18090373-12	2008	CONCLUSION: The results provide functional evidence that aspirin at high concentrations and the COX-2 selective inhibitor nimesulide potentiate the contractile response of gastroepiploic artery to vasopressin, thus suggesting the release of relaxant prostaglandins by the peptide.	nimesulide	122-132	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	96-101
18090373-12	2008	CONCLUSION: The results provide functional evidence that aspirin at high concentrations and the COX-2 selective inhibitor nimesulide potentiate the contractile response of gastroepiploic artery to vasopressin, thus suggesting the release of relaxant prostaglandins by the peptide.	nimesulide	122-132	arginine vasopressin	Homo sapiens	197-208
17604186-3	2007	With this background, the present study was designed to explore the possible effect of nimesulide (a preferential COX-2 inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.	nimesulide	87-97	cytochrome c oxidase II, mitochondrial	Mus musculus	114-119
17604186-13	2007	These results suggested that nimesulide, a preferential COX-2 inhibitor offered neuroprotection against PTZ-induced kindling in mice.	nimesulide	29-39	cytochrome c oxidase II, mitochondrial	Mus musculus	56-61
17766482-10	2007	The G(i) protein inhibitor, pertussis toxin (PTX), the protein kinase A (PKA) inhibitor, KT-5720, and the specific cyclooxygenase 2 (COX-2) inhibitor, nimesulide, reversed the LPS-induced reduction in peak I(Ca,L).	nimesulide	151-161	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	115-131
17689613-1	2007	Copper conjugates of Schiff base derivatives of nimesulide (1), a well-known cyclooxygenase-2 (COX-2) inhibitor, were synthesized, structurally characterized and evaluated for their COX selectivity indices and cytotoxicities on pancreatic tumor, BxPC-3 (COX-2 positive) and MiaPaCa (COX-2 negative) cell lines.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Homo sapiens	77-93
17940709-0	2007	COX-2 inhibitor nimesulide protects rat heart against oxidative stress by improving endothelial function and enhancing NO production.	nimesulide	16-26	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5
17689613-1	2007	Copper conjugates of Schiff base derivatives of nimesulide (1), a well-known cyclooxygenase-2 (COX-2) inhibitor, were synthesized, structurally characterized and evaluated for their COX selectivity indices and cytotoxicities on pancreatic tumor, BxPC-3 (COX-2 positive) and MiaPaCa (COX-2 negative) cell lines.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Homo sapiens	95-100
17689613-1	2007	Copper conjugates of Schiff base derivatives of nimesulide (1), a well-known cyclooxygenase-2 (COX-2) inhibitor, were synthesized, structurally characterized and evaluated for their COX selectivity indices and cytotoxicities on pancreatic tumor, BxPC-3 (COX-2 positive) and MiaPaCa (COX-2 negative) cell lines.	nimesulide	48-58	cytochrome c oxidase subunit 8A	Homo sapiens	95-98
17689613-1	2007	Copper conjugates of Schiff base derivatives of nimesulide (1), a well-known cyclooxygenase-2 (COX-2) inhibitor, were synthesized, structurally characterized and evaluated for their COX selectivity indices and cytotoxicities on pancreatic tumor, BxPC-3 (COX-2 positive) and MiaPaCa (COX-2 negative) cell lines.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Homo sapiens	254-259
17689613-1	2007	Copper conjugates of Schiff base derivatives of nimesulide (1), a well-known cyclooxygenase-2 (COX-2) inhibitor, were synthesized, structurally characterized and evaluated for their COX selectivity indices and cytotoxicities on pancreatic tumor, BxPC-3 (COX-2 positive) and MiaPaCa (COX-2 negative) cell lines.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Homo sapiens	254-259
18201523-1	2007	OBJECTIVE: To investigate the expression of cyclooxygenase-2 (COX-2) in pterygium and the effect of selective COX-2 inhibitor (Nimesulide) on proliferation of human pterygium fibroblasts (HPF) in culture.	nimesulide	127-137	prostaglandin-endoperoxide synthase 2	Homo sapiens	110-115
17710005-6	2007	All 3 treatments were well tolerated, with a lower number of patients reporting adverse events in the nimesulide group.	nimesulide	102-112	paired box 5	Homo sapiens	0-5
17610876-1	2007	The present in vitro study was designed to assess the inhibition of the myeloperoxidase (MPO)/H(2)O(2)/Cl(-) system by several non steroidal anti-inflammatory drugs (NSAIDs) of the oxicam family and of nimesulide and to compare their effect with flufenamic acid in order to investigate their influence on the chlorinating activity of MPO as a protective mechanism during chronic inflammatory syndromes.	nimesulide	202-212	myeloperoxidase	Homo sapiens	72-87
17610876-1	2007	The present in vitro study was designed to assess the inhibition of the myeloperoxidase (MPO)/H(2)O(2)/Cl(-) system by several non steroidal anti-inflammatory drugs (NSAIDs) of the oxicam family and of nimesulide and to compare their effect with flufenamic acid in order to investigate their influence on the chlorinating activity of MPO as a protective mechanism during chronic inflammatory syndromes.	nimesulide	202-212	myeloperoxidase	Homo sapiens	89-92
17716351-3	2007	This study investigated the preventive effect of nimesulide, a selective COX-2 inhibitor, on colorectal carcinogenesis in an experimental model of murine UC.	nimesulide	49-59	cytochrome c oxidase II, mitochondrial	Mus musculus	73-78
17420946-0	2007	Nimesulide inhibits crypt epithelial cell proliferation at 6 hours in the small intestine in CD-1 mice.	nimesulide	0-10	CD1 antigen complex	Mus musculus	93-97
17716351-12	2007	CONCLUSIONS: The administration of the selective COX-2 inhibitor nimesulide (especially during the remission phase) exerts a suppressive effect on the development of dysplasia and/or cancer in a murine model of DSS-induced colitis.	nimesulide	65-75	cytochrome c oxidase II, mitochondrial	Mus musculus	49-54
18080691-5	2007	In the study acetylsalicylic acid (ASA) as COX-1 and COX-2 inhibitors, and nimesulide as selective COX-2 inhibitor were used.	nimesulide	75-85	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	99-104
17652141-13	2007	In summary, we found that the selective COX-2 inhibitor nimesulide delays the progression of pancreatic cancer precursor lesions in a preclinical animal model.	nimesulide	56-66	prostaglandin-endoperoxide synthase 2	Homo sapiens	40-45
17631696-0	2007	Effect of the NSAID nimesulide on the radical scavenger glutathione S-transferase in patients with osteoarthritis of the knee.	nimesulide	20-30	glutathione S-transferase kappa 1	Homo sapiens	56-81
17631696-3	2007	The aim of this pilot study was to examine the antioxidative potency of the non-steroidal anti-inflammatory drug (NSAID) nimesulide on glutathione S-transferase (GST), an enzymatic free radical scavenger.	nimesulide	121-131	glutathione S-transferase kappa 1	Homo sapiens	135-160
17631696-3	2007	The aim of this pilot study was to examine the antioxidative potency of the non-steroidal anti-inflammatory drug (NSAID) nimesulide on glutathione S-transferase (GST), an enzymatic free radical scavenger.	nimesulide	121-131	glutathione S-transferase kappa 1	Homo sapiens	162-165
17631696-9	2007	RESULTS: During the 3-week treatment period with nimesulide 100 mg b.i.d., both scavenger GST and the TIMP-1/MMP-3 ratio significantly increased.	nimesulide	49-59	glutathione S-transferase kappa 1	Homo sapiens	90-93
17691971-1	2007	The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI).	nimesulide	84-94	matrix metallopeptidase 9	Rattus norvegicus	136-162
17631696-9	2007	RESULTS: During the 3-week treatment period with nimesulide 100 mg b.i.d., both scavenger GST and the TIMP-1/MMP-3 ratio significantly increased.	nimesulide	49-59	TIMP metallopeptidase inhibitor 1	Homo sapiens	102-108
17631696-9	2007	RESULTS: During the 3-week treatment period with nimesulide 100 mg b.i.d., both scavenger GST and the TIMP-1/MMP-3 ratio significantly increased.	nimesulide	49-59	matrix metallopeptidase 3	Homo sapiens	109-114
17691971-1	2007	The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI).	nimesulide	84-94	matrix metallopeptidase 9	Rattus norvegicus	164-169
17691971-1	2007	The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI).	nimesulide	84-94	matrix metallopeptidase 2	Rattus norvegicus	178-204
17590218-9	2007	Both after a single or repeated administration, nimesulide significantly reduced the synovial fluid concentrations of SP and IL-6.	nimesulide	48-58	tachykinin precursor 1	Homo sapiens	118-120
17691971-1	2007	The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI).	nimesulide	84-94	matrix metallopeptidase 2	Rattus norvegicus	206-211
17691971-4	2007	Quantitative analysis of immunohistochemical staining of brain slices showed that the neuron number expressing MMP-9 and MMP-2 increased in the model animals treated with vehicle (p<0.01 vs sham group), and significantly decreased in nimesulide-treated animals (p<0.05 or p<0.01 vs vehicle group).	nimesulide	237-247	matrix metallopeptidase 9	Rattus norvegicus	111-116
17691971-5	2007	Our results demonstrate that nimesulide significantly reduces the degree of neuronal injury and hemorrhage transformation caused by thrombolytic reperfusion after the embolic FCI, and that inhibition of MMP-9 and MMP-2 expression contributes at least in part to the neuroprotection.	nimesulide	29-39	matrix metallopeptidase 2	Rattus norvegicus	213-218
17590218-9	2007	Both after a single or repeated administration, nimesulide significantly reduced the synovial fluid concentrations of SP and IL-6.	nimesulide	48-58	interleukin 6	Homo sapiens	125-129
17345100-2	2007	PIPC-induced fever could be antagonized by treatment with the non-selective cyclooxygenase (COX) inhibitor diclofenac and was, in part, attenuated by the administration of the selective COX-2-inhibitor nimesulide (dose: 5 mg/kg for both COX inhibitors).	nimesulide	202-212	cytochrome c oxidase subunit II	Cavia porcellus	186-191
17675820-0	2007	[Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide].	nimesulide	146-156	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	1-23
17675820-0	2007	[Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide].	nimesulide	146-156	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	130-135
17675820-3	2007	One group was given commercial chow (control group), and the other group was given experimental chow containing nimesulide, a selective COX-2 inhibitor (nimesulide group).	nimesulide	112-122	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	136-141
17675820-10	2007	Nimesulide is effective in preventing BE and EAC by suppressing COX-2 activity.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	64-69
17613921-5	2007	RESULTS: The semi-selective NSAIDs (nimesulide, nabumetone, meloxicam, etodolac) had the highest odds ratio for upper GI events even after adjusting for various potential confounders (adjusted odds ratio (AOR) 3.63; 95% CI 3.08-4.28), followed by non-selective (2.98; 2.70-3.29) and COX-2 selective NSAIDs (2.53; 2.09-3.07).	nimesulide	36-46	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	283-288
17379757-5	2007	Thrombin"s effect on basal migration was dependent on cyclooxygenase 2 (COX-2) activation because it was blocked by the COX-2 inhibitors NS-398 and nimesulide, and pharmacological studies showed that it was relayed through prostaglandin E(2) and its EP(2) receptor.	nimesulide	148-158	coagulation factor II, thrombin	Homo sapiens	0-8
17379757-5	2007	Thrombin"s effect on basal migration was dependent on cyclooxygenase 2 (COX-2) activation because it was blocked by the COX-2 inhibitors NS-398 and nimesulide, and pharmacological studies showed that it was relayed through prostaglandin E(2) and its EP(2) receptor.	nimesulide	148-158	prostaglandin-endoperoxide synthase 2	Homo sapiens	54-70
17379757-5	2007	Thrombin"s effect on basal migration was dependent on cyclooxygenase 2 (COX-2) activation because it was blocked by the COX-2 inhibitors NS-398 and nimesulide, and pharmacological studies showed that it was relayed through prostaglandin E(2) and its EP(2) receptor.	nimesulide	148-158	prostaglandin-endoperoxide synthase 2	Homo sapiens	72-77
17379757-5	2007	Thrombin"s effect on basal migration was dependent on cyclooxygenase 2 (COX-2) activation because it was blocked by the COX-2 inhibitors NS-398 and nimesulide, and pharmacological studies showed that it was relayed through prostaglandin E(2) and its EP(2) receptor.	nimesulide	148-158	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-125
17878525-11	2007	By using the COX-2 inhibitors rofecoxib and nimesulide, we were able to delay tumor-mediated wasting in vivo.	nimesulide	44-54	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	13-18
17485013-0	2007	Aspirin and COX-2 inhibitor nimesulide potentiate adrenergic contractions of human gastroepiploic artery.	nimesulide	28-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	12-17
17485013-5	2007	RESULTS: The COX-1 and COX-2 inhibitor aspirin at high concentrations (10(-6) to 10(-5) mol/L) and the COX-2 inhibitor nimesulide (10(-6) mol/L) potentiated the contractile responses of the arterial rings to sympathetic neurogenic stimulation and norepinephrine.	nimesulide	119-129	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	103-108
17485013-9	2007	Aspirin at high concentrations and the COX-2 selective inhibitor nimesulide potentiated the contractile response of gastroepiploic artery to adrenergic stimulation by inhibiting COX-2-derived PGI(2).	nimesulide	65-75	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	39-44
17485013-9	2007	Aspirin at high concentrations and the COX-2 selective inhibitor nimesulide potentiated the contractile response of gastroepiploic artery to adrenergic stimulation by inhibiting COX-2-derived PGI(2).	nimesulide	65-75	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	178-183
17624748-0	2007	Localization of cyclooxygenase-2 in mice testis and assessment of its possible role through suppressing its expression using nimesulide: a preferential cyclooxygenase-2 inhibitor.	nimesulide	125-135	prostaglandin-endoperoxide synthase 2	Mus musculus	16-32
17624748-0	2007	Localization of cyclooxygenase-2 in mice testis and assessment of its possible role through suppressing its expression using nimesulide: a preferential cyclooxygenase-2 inhibitor.	nimesulide	125-135	prostaglandin-endoperoxide synthase 2	Mus musculus	152-168
17624748-4	2007	To correlate the localization of COX-2 with its function we suppressed COX-2 expression with the aid of nimesulide a preferential COX-2 inhibitor.	nimesulide	104-114	prostaglandin-endoperoxide synthase 2	Mus musculus	33-38
17382448-0	2007	Localization of cyclooxygenase-2 in mice vas deferens and its effects on fertility upon suppression using nimesulide: a preferential cyclooxygenase-2 inhibitor.	nimesulide	106-116	prostaglandin-endoperoxide synthase 2	Mus musculus	16-32
17382448-0	2007	Localization of cyclooxygenase-2 in mice vas deferens and its effects on fertility upon suppression using nimesulide: a preferential cyclooxygenase-2 inhibitor.	nimesulide	106-116	prostaglandin-endoperoxide synthase 2	Mus musculus	133-149
17382448-6	2007	Further they suppressed the expression of COX-2 using a preferential COX-2 inhibitor nimesulide and analyzed the sperm from vas deferens for any defects.	nimesulide	85-95	prostaglandin-endoperoxide synthase 2	Mus musculus	42-47
17382448-7	2007	COX-2 was intensely expressed in the epithelial cells of mice vas deferens and nimesulide was able to effectively suppress most of COX-2 expression.	nimesulide	79-89	prostaglandin-endoperoxide synthase 2	Mus musculus	0-5
17382448-7	2007	COX-2 was intensely expressed in the epithelial cells of mice vas deferens and nimesulide was able to effectively suppress most of COX-2 expression.	nimesulide	79-89	prostaglandin-endoperoxide synthase 2	Mus musculus	131-136
17382448-9	2007	The motility of sperm was affected severely after 6h of nimesulide administration that suggested a crucial role of COX-2 towards fertility of mice sperm.	nimesulide	56-66	prostaglandin-endoperoxide synthase 2	Mus musculus	115-120
17515698-13	2007	After administration of the COX 2 inhibitor nimesulide, both the PGE 1 vasodepressor responses and arachidonic acid-induced vasopressor responses were significantly decreased while the U46619, angiotensin II, and norepinephrine-induced vasopressor responses were not significantly attenuated.	nimesulide	44-54	cytochrome c oxidase subunit II	Felis catus	28-33
17380299-0	2007	The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture.	nimesulide	31-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
17485303-2	2007	This study was designed to examine the action of COX-2 in rat ovulation, implantation and decidualization by using two specific inhibitors of COX-2 (nimesulide and niflumic acid).	nimesulide	149-159	prostaglandin-endoperoxide synthase 2	Mus musculus	49-54
17485303-2	2007	This study was designed to examine the action of COX-2 in rat ovulation, implantation and decidualization by using two specific inhibitors of COX-2 (nimesulide and niflumic acid).	nimesulide	149-159	prostaglandin-endoperoxide synthase 2	Mus musculus	142-147
17485303-4	2007	Although nimesulide had no obvious effects on the number of implantation sites and the vascular permeability, the expression of PPARdelta, HB-EGF and vimentin proteins was down-regulated in the nimesulide-treated groups.	nimesulide	194-204	heparin-binding EGF-like growth factor	Rattus norvegicus	139-145
17485303-4	2007	Although nimesulide had no obvious effects on the number of implantation sites and the vascular permeability, the expression of PPARdelta, HB-EGF and vimentin proteins was down-regulated in the nimesulide-treated groups.	nimesulide	194-204	vimentin	Rattus norvegicus	150-158
17485303-5	2007	COX-1 protein was upregulated by nimesulide treatment.	nimesulide	33-43	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	0-5
17485303-8	2007	Based on our data, rat implantation and decidualization were delayed by nimesulide treatment, resulting in the reduction of litter size and birth weight and the prolongation of gestational length, suggesting that COX-2 plays an important role in implantation and decidualization.	nimesulide	72-82	prostaglandin-endoperoxide synthase 2	Mus musculus	213-218
17592669-8	2007	The FAAH inhibitor URB597 had no effect on the suppression of I(K(V)), whereas nimesulide, a COX-2 inhibitor, prolonged the effects of the K+ puff 10-fold.	nimesulide	79-89	cytochrome c oxidase subunit II	Carassius langsdorfii	93-98
17315855-4	2007	Our previous study demonstrated that COX-2 selective inhibitor nimesulide decreased aromatase activity from the transcriptional level in breast cancer cells.	nimesulide	63-73	prostaglandin-endoperoxide synthase 2	Homo sapiens	37-42
17377112-10	2007	Conversely, a prevention of the increase in TNF-alpha levels was observed only in rats treated with nimesulide or tramadol and paracetamol in combination.	nimesulide	100-110	tumor necrosis factor	Rattus norvegicus	44-53
17348902-1	2007	The pharmacokinetic properties and bioavailability of cyclooxygenase (COX)-2 selective nonsteroidal anti-inflammatory drug nimesulide were investigated in female goats following intravenous (i.v.)	nimesulide	123-133	cytochrome c oxidase subunit II	Capra hircus	54-76
17245358-7	2007	Inhibition of COX-1 by indomethacin (10 microM) potentiated relaxations to 2-AG, whereas inhibition of COX-2 by nimesulide (10 microM) potentiated anandamide-induced relaxation.	nimesulide	112-122	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	103-108
17983199-1	2007	UNLABELLED: Nimesulide is a nonsteroidal antiinflammatory (NSAID) drug whose mechanism of action is characterized by selective inhibition of cyclooxygenase-2.	nimesulide	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	141-157
17258197-8	2007	In contrast, COX-2 inhibitors, nimesulide and NS-398, had no effect on the exudate volume, but they increased the number of COX-2- and mPGES-1-expressing cells and extension of their dendritic processes with significant increase in the COX-2 level, which were antagonised by ketorolac.	nimesulide	31-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18
17258197-8	2007	In contrast, COX-2 inhibitors, nimesulide and NS-398, had no effect on the exudate volume, but they increased the number of COX-2- and mPGES-1-expressing cells and extension of their dendritic processes with significant increase in the COX-2 level, which were antagonised by ketorolac.	nimesulide	31-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	124-129
17258197-8	2007	In contrast, COX-2 inhibitors, nimesulide and NS-398, had no effect on the exudate volume, but they increased the number of COX-2- and mPGES-1-expressing cells and extension of their dendritic processes with significant increase in the COX-2 level, which were antagonised by ketorolac.	nimesulide	31-41	prostaglandin E synthase	Mus musculus	135-142
17258197-8	2007	In contrast, COX-2 inhibitors, nimesulide and NS-398, had no effect on the exudate volume, but they increased the number of COX-2- and mPGES-1-expressing cells and extension of their dendritic processes with significant increase in the COX-2 level, which were antagonised by ketorolac.	nimesulide	31-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	124-129
17380299-8	2007	VEGF was decreased with 10 microM nimesulide in cancer cells whereas it remained unaltered in normal cells.	nimesulide	34-44	vascular endothelial growth factor A	Homo sapiens	0-4
17380299-10	2007	MCP-1 levels were decreased with both doses of nimesulide in normal cells, whereas IL-8 levels were significantly affected only by 50 microM of nimesulide.	nimesulide	47-57	C-C motif chemokine ligand 2	Homo sapiens	0-5
17431384-2	2007	AIM: This study was designed to investigate the role of COX-2 inhibitor nimesulide in cell growth and apoptosis of the cultured human hepatocellular carcinoma HepG2 cells.	nimesulide	72-82	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	56-61
17378442-1	2007	REASONS FOR PERFORMING STUDY: The selective COX-2-inhibitor nimesulide is used extra-label in equine veterinary practice as an anti-inflammatory agent.	nimesulide	60-70	cytochrome c oxidase subunit II	Equus caballus	44-49
17431384-4	2007	RESULTS: Our results showed that the treatment of HepG2 cells with more than 50 microM of nimesulide suppressed COX-2 enzyme activity because of reduced PGE(2) production, and then induced growth inhibition and cell apoptosis despite no alterations of COX-2 protein expression.	nimesulide	90-100	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	112-117
17431384-4	2007	RESULTS: Our results showed that the treatment of HepG2 cells with more than 50 microM of nimesulide suppressed COX-2 enzyme activity because of reduced PGE(2) production, and then induced growth inhibition and cell apoptosis despite no alterations of COX-2 protein expression.	nimesulide	90-100	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	252-257
17431384-5	2007	Importantly, the combination of 50 microM or 100 microM of nimesulide and low concentrations (5 microM to 20 microM) of doxorubicin resulted in enhanced cell growth inhibition, apoptosis induction and reduced VEGF production.	nimesulide	59-69	vascular endothelial growth factor A	Homo sapiens	209-213
17166728-5	2007	Pups pretreated with interleukin-1-beta developed greater ibotenate-induced brain damage than controls, an effect blocked by the co-administration of nimesulide (cyclooxygenase-2 inhibitor) or indomethacin (cyclooxygenase-1 and -2 inhibitor).	nimesulide	150-160	interleukin 1 beta	Mus musculus	21-39
17166728-5	2007	Pups pretreated with interleukin-1-beta developed greater ibotenate-induced brain damage than controls, an effect blocked by the co-administration of nimesulide (cyclooxygenase-2 inhibitor) or indomethacin (cyclooxygenase-1 and -2 inhibitor).	nimesulide	150-160	prostaglandin-endoperoxide synthase 2	Mus musculus	162-178
17166728-5	2007	Pups pretreated with interleukin-1-beta developed greater ibotenate-induced brain damage than controls, an effect blocked by the co-administration of nimesulide (cyclooxygenase-2 inhibitor) or indomethacin (cyclooxygenase-1 and -2 inhibitor).	nimesulide	150-160	prostaglandin-endoperoxide synthase 1	Mus musculus	207-230
17176264-4	2007	Furthermore, nimesulide significantly attenuated the blood-brain barrier (BBB) damage and leukocyte infiltration (as measured by EB leakage and MPO activity, respectively) seen at 48 h after the initial ischaemic episode.	nimesulide	13-23	myeloperoxidase	Rattus norvegicus	144-147
17098211-4	2007	The effects of the inhibitors niflumic acid, nimesulide and rofecoxib on activities and phosphorylation state of key proteins in the insulin transduction pathway were determined.	nimesulide	45-55	insulin	Homo sapiens	133-140
17226071-3	2007	Interestingly, low doses of nimesulide and celecoxib increase the levels of Prostaglandin E(2) and COX-2, and protect against subsequent 100% ethanol exposition, suggesting that these drugs may act as "mild irritants" to gastric mucosa.	nimesulide	28-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-104
17176264-0	2007	Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats.	nimesulide	61-71	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	34-50
17176264-5	2007	These studies provide the first experimental evidence that COX-2 inhibition with nimesulide is able to limit BBB disruption and leukocyte infiltration following transient focal cerebral ischaemia.	nimesulide	81-91	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	59-64
17176264-6	2007	Neuroprotection afforded by nimesulide is observed even when the treatment is delayed until 6 h after the onset of ischaemia, confirming a wide therapeutic window of COX-2 inhibitors in experimental stroke.	nimesulide	28-38	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	166-171
17164136-4	2007	In contrast, the tNSAIDs meloxicam, nimesulide and diclofenac (which are from 18- to 29-fold more potent towards COX-2 in vitro) and coxibs (i.e. celecoxib, valdecoxib, rofecoxib, etoricoxib and lumiracoxib, which are from 30- to 433-fold more potent towards COX-2 in vitro) should be comprised into the cluster of COX-2 inhibitors.	nimesulide	36-46	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	113-118
17915641-1	2007	A rapid and simple high-performance liquid chromatography-reversed phase (HPLC-RV) method with ultraviolet detection (258 nm) was developed and validated for the quantitation of nimesulide (CAS 51803-78-2) in human plasma.	nimesulide	178-188	BCAR1 scaffold protein, Cas family member	Homo sapiens	190-193
17235241-4	2007	Annexin V was induced by nimesulide, 4-hydroxyphenylretinamide, and difluoromethylornithine in ultraviolet-B-treated radial growth-phase-like melanoma cells.	nimesulide	25-35	annexin A5	Homo sapiens	0-9
17762157-9	2007	Under these conditions, the expression of COX-2 was reduced by L-NAME (NO-synthesis inhibitor) and of iNOS by nimesulide (PGs-synthesis inhibitor).	nimesulide	110-120	cytochrome c oxidase II, mitochondrial	Mus musculus	42-47
17762157-9	2007	Under these conditions, the expression of COX-2 was reduced by L-NAME (NO-synthesis inhibitor) and of iNOS by nimesulide (PGs-synthesis inhibitor).	nimesulide	110-120	nitric oxide synthase 2, inducible	Mus musculus	102-106
17427176-2	2007	One such example is nimesulide, a preferential cyclooxygenase 2-inhibitor, widely used for the treatment of inflammation and pain.	nimesulide	20-30	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	47-63
17146966-0	2006	Anti-ischemic effects of nimesulide, a cyclooxygenase-2 inhibitor on the ischemic model of rabbit induced by isoproterenol.	nimesulide	25-35	prostaglandin G/H synthase 2	Oryctolagus cuniculus	39-55
16844276-12	2006	Rofecoxib (1 mg/kg) or nimesulide (1 mg/kg) also enhanced the sub-protective effect of diazepam or muscimol showing GABAergic modulation of COX-2 inhibitors.	nimesulide	23-33	cytochrome c oxidase II, mitochondrial	Mus musculus	140-145
17030482-5	2006	Five of them show COX-2 inhibition close to that of nimesulide and rofecoxib, two reference COX-2 selective inhibitors.	nimesulide	52-62	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	18-23
17146966-10	2006	Coronary perfusion rates (CPR) and heart rate (HR) of the infarcted and nimesulide (a COX-2 inhibitor) treated rabbits displayed significant improvement (n=11) on each corresponding day after infarction as compared to the infarcted and saline treated rabbits (P<0.05).	nimesulide	72-82	cytochrome c oxidase subunit II	Oryctolagus cuniculus	86-91
17073578-7	2006	Nimesulide, meclofenamate, and piroxicam were more selective towards SULT1A1 inhibition, while sulindac and ibuprofen were more selective towards SULT1E1 inhibition.	nimesulide	0-10	sulfotransferase family 1A member 1	Homo sapiens	69-76
17147060-5	2006	Significant decrease was also observed in the level of reduced glutathione (GSH), superoxide dismutase (SOD), glutathione-s-transferase and catalase activities for aspirin and nimesulide group while Celecoxib caused an increase in glutathione reductase (GR).	nimesulide	176-186	glutathione-disulfide reductase	Rattus norvegicus	231-252
17147060-5	2006	Significant decrease was also observed in the level of reduced glutathione (GSH), superoxide dismutase (SOD), glutathione-s-transferase and catalase activities for aspirin and nimesulide group while Celecoxib caused an increase in glutathione reductase (GR).	nimesulide	176-186	glutathione-disulfide reductase	Rattus norvegicus	254-256
17147060-6	2006	Aspirin and nimesulide exhibited an increase in the brush border membrane (BBM) bound enzyme activities like sucrase, lactase, maltase and alkaline phosphatase in the small intestine while celecoxib showed decrease in lactase, maltase and alkaline phosphatase.	nimesulide	12-22	lactase	Rattus norvegicus	118-125
17147060-6	2006	Aspirin and nimesulide exhibited an increase in the brush border membrane (BBM) bound enzyme activities like sucrase, lactase, maltase and alkaline phosphatase in the small intestine while celecoxib showed decrease in lactase, maltase and alkaline phosphatase.	nimesulide	12-22	lactase	Rattus norvegicus	218-225
17073578-9	2006	Kinetic studies determined the type of inhibition of SULT1A1 for three agents (meclofenamate, nimesulide, aspirin) to be non-competitive or partial non-competitive versus both substrate (p-nitrophenol) and cofactor (PAPS).	nimesulide	94-104	sulfotransferase family 1A member 1	Homo sapiens	53-60
17073578-11	2006	The inhibition of SULT1A1 by meclofenamate, nimesulide, salicylate and aspirin may be clinically relevant based on ratio of inhibition constant to predicted in vivo inhibitor concentration ([I]/IC(50) > 1).	nimesulide	44-54	sulfotransferase family 1A member 1	Homo sapiens	18-25
17133737-8	2006	NIM administration (8 mg/kg body wt) for 7 days caused significant depletion of the levels of SOD, CAT and reduced GSH, along with the increased levels of lipid peroxidation.	nimesulide	0-3	catalase	Mus musculus	99-102
16888076-5	2006	We aimed at evaluating whether PGE(2) induces Ar and Ep syntheses in human granulosa cells and whether the inhibition of PGE(2) production by selective COX-2 inhibitor, nimesulide, affects LH-induced Ar and Ep biosynthesis.	nimesulide	169-179	prostaglandin-endoperoxide synthase 2	Homo sapiens	152-157
16969492-19	2006	6 Gy radiation caused an initial elevation of MnSOD protein levels which was inhibited by prior treatment of nimesulide suggesting an inhibition of radiation induced NF-kappaB target genes.	nimesulide	109-119	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175
16969492-20	2006	These results support the hypothesis that COX-2 inhibitors such as nimesulide can increase the efficacy of radiation therapy.	nimesulide	67-77	prostaglandin-endoperoxide synthase 2	Mus musculus	42-47
16969492-21	2006	In vitro, our results suggest that the radiosensitization of A549 tumor cells by nimesulide is mediated by the suppression of NF-kappaB-mediated, radiation-induced cytoprotective genes.	nimesulide	81-91	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	126-135
16969492-0	2006	Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.	nimesulide	28-38	prostaglandin-endoperoxide synthase 2	Mus musculus	0-16
16969492-6	2006	We hypothesize that the COX-2 inhibitor, nimesulide, will improve the efficacy of radiation therapy (RT), at least in part, via the suppression of NF-kappaB mediated cytoprotective pathways.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Mus musculus	24-29
16969492-6	2006	We hypothesize that the COX-2 inhibitor, nimesulide, will improve the efficacy of radiation therapy (RT), at least in part, via the suppression of NF-kappaB mediated cytoprotective pathways.	nimesulide	41-51	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156
16969492-7	2006	In this study we used the COX-2 inhibitor nimesulide to improve the efficacy of RT when measured by tumor regrowth assays in vivo and clonegenic survival in vitro.	nimesulide	42-52	prostaglandin-endoperoxide synthase 2	Mus musculus	26-31
16969492-13	2006	The NF-kappaB mediated mechanism of nimesulide was measured by Western blot analysis of NF-kappaB target genes, MnSOD and survivin.	nimesulide	36-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	4-13
16969492-13	2006	The NF-kappaB mediated mechanism of nimesulide was measured by Western blot analysis of NF-kappaB target genes, MnSOD and survivin.	nimesulide	36-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	88-97
16969492-13	2006	The NF-kappaB mediated mechanism of nimesulide was measured by Western blot analysis of NF-kappaB target genes, MnSOD and survivin.	nimesulide	36-46	superoxide dismutase 2, mitochondrial	Mus musculus	112-117
16622181-3	2006	Mean arterial pressure (MAP) and renal hemodynamics were measured in pentobarbital sodium-anesthetized Cyp1a1-Ren2 rats during control conditions, following administration of the COX-2 inhibitor nimesulide (3 mg/kg iv), and following administration of the nonspecific COX inhibitor meclofenamate (5 mg/kg iv).	nimesulide	195-205	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	179-184
16969492-13	2006	The NF-kappaB mediated mechanism of nimesulide was measured by Western blot analysis of NF-kappaB target genes, MnSOD and survivin.	nimesulide	36-46	baculoviral IAP repeat-containing 5	Mus musculus	122-130
16969492-18	2006	Nimesulide alone reduced MnSOD and survivin protein levels in a dose-dependent manner.	nimesulide	0-10	superoxide dismutase 2, mitochondrial	Mus musculus	25-30
16969492-18	2006	Nimesulide alone reduced MnSOD and survivin protein levels in a dose-dependent manner.	nimesulide	0-10	baculoviral IAP repeat-containing 5	Mus musculus	35-43
16969492-19	2006	6 Gy radiation caused an initial elevation of MnSOD protein levels which was inhibited by prior treatment of nimesulide suggesting an inhibition of radiation induced NF-kappaB target genes.	nimesulide	109-119	superoxide dismutase 2, mitochondrial	Mus musculus	46-51
16552621-0	2006	Inhibition of human neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor nimesulide.	nimesulide	88-98	cytochrome c oxidase II, mitochondrial	Mus musculus	72-77
16814279-6	2006	Nimesulide or indomethacin administered i.p 30 min prior LPS, IL-1beta, IL-6, TNF-alpha or arachidonic acid reduced the febrile response and PGE(2) or PGF(2alpha) levels in LPS-febrile rats but did not modify PGE(2)-induced fever.	nimesulide	0-10	interleukin 1 beta	Rattus norvegicus	62-70
16814279-6	2006	Nimesulide or indomethacin administered i.p 30 min prior LPS, IL-1beta, IL-6, TNF-alpha or arachidonic acid reduced the febrile response and PGE(2) or PGF(2alpha) levels in LPS-febrile rats but did not modify PGE(2)-induced fever.	nimesulide	0-10	interleukin 6	Rattus norvegicus	72-76
16814279-6	2006	Nimesulide or indomethacin administered i.p 30 min prior LPS, IL-1beta, IL-6, TNF-alpha or arachidonic acid reduced the febrile response and PGE(2) or PGF(2alpha) levels in LPS-febrile rats but did not modify PGE(2)-induced fever.	nimesulide	0-10	tumor necrosis factor	Rattus norvegicus	78-87
16814279-7	2006	Nimesulide, but not indomethacin, reduced the fever induced by MIP-1alpha, PGF(2alpha), CRF or ET-1.	nimesulide	0-10	C-C motif chemokine ligand 3	Rattus norvegicus	63-73
16814279-7	2006	Nimesulide, but not indomethacin, reduced the fever induced by MIP-1alpha, PGF(2alpha), CRF or ET-1.	nimesulide	0-10	endothelin 1	Rattus norvegicus	95-99
16814279-8	2006	Plasma TNF-alpha levels in LPS-treated rats were also reduced by nimesulide.	nimesulide	65-75	tumor necrosis factor	Rattus norvegicus	7-16
16814279-1	2006	This study evaluates the antipyretic activity of nimesulide, a cyclooxygenase (COX-2) selective inhibitor in rats.	nimesulide	49-59	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	79-84
16846549-3	2006	FINDINGS: The members of the Consensus Report Group on Nimesulide (CRGN) recognised that nimesulide is an NSAID which exerts its analgesic, anti-inflammatory and antipyretic activities thanks to unique chemical and pharmacokinetic characteristics, and to a multifactorial mechanism of action, which goes beyond its preferential inhibitory activity on the COX-2 enzyme.	nimesulide	55-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	355-360
16846549-3	2006	FINDINGS: The members of the Consensus Report Group on Nimesulide (CRGN) recognised that nimesulide is an NSAID which exerts its analgesic, anti-inflammatory and antipyretic activities thanks to unique chemical and pharmacokinetic characteristics, and to a multifactorial mechanism of action, which goes beyond its preferential inhibitory activity on the COX-2 enzyme.	nimesulide	89-99	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	355-360
16552621-3	2006	We evaluated the efficacy of a low dose of the selective cyclooxygenase-2 inhibitor Nimesulide in preventing human Neuroblastoma tumor growth in Severe Combined Immune-deficient mice.	nimesulide	84-94	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-73
16552621-5	2006	There was a reduction in the level of cyclooxygenase-2 protein and induction of effecter caspases in tumors treated with Nimesulide.	nimesulide	121-131	prostaglandin-endoperoxide synthase 2	Homo sapiens	38-54
16536784-7	2006	When a nonselective (naproxen) and a selective (nimesulide) COX-2 inhibitor were tested in rats with bladders infused with saline 5 days after catheterization, their effects on BVC were significantly lower than those evaluated at 1 day.	nimesulide	48-58	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65
16531030-7	2006	We modulated the fibronectin affinity exhibited by both cell types using Nimesulide, an inhibitor of fibronectin integrin receptors alpha5beta1 and alphavbeta3.	nimesulide	73-83	fibronectin 1	Homo sapiens	17-28
16531030-7	2006	We modulated the fibronectin affinity exhibited by both cell types using Nimesulide, an inhibitor of fibronectin integrin receptors alpha5beta1 and alphavbeta3.	nimesulide	73-83	fibronectin 1	Homo sapiens	101-112
16712451-3	2006	The present review focuses on the state of the art in cancer research developed with COX-2 preferential/selective inhibitors belonging to the family of N-arylmethanesulfonamides, in particular nimesulide and NS-398.	nimesulide	193-203	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	85-90
16756774-11	2006	CONCLUSION: Using this model, it was found that nimesulide, a COX-2 inhibitor, exerted a cardioprotective effects in MI.	nimesulide	48-58	prostaglandin G/H synthase 2	Oryctolagus cuniculus	62-67
16388017-7	2006	When pregnant rats on day 5 were treated with nimesulide for 24 h, mPGES-1 protein expression was completely inhibited.	nimesulide	46-56	prostaglandin E synthase	Mus musculus	67-74
16595938-1	2006	The mechanism of binding of anti-inflammatory drug, nimesulide (NIM) with bovine serum albumin (BSA) was investigated by fluorescence, absorption, circular dichroism (CD) and lifetime measurements under simulative physiological conditions.	nimesulide	52-62	albumin	Homo sapiens	81-94
16595938-1	2006	The mechanism of binding of anti-inflammatory drug, nimesulide (NIM) with bovine serum albumin (BSA) was investigated by fluorescence, absorption, circular dichroism (CD) and lifetime measurements under simulative physiological conditions.	nimesulide	64-67	albumin	Homo sapiens	81-94
16243362-0	2006	Nimesulide inhibits lipopolysaccharide-induced production of superoxide anions and nitric oxide and iNOS expression in alveolar macrophages.	nimesulide	0-10	nitric oxide synthase 2	Rattus norvegicus	100-104
16243362-9	2006	Nimesulide also suppressed LPS-induced iNOS expression in AMs in vivo and in vitro.	nimesulide	0-10	nitric oxide synthase 2	Rattus norvegicus	39-43
16243362-10	2006	Nimesulide could also normalize LPS-induced changes in the levels of superoxide dismutase (SOD), glutathione reductase (GR) and reduced glutathione (GSH) in AMs.	nimesulide	0-10	glutathione-disulfide reductase	Rattus norvegicus	97-118
16243362-10	2006	Nimesulide could also normalize LPS-induced changes in the levels of superoxide dismutase (SOD), glutathione reductase (GR) and reduced glutathione (GSH) in AMs.	nimesulide	0-10	glutathione-disulfide reductase	Rattus norvegicus	120-122
16447059-5	2006	RESULTS: The inhibitors niflumic acid, nimesulide and rofecoxib increased the rate of hexose uptake in L6 myotubes in the absence of insulin and in a dose- and time-dependent manner.	nimesulide	39-49	insulin	Homo sapiens	133-140
17274466-5	2006	Catalase activity was statistically decreased after both doses of nimesulid and acetylsalicylic acid at the dose of 10 mg/kg body weight.	nimesulide	66-75	catalase	Rattus norvegicus	0-8
16612843-6	2006	Nimesulide enhanced endothelin-1 contractions both in control and diabetic arteries.	nimesulide	0-10	endothelin-1	Oryctolagus cuniculus	20-32
16376453-3	2006	Here, we demonstrate that two COX-2 inhibitors (NS398 and Nimesulide) inhibit proliferation and induce apoptosis in NSCLC cells, and these effects were associated with induction of p21 mRNA and protein expression.	nimesulide	58-68	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	30-35
16376453-3	2006	Here, we demonstrate that two COX-2 inhibitors (NS398 and Nimesulide) inhibit proliferation and induce apoptosis in NSCLC cells, and these effects were associated with induction of p21 mRNA and protein expression.	nimesulide	58-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	181-184
16376453-6	2006	Furthermore, we show that both NS398 and Nimesulide induced p21 gene promoter activity and this was prevented by PD98095.	nimesulide	41-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-63
16489006-9	2006	The COX-2 inhibitors, NS-398 and nimesulide, significantly suppressed bone metastases with decreased osteoclast number and increased apoptosis in MDA-MB-231 cells.	nimesulide	33-43	prostaglandin-endoperoxide synthase 2	Homo sapiens	4-9
16469680-10	2006	Selective COX-2 inhibition with nimesulide and COX-1 inhibition with low-dose aspirin appear to be well-tolerated in the short-term.	nimesulide	32-42	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	10-15
16443156-0	2006	Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice.	nimesulide	0-10	superoxide dismutase 2, mitochondrial	Mus musculus	64-68
16443156-1	2006	Nimesulide, a preferential COX-2 inhibitor, has been associated with rare idiosyncratic hepatotoxicity.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	27-32
16443156-5	2006	Nimesulide was administered for 4 weeks (10 mg/kg, ip, bid), at a dose equivalent to human therapeutic dosage.	nimesulide	0-10	BH3 interacting domain death agonist	Homo sapiens	55-58
16443156-7	2006	Furthermore, the nimesulide-treated mutant mice exhibited increased hepatic cytosolic levels of cytochrome c and caspase-3 activity, as well as increased numbers of apoptotic hepatocytes.	nimesulide	17-27	caspase 3	Mus musculus	113-122
16443156-8	2006	Finally, nimesulide in vitro caused a concentration-dependent net increase in superoxide anion in mitochondria from Sod2(+/-), but not Sod2(+/+) mice.	nimesulide	9-19	superoxide dismutase 2, mitochondrial	Mus musculus	116-120
16391822-9	2006	The combination of the COX-1 inhibitor with nimesulide and CAY10404, two selective COX-2 inhibitors, resulted in additive effects on cell growth inhibition.	nimesulide	44-54	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	83-88
16331303-4	2006	Most interestingly, we found that inhibition of COX-2-mediated generation of prostaglandin (PG)-E2 in H4 neuronal cells with the preferential COX-2 inhibitor nimesulide protects against N141I PS2-mediated apoptotic cell death coincidental with an inhibition of GSK-3beta activity and subsequent normalization of beta-catenin cellular distribution.	nimesulide	158-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	48-53
16331303-4	2006	Most interestingly, we found that inhibition of COX-2-mediated generation of prostaglandin (PG)-E2 in H4 neuronal cells with the preferential COX-2 inhibitor nimesulide protects against N141I PS2-mediated apoptotic cell death coincidental with an inhibition of GSK-3beta activity and subsequent normalization of beta-catenin cellular distribution.	nimesulide	158-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	142-147
16331303-4	2006	Most interestingly, we found that inhibition of COX-2-mediated generation of prostaglandin (PG)-E2 in H4 neuronal cells with the preferential COX-2 inhibitor nimesulide protects against N141I PS2-mediated apoptotic cell death coincidental with an inhibition of GSK-3beta activity and subsequent normalization of beta-catenin cellular distribution.	nimesulide	158-168	presenilin 2	Homo sapiens	192-195
16331303-4	2006	Most interestingly, we found that inhibition of COX-2-mediated generation of prostaglandin (PG)-E2 in H4 neuronal cells with the preferential COX-2 inhibitor nimesulide protects against N141I PS2-mediated apoptotic cell death coincidental with an inhibition of GSK-3beta activity and subsequent normalization of beta-catenin cellular distribution.	nimesulide	158-168	glycogen synthase kinase 3 alpha	Homo sapiens	261-270
16331303-4	2006	Most interestingly, we found that inhibition of COX-2-mediated generation of prostaglandin (PG)-E2 in H4 neuronal cells with the preferential COX-2 inhibitor nimesulide protects against N141I PS2-mediated apoptotic cell death coincidental with an inhibition of GSK-3beta activity and subsequent normalization of beta-catenin cellular distribution.	nimesulide	158-168	catenin beta 1	Homo sapiens	312-324
16055511-7	2005	The unspecific cyclooxygenase (COX) inhibitor aspirin (100 microM, P < 0.001) and the specific COX-2 inhibitor nimesulide (10 microM, P < 0.01) completely prevented pulmonary hypertension after 5 microM anandamide.	nimesulide	114-124	cytochrome c oxidase subunit II	Oryctolagus cuniculus	98-103
17154669-6	2006	Preferential COX-2 inhibitors (nimesulide, meloxicam) are tolerated by the majority but not all hypersensitive patients.	nimesulide	31-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	13-18
16225966-0	2005	A new potential cyclooxygenase-2 inhibitor, pyridinic analogue of nimesulide.	nimesulide	66-76	prostaglandin-endoperoxide synthase 2	Homo sapiens	16-32
16225966-1	2005	In this paper, the binding mode of original pyridinic compounds structurally related to nimesulide, a preferential cyclooxygenase (COX)-2 inhibitor, is analyzed by docking simulations in order to understand structure-activity relationships of this family.	nimesulide	88-98	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	115-137
16205617-3	2005	Recently, it has been acquired that, among NSAIDs, nimesulide has a more selective action on the isoform COX-2 that is more strictly related to inflammatory phenomena.	nimesulide	51-61	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-110
16240325-0	2005	The effect of nimesulide, a selective cyclooxygenase-2 inhibitor, on Ets-1 and Ets-2 expression in head and neck cancer cell lines.	nimesulide	14-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	38-54
16240325-0	2005	The effect of nimesulide, a selective cyclooxygenase-2 inhibitor, on Ets-1 and Ets-2 expression in head and neck cancer cell lines.	nimesulide	14-24	ETS proto-oncogene 1, transcription factor	Homo sapiens	69-74
16240325-0	2005	The effect of nimesulide, a selective cyclooxygenase-2 inhibitor, on Ets-1 and Ets-2 expression in head and neck cancer cell lines.	nimesulide	14-24	ETS proto-oncogene 2, transcription factor	Homo sapiens	79-84
16240325-2	2005	Nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, has antiproliferative effects on tumor cells.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-40
16240325-2	2005	Nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, has antiproliferative effects on tumor cells.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	42-47
16240325-7	2005	In both cell lines, Ets-1 and Ets-2 expression were reduced after 24 and 48 hours by nimesulide.	nimesulide	85-95	ETS proto-oncogene 1, transcription factor	Homo sapiens	20-25
16240325-7	2005	In both cell lines, Ets-1 and Ets-2 expression were reduced after 24 and 48 hours by nimesulide.	nimesulide	85-95	ETS proto-oncogene 2, transcription factor	Homo sapiens	30-35
16240325-9	2005	Inhibition of Ets-1 and Ets-2 expression in head and neck cancer cell lines by nimesulide might explain the proapoptotic property of this COX-2 inhibitor.	nimesulide	79-89	ETS proto-oncogene 1, transcription factor	Homo sapiens	14-19
16240325-9	2005	Inhibition of Ets-1 and Ets-2 expression in head and neck cancer cell lines by nimesulide might explain the proapoptotic property of this COX-2 inhibitor.	nimesulide	79-89	ETS proto-oncogene 2, transcription factor	Homo sapiens	24-29
16240325-9	2005	Inhibition of Ets-1 and Ets-2 expression in head and neck cancer cell lines by nimesulide might explain the proapoptotic property of this COX-2 inhibitor.	nimesulide	79-89	prostaglandin-endoperoxide synthase 2	Homo sapiens	138-143
16273249-0	2005	Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.	nimesulide	70-80	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-59
16273249-5	2005	The aim of this study was to investigate if the selective cyclooxygenase-2 inhibitor nimesulide could enhance cytotoxicity of the standard chemotherapeutic agent cisplatin.	nimesulide	85-95	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-74
15863457-3	2005	Pulmonary pressor and systemic depressor responses were attenuated by SC-560 and nimesulide, inhibitors of COX-1 and COX-2, in doses that did not alter responses to injected prostanoids.	nimesulide	81-91	cytochrome c oxidase I, mitochondrial	Mus musculus	107-112
15863457-3	2005	Pulmonary pressor and systemic depressor responses were attenuated by SC-560 and nimesulide, inhibitors of COX-1 and COX-2, in doses that did not alter responses to injected prostanoids.	nimesulide	81-91	cytochrome c oxidase II, mitochondrial	Mus musculus	117-122
15851630-4	2005	The aim of this study was to determine whether the cyclooxygenase-2 selective inhibitors rofecoxib and nimesulide possess antioxidative and cardiovascular protective effects against angiotensin II.	nimesulide	103-113	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	51-67
15825163-7	2005	We found that the selective COX-2 inhibitors NS398 and Nimesulide decreased mRNA expression and protein production of the integrin alpha5 subunit.	nimesulide	55-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	28-33
15825163-7	2005	We found that the selective COX-2 inhibitors NS398 and Nimesulide decreased mRNA expression and protein production of the integrin alpha5 subunit.	nimesulide	55-65	integrin subunit alpha 5	Homo sapiens	122-137
16287549-1	2005	BACKGROUND: Nimesulide is a cyclooxygenase (COX) inhibitor with a high degree of selectivity to COX-2.	nimesulide	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	96-101
16085140-0	2005	Mechanism of interaction of the non-steroidal antiinflammatory drugs meloxicam and nimesulide with serum albumin.	nimesulide	83-93	albumin	Homo sapiens	99-112
16085140-1	2005	The mechanism of interaction of the non-steroidal antiinflammatory drugs meloxicam and nimesulide with human and bovine serum albumin has been studied using fluorescence spectroscopy.	nimesulide	87-97	albumin	Homo sapiens	120-133
16085140-4	2005	Binding studies in the presence of the hydrophobic probe 1-anilinonaphthalene-8-sulfonate (ANS) showed that the binding of meloxicam and nimesulide to serum albumin involves predominantly hydrophobic interactions.	nimesulide	137-147	albumin	Homo sapiens	151-164
16120189-8	2005	The cyclo-oxygenase (COX)-1 inhibitor flurbiprofen (0.01-1 micromol/L) and the COX-2 inhibitor nimesulide (0.01-1 micromol/L) attenuated the NA-induced contraction in a concentration-dependent manner and the inhibitory effect of flurbiprofen was significantly more potent than that of nimesulide (P < 0.05).	nimesulide	95-105	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	79-84
16120189-8	2005	The cyclo-oxygenase (COX)-1 inhibitor flurbiprofen (0.01-1 micromol/L) and the COX-2 inhibitor nimesulide (0.01-1 micromol/L) attenuated the NA-induced contraction in a concentration-dependent manner and the inhibitory effect of flurbiprofen was significantly more potent than that of nimesulide (P < 0.05).	nimesulide	285-295	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	4-27
16120189-8	2005	The cyclo-oxygenase (COX)-1 inhibitor flurbiprofen (0.01-1 micromol/L) and the COX-2 inhibitor nimesulide (0.01-1 micromol/L) attenuated the NA-induced contraction in a concentration-dependent manner and the inhibitory effect of flurbiprofen was significantly more potent than that of nimesulide (P < 0.05).	nimesulide	285-295	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	79-84
16194365-0	2005	[The effect of selective cyclooxygenase-2 inhibitor nimesulide on breast cancer induced by dimethylbenzoic acid in rats].	nimesulide	52-62	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	25-41
15905461-3	2005	Deletion of the PGI2 receptor (IP) or suppression of PGI2 with the selective COX-2 inhibitor, nimesulide, both augment intimal hyperplasia while preserving luminal geometry in mouse models of transplant arteriosclerosis or flow-induced vascular remodeling.	nimesulide	94-104	cytochrome c oxidase II, mitochondrial	Mus musculus	77-82
15905461-6	2005	Deletion of the TxA2 receptor (TP) reduces the hyperplastic response to nimesulide and carotid ligation, despite further augmentation of TP ligand production.	nimesulide	72-82	thromboxane A2 receptor	Mus musculus	16-29
15851630-4	2005	The aim of this study was to determine whether the cyclooxygenase-2 selective inhibitors rofecoxib and nimesulide possess antioxidative and cardiovascular protective effects against angiotensin II.	nimesulide	103-113	angiotensinogen	Rattus norvegicus	182-196
15851630-7	2005	Similar to acetylsalicylic acid, rofecoxib or nimesulide treatments significantly attenuated angiotensin II-induced oxidative stress, hypertension, and cardiac NAD(P)H oxidase subunit p47(phox) expression.	nimesulide	46-56	angiotensinogen	Rattus norvegicus	93-107
15851630-7	2005	Similar to acetylsalicylic acid, rofecoxib or nimesulide treatments significantly attenuated angiotensin II-induced oxidative stress, hypertension, and cardiac NAD(P)H oxidase subunit p47(phox) expression.	nimesulide	46-56	NSFL1 cofactor	Rattus norvegicus	184-187
15705899-10	2005	In vivo, nimesulide increased VEGF production by cancer cells in COX-2-positive and COX-2-negative pancreatic tumors.	nimesulide	9-19	vascular endothelial growth factor A	Homo sapiens	30-34
15892897-8	2005	Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.	nimesulide	13-23	proliferating cell nuclear antigen	Mus musculus	55-89
15892897-8	2005	Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.	nimesulide	13-23	proliferating cell nuclear antigen	Mus musculus	91-95
15892897-8	2005	Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.	nimesulide	13-23	catenin (cadherin associated protein), beta 1	Mus musculus	130-142
15892897-8	2005	Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.	nimesulide	13-23	cytochrome c oxidase II, mitochondrial	Mus musculus	144-149
15892897-8	2005	Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.	nimesulide	13-23	nitric oxide synthase 2, inducible	Mus musculus	151-182
15892897-8	2005	Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear antigen (PCNA)-labeling index and expression of beta-catenin, COX-2, inducible nitric oxide synthase (iNOS) and nitrotyrosine.	nimesulide	13-23	nitric oxide synthase 2, inducible	Mus musculus	184-188
15866108-9	2005	The selective PGHS-2 inhibitor, Nimesulide (Cayman Chemical, Ann Arbor, MI), significantly decreased plasma PGE2 concentrations.	nimesulide	32-42	prostaglandin G/H synthase 2	Ovis aries	14-20
15700024-10	2005	Pretreatment of allergic mice with either indomethacin (1 mg kg(-1), dual COX inhibitor) or nimesulide (3 mg kg(-1), COX-2-selective inhibitor) blocked SLIGRL-induced reductions in BAL eosinophils.	nimesulide	92-102	cytochrome c oxidase II, mitochondrial	Mus musculus	117-122
15643499-10	2005	In conclusion, nimesulide induces apoptosis and promotes down-regulation of Akt-expression in squamous cell carcinoma cells, independently of ERK activity.	nimesulide	15-25	AKT serine/threonine kinase 1	Homo sapiens	76-79
15626595-6	2005	In contrast, selective COX-2 inhibitors (rofecoxib>>celecoxib>nimesulide>NS 398) were thrombogenic, and abolished THR and rise in 6-keto-PGF(1 alpha) induced by ACE-Is.	nimesulide	71-81	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28
15892673-5	2005	Selective cyclooxygenase-2 (COX-2) inhibitors represent a new group of pharmaceutical products termed "coxibs" that include meloxicam, nimesulide, etodolac and celecoxib.	nimesulide	135-145	prostaglandin-endoperoxide synthase 2	Homo sapiens	10-26
15892673-5	2005	Selective cyclooxygenase-2 (COX-2) inhibitors represent a new group of pharmaceutical products termed "coxibs" that include meloxicam, nimesulide, etodolac and celecoxib.	nimesulide	135-145	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	28-33
15615524-0	2004	Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.	nimesulide	76-86	prostaglandin-endoperoxide synthase 2	Homo sapiens	90-106
15359292-6	2004	The growth rate of HSV-tk-transduced murine tumors was significantly reduced by treatment with the selective COX-2 inhibitor nimesulide.	nimesulide	125-135	prostaglandin-endoperoxide synthase 2	Mus musculus	109-114
15892897-3	2005	In the present study we investigated whether a cyclooxygenase (COX)-2 inhibitor nimesulide and ligands for peroxisome proliferator-activated receptors (PPARs), troglitazone (a PPARgamma ligand) and bezafibrate (a PPARalpha ligand) inhibit colitis-related colon carcinogenesis using our model to evaluate the efficacy of these drugs in prevention of IBD-related colon carcinogenesis.	nimesulide	80-90	cytochrome c oxidase II, mitochondrial	Mus musculus	47-69
15564788-6	2005	Nimesulide (1 micromol/l), an inhibitor of COX-2, did not change any of the effects caused by nucleotides.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	43-48
15705899-12	2005	In COX-2-positive pancreatic cancer, the nimesulide-induced increase of VEGF production by the cancer cells was offset by a decrease in VEGF production by the nonmalignant cell types leading to reduced tumor angiogenesis and growth.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	3-8
15705899-12	2005	In COX-2-positive pancreatic cancer, the nimesulide-induced increase of VEGF production by the cancer cells was offset by a decrease in VEGF production by the nonmalignant cell types leading to reduced tumor angiogenesis and growth.	nimesulide	41-51	vascular endothelial growth factor A	Homo sapiens	72-76
15705899-12	2005	In COX-2-positive pancreatic cancer, the nimesulide-induced increase of VEGF production by the cancer cells was offset by a decrease in VEGF production by the nonmalignant cell types leading to reduced tumor angiogenesis and growth.	nimesulide	41-51	vascular endothelial growth factor A	Homo sapiens	136-140
15567877-6	2005	METHODS: The selective COX-2 inhibitor, nimesulide, was administered to estrogen-supplemented nude mice implanted with human endometrial tissue.	nimesulide	40-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	23-28
15643499-0	2005	Expression levels of Akt in nimesulide-treated squamous carcinoma cell lines of the head and neck.	nimesulide	28-38	AKT serine/threonine kinase 1	Homo sapiens	21-24
15643499-1	2005	Nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, is known to induce apoptosis in various cell lines.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-40
15643499-1	2005	Nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, is known to induce apoptosis in various cell lines.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	42-47
15643499-4	2005	The aim of our study was to describe the effect of treatment with nimesulide and ERK inhibitor PD 98059 on the expression patterns of Akt within the head and neck cancer cell lines SCC 9 and SCC 25.	nimesulide	66-76	AKT serine/threonine kinase 1	Homo sapiens	134-137
15643499-8	2005	In both cell lines, nimesulide treatment induced apoptosis and resulted in a decrease of Akt expression.	nimesulide	20-30	AKT serine/threonine kinase 1	Homo sapiens	89-92
15656909-0	2005	Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat.	nimesulide	42-52	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	15-31
15656909-1	2005	BACKGROUND: Previous studies suggest that the cyclooxygenase-2 (COX-2) inhibitor nimesulide has a remarkable protective effect against different types of brain injury including ischemia.	nimesulide	81-91	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	46-62
15656909-1	2005	BACKGROUND: Previous studies suggest that the cyclooxygenase-2 (COX-2) inhibitor nimesulide has a remarkable protective effect against different types of brain injury including ischemia.	nimesulide	81-91	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	64-69
15591708-0	2005	Effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on cardiovascular alterations in endotoxemia.	nimesulide	11-21	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	35-51
16128596-1	2005	BACKGROUND AND AIM: Because in vitro studies have shown that nimesulide not only preferentially inhibits COX-2 but also reduces the action/release of pro-inflammatory cytokines, down-regulates the synthesis and/or activity of collagenase(s), and releases reactive oxygen species and other toxic substances from neutrophils, this study investigated whether nimesulide and ibuprofen could affect levels of biochemical markers of joint inflammation and collagen catabolism in patients with flare-up of knee or hip osteoarthritis.	nimesulide	61-71	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-110
16128596-7	2005	Nimesulide also reduced the serum levels of both MMP-3 (p < 0.05) and MMP-13 (p < 0.001).	nimesulide	0-10	matrix metallopeptidase 3	Homo sapiens	49-54
16128596-7	2005	Nimesulide also reduced the serum levels of both MMP-3 (p < 0.05) and MMP-13 (p < 0.001).	nimesulide	0-10	matrix metallopeptidase 13	Homo sapiens	73-79
16128596-8	2005	Furthermore, in the nimesulide group, the decrease in levels of CTX-II correlated significantly with the decrease in levels of HA and MMP-13.	nimesulide	20-30	matrix metallopeptidase 13	Homo sapiens	134-140
18426087-8	2005	Coronary perfusion rates (CPR) of the infarcted and nimesulide (a COX-2 inhibitor) treated rabbits displayed significant improvement on each corresponding day after infarction as compared to the infarcted and saline treated rabbits (P<0.01).	nimesulide	52-62	prostaglandin G/H synthase 2	Oryctolagus cuniculus	66-71
18426087-9	2005	These results suggest that nimesulide, a COX-2 inhibitor exhibit cardioprotective effects in MI.	nimesulide	27-37	prostaglandin G/H synthase 2	Oryctolagus cuniculus	41-46
15615524-1	2004	In this study, we report the synthesis and pharmacological evaluation of original pyridinic sulfonamides related to nimesulide, a cyclooxygenase-2 (COX-2) preferential inhibitor widely used as an anti-inflammatory agent.	nimesulide	116-126	prostaglandin-endoperoxide synthase 2	Homo sapiens	130-146
15615524-1	2004	In this study, we report the synthesis and pharmacological evaluation of original pyridinic sulfonamides related to nimesulide, a cyclooxygenase-2 (COX-2) preferential inhibitor widely used as an anti-inflammatory agent.	nimesulide	116-126	prostaglandin-endoperoxide synthase 2	Homo sapiens	148-153
15705899-10	2005	In vivo, nimesulide increased VEGF production by cancer cells in COX-2-positive and COX-2-negative pancreatic tumors.	nimesulide	9-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	65-70
15705899-10	2005	In vivo, nimesulide increased VEGF production by cancer cells in COX-2-positive and COX-2-negative pancreatic tumors.	nimesulide	9-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	84-89
15865061-3	2004	Although X-ray structures of COX-2 complexed with a small number of ligands are available, experimental data are missing for two well-known selective COX-2 inhibitors (rofecoxib and nimesulide) and docking results reported are controversial.	nimesulide	182-192	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	150-155
16035398-0	2004	Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study.	nimesulide	10-20	matrix metallopeptidase 3	Homo sapiens	59-72
15478205-5	2004	Rofecoxib (2 mg/kg) and nimesulide (2 mg/kg), COX-2 inhibitors, also reversed the LPS-induced immobility, which was significantly potentiated by concomitant administration of GTE.	nimesulide	24-34	cytochrome c oxidase II, mitochondrial	Mus musculus	46-51
16035398-3	2004	Nimesulide significantly reduced the serum levels of both HA and MMP-3, whereas ibuprofen increased moderately but significantly the serum concentrations of MMP-3 and had no effect on the serum concentrations of HA.	nimesulide	0-10	matrix metallopeptidase 3	Homo sapiens	65-70
15327557-3	2004	OBJECTIVE: To confirm that COX-2 could be a molecular target in adjunctive therapy to ALA-based PDT, we investigated (i) COX-2 expression in various skin and oral diseases, and (ii) the inhibitory effects on cellular growth of COX-2 selective inhibitor (nimesulide), ALA-based PDT and their combination on human oral squamous cell carcinoma (SCC) cell lines.	nimesulide	254-264	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	27-32
15327557-10	2004	Nimesulide had an inhibitory effect in vitro on HSC-2 (proven to be a COX-2 high expresser), but not on HSC-4 (a COX-2 non-expresser).	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	70-75
15309882-0	2004	Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line.	nimesulide	27-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
21232215-1	2004	BACKGROUND: To study the effect and possible mechanism of cyclooxygenase-2 selective inhibitor, nimesulide (NIM), combined with cisplatin (DDP) on human lung cancer.	nimesulide	96-106	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-74
21232215-1	2004	BACKGROUND: To study the effect and possible mechanism of cyclooxygenase-2 selective inhibitor, nimesulide (NIM), combined with cisplatin (DDP) on human lung cancer.	nimesulide	108-111	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-74
21232215-6	2004	Both NIM (25 mumol/L) and DDP (3 mg/L) could significantly increase the apoptosis of A549 cells ( P < 0.05, P < 0.01), and this action was remarkably increased when DDP was combined with NIM ( P < 0.01, P < 0.01).	nimesulide	5-8	translocase of inner mitochondrial membrane 8A	Homo sapiens	171-174
15198222-8	2004	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	nimesulide	88-98	cytochrome c oxidase subunit II	Canis lupus familiaris	43-48
15242723-3	2004	Partial inhibitors of both COX-1 and COX-2, such as nimesulide and meloxicam, also cross-react but only at high drug doses.	nimesulide	52-62	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-42
15309882-0	2004	Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line.	nimesulide	27-37	AKT serine/threonine kinase 1	Homo sapiens	81-84
15309882-0	2004	Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line.	nimesulide	27-37	AKT serine/threonine kinase 1	Homo sapiens	85-88
15309882-2	2004	We aimed to study the effects of the selective COX-2 inhibitor, nimesulide, on cell viability and telomerase and Akt/PKB activity in the human gastric cancer cell line MKN-45 and to explore the molecular mechanism for the antitumor activity of the selective COX-2 inhibitor.	nimesulide	64-74	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	47-52
15309882-2	2004	We aimed to study the effects of the selective COX-2 inhibitor, nimesulide, on cell viability and telomerase and Akt/PKB activity in the human gastric cancer cell line MKN-45 and to explore the molecular mechanism for the antitumor activity of the selective COX-2 inhibitor.	nimesulide	64-74	AKT serine/threonine kinase 1	Homo sapiens	113-120
15309882-2	2004	We aimed to study the effects of the selective COX-2 inhibitor, nimesulide, on cell viability and telomerase and Akt/PKB activity in the human gastric cancer cell line MKN-45 and to explore the molecular mechanism for the antitumor activity of the selective COX-2 inhibitor.	nimesulide	64-74	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	258-263
15309882-6	2004	In the gastric cancer cell line MKN-45 nimesulide caused a time- and dose-dependent reduction in cell numbers and significantly inhibited telomerase and Akt/PKB activity; the inhibition of telomerase activity was partly associated with the attenuation of Akt/PKB activity.	nimesulide	39-49	AKT serine/threonine kinase 1	Homo sapiens	153-156
15309882-6	2004	In the gastric cancer cell line MKN-45 nimesulide caused a time- and dose-dependent reduction in cell numbers and significantly inhibited telomerase and Akt/PKB activity; the inhibition of telomerase activity was partly associated with the attenuation of Akt/PKB activity.	nimesulide	39-49	AKT serine/threonine kinase 1	Homo sapiens	157-160
15309882-6	2004	In the gastric cancer cell line MKN-45 nimesulide caused a time- and dose-dependent reduction in cell numbers and significantly inhibited telomerase and Akt/PKB activity; the inhibition of telomerase activity was partly associated with the attenuation of Akt/PKB activity.	nimesulide	39-49	AKT serine/threonine kinase 1	Homo sapiens	255-258
15309882-6	2004	In the gastric cancer cell line MKN-45 nimesulide caused a time- and dose-dependent reduction in cell numbers and significantly inhibited telomerase and Akt/PKB activity; the inhibition of telomerase activity was partly associated with the attenuation of Akt/PKB activity.	nimesulide	39-49	AKT serine/threonine kinase 1	Homo sapiens	259-262
15086448-7	2004	The changes in basal membrane potential and in the nicotinic receptor response were suppressed by the non-selective cyclooxygenase (COX) inhibitor indomethacin (10 microm), and the COX II-specific inhibitor, nimesulide (100 microm), whereas the COX-I selective inhibitor SC-560 (5 microm) and the proteintyrosinekinase inhibitor genistein (50 microm) only partially inhibited the action of TNF-alpha.	nimesulide	208-218	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	181-187
15064140-2	2004	The purpose of this study was to evaluate the neuroprotective effects of the selective COX-2 inhibitor nimesulide on cerebral infarction and neurological deficits in a standardized model of transient focal cerebral ischemia in rats.	nimesulide	103-113	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	87-92
15064140-10	2004	Further, administration of nimesulide in a delayed treatment paradigm completely abolished PGE(2) accumulation in the postischemic brain, suggesting that COX-2 inhibition is a promising therapeutic strategy for cerebral ischemia to target the late-occurring inflammatory events which amplify initial damage.	nimesulide	27-37	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	154-159
15086448-7	2004	The changes in basal membrane potential and in the nicotinic receptor response were suppressed by the non-selective cyclooxygenase (COX) inhibitor indomethacin (10 microm), and the COX II-specific inhibitor, nimesulide (100 microm), whereas the COX-I selective inhibitor SC-560 (5 microm) and the proteintyrosinekinase inhibitor genistein (50 microm) only partially inhibited the action of TNF-alpha.	nimesulide	208-218	tumor necrosis factor	Rattus norvegicus	390-399
14510637-3	2004	With the detergent genapol X-100 (2 mM) present, the potencies of nimesulide, ibuprofen, flufenamic acid, niflumic acid and naproxen were increased over 100-fold against Cox-2 and titration curve shapes changed, so that maximal inhibition now approached 100%.	nimesulide	66-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	170-175
15063765-4	2004	As a result, expression of VEGF in HSCs was markedly elevated; and pretreatment with COX-2 inhibitors (nimesulide or indomethacin) could significantly ameliorate the angiogenic event.	nimesulide	103-113	vascular endothelial growth factor A	Rattus norvegicus	27-31
15063765-4	2004	As a result, expression of VEGF in HSCs was markedly elevated; and pretreatment with COX-2 inhibitors (nimesulide or indomethacin) could significantly ameliorate the angiogenic event.	nimesulide	103-113	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	85-90
15312381-0	2004	[Nimesulide, a selective cyclooxygenase-2 inhibitor inhibits telomerase activity by blocking activation of PKB in gastric cancer cell line].	nimesulide	1-11	protein tyrosine kinase 2 beta	Homo sapiens	107-110
15312381-1	2004	OBJECTIVE: To study the effects of nimesulide, a selective COX-2 inhibitor, on cell viability, telomerase and PKB activities in human gastric cancer cell line SGC7901 and to explore its molecular mechanism of selective growth inhibition.	nimesulide	35-45	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	59-64
15312381-1	2004	OBJECTIVE: To study the effects of nimesulide, a selective COX-2 inhibitor, on cell viability, telomerase and PKB activities in human gastric cancer cell line SGC7901 and to explore its molecular mechanism of selective growth inhibition.	nimesulide	35-45	protein tyrosine kinase 2 beta	Homo sapiens	110-113
15312381-6	2004	CONCLUSION: Selective COX-2 inhibitor nimesulide inhibits telomerase activity of gastric cancer cells by partly blocking the activation of protein kinase B.	nimesulide	38-48	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27
15312381-6	2004	CONCLUSION: Selective COX-2 inhibitor nimesulide inhibits telomerase activity of gastric cancer cells by partly blocking the activation of protein kinase B.	nimesulide	38-48	protein tyrosine kinase 2 beta	Homo sapiens	139-155
14975458-7	2004	In contrast, the combination of nimesulide and aspirin inhibited PGI-M excretion to a greater extent than aspirin (p = 0.001).	nimesulide	32-42	glucose-6-phosphate isomerase	Homo sapiens	65-68
14977856-0	2004	Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.	nimesulide	50-60	prostaglandin-endoperoxide synthase 2	Mus musculus	22-38
14977856-0	2004	Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.	nimesulide	50-60	prostaglandin-endoperoxide synthase 2	Mus musculus	115-185
14977856-1	2004	PURPOSE: The objectives of this study were to evaluate the effect of a cyclooxygenase (COX)-2 inhibitor, nimesulide, on the growth inhibition of s.c. human lung A549 adenocarcinoma tumors and to assess the effect of nimesulide on the expression of COX-2 and peroxisome proliferator-activated receptor (PPAR)-gamma in lung tumors harvested from mice.	nimesulide	105-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	71-93
14977856-1	2004	PURPOSE: The objectives of this study were to evaluate the effect of a cyclooxygenase (COX)-2 inhibitor, nimesulide, on the growth inhibition of s.c. human lung A549 adenocarcinoma tumors and to assess the effect of nimesulide on the expression of COX-2 and peroxisome proliferator-activated receptor (PPAR)-gamma in lung tumors harvested from mice.	nimesulide	105-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	248-253
14977856-1	2004	PURPOSE: The objectives of this study were to evaluate the effect of a cyclooxygenase (COX)-2 inhibitor, nimesulide, on the growth inhibition of s.c. human lung A549 adenocarcinoma tumors and to assess the effect of nimesulide on the expression of COX-2 and peroxisome proliferator-activated receptor (PPAR)-gamma in lung tumors harvested from mice.	nimesulide	105-115	peroxisome proliferator activated receptor gamma	Homo sapiens	258-313
14977856-6	2004	Western blotting experiments showed similar expression of COX-2 in both control and nimesulide (250-1500 ppm)-treated mice tumor tissues.	nimesulide	84-94	cytochrome c oxidase II, mitochondrial	Mus musculus	58-63
14977856-7	2004	PPAR-gamma was found to be overexpressed as a result of 1500 ppm nimesulide treatment and was not detected in tumors from control or 250-1000 ppm nimesulide-treated mice.	nimesulide	65-75	peroxisome proliferator activated receptor gamma	Mus musculus	0-10
15078741-12	2004	RESULTS: At the doses used, nimesulide was selective for COX-2, while ibuprofen was nonselective based on serum TXB(2) levels.	nimesulide	28-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
15078741-16	2004	This suggests that the inducible COX-2 mediates central PG synthesis, which may be important in the generation of pain, as the use of nimesulide also resulted in significant decreases in postoperative pain perception.	nimesulide	134-144	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	33-38
15203612-0	2004	Experience of the use of nimesulide, a cyclo-oxygenase-2 selective prostaglandin synthesis inhibitor, in the prevention of preterm labour in 44 high-risk cases.	nimesulide	25-35	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-56
14977856-10	2004	Nimesulide-induced enhancement of the expression of PPAR-gamma may also contribute to its antitumor effect, which needs to be further investigated.	nimesulide	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	52-62
14984594-8	2004	When DC were activated with LPS in the presence of nimesulide, a COX-2 selective inhibitor, IL-10 synthesis was inhibited, indicating that endogenous prostaglandins regulate DC cytokine production.	nimesulide	51-61	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	65-70
14984594-8	2004	When DC were activated with LPS in the presence of nimesulide, a COX-2 selective inhibitor, IL-10 synthesis was inhibited, indicating that endogenous prostaglandins regulate DC cytokine production.	nimesulide	51-61	interleukin 10	Homo sapiens	92-97
14605244-0	2004	Nimesulide, a cyclooxygenase-2 preferential inhibitor, impairs renal function in the newborn rabbit.	nimesulide	0-10	prostaglandin G/H synthase 2	Oryctolagus cuniculus	14-30
14605244-2	2004	Recently, the use of the cyclooxygenase-2 (COX2) preferential NSAID nimesulide has been proposed.	nimesulide	68-78	prostaglandin G/H synthase 2	Oryctolagus cuniculus	25-41
14605244-2	2004	Recently, the use of the cyclooxygenase-2 (COX2) preferential NSAID nimesulide has been proposed.	nimesulide	68-78	prostaglandin G/H synthase 2	Oryctolagus cuniculus	43-47
14648334-7	2004	More recently, the use of nimesulide, a selective COX-2 inhibitor, as a tocolytic agent has been advocated.	nimesulide	26-36	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	50-55
14688622-7	2004	Also, treatment with a selective COX-2 inhibitor, nimesulide, after ischemia decreased hippocampal neuronal damages.	nimesulide	50-60	prostaglandin-endoperoxide synthase 2	Mus musculus	33-38
15077593-1	2004	This review paper presents some basic information of a "rediscovered" nonsteroidal anti-inflammatory drug Nimesulid which is one of the first selective inhibitors of cyclooxygenase-2, has a history of good clinical results, and is relatively well tolerated with patients.	nimesulide	106-115	prostaglandin-endoperoxide synthase 2	Homo sapiens	166-182
16146090-0	2004	Effect of nimesulide-a preferential COX-2 inhibitor on arterial blood pressure, compared to ketoprofen.	nimesulide	10-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	36-41
16146090-2	2004	In these study the effect of nimesulide--preferential COX-2 inhibitor, administration on 24-hour blood pressure profile was investigated in 40 adult individuals on antihypertensive therapy with pain states caused by osteoartritis.	nimesulide	29-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	54-59
15315158-1	2004	To study the effects of cyclooxygenase 2 selective inhibitor Nimesulide (NIM) combined with Cisplatin (DDP) on human lung cancer and the possible mechanisms, the proliferation and apoptosis of human lung cancer cell line A549 were evaluated by MTT reduction assay and flow cytometry respectively.	nimesulide	61-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-40
15315158-1	2004	To study the effects of cyclooxygenase 2 selective inhibitor Nimesulide (NIM) combined with Cisplatin (DDP) on human lung cancer and the possible mechanisms, the proliferation and apoptosis of human lung cancer cell line A549 were evaluated by MTT reduction assay and flow cytometry respectively.	nimesulide	73-76	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-40
14871027-5	2003	Cyclooxygenase-1 inhibitors (flurbiprofen, 10(-7) M) attenuated the noradrenaline-induced contraction and cyclooxygenase-2 (nimesulide, 10(-7) M) slightly attenuated the contraction.	nimesulide	124-134	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	0-16
14871027-5	2003	Cyclooxygenase-1 inhibitors (flurbiprofen, 10(-7) M) attenuated the noradrenaline-induced contraction and cyclooxygenase-2 (nimesulide, 10(-7) M) slightly attenuated the contraction.	nimesulide	124-134	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	106-122
14753029-1	2003	INTRODUCTION: Nimesulid (Mesulid) is a non-steroid anti-inflammatory drug (NSAID), acting by the selective inhibition of the Cyclooxygenase-2 (COX-2) isoenzyme.	nimesulide	14-23	prostaglandin-endoperoxide synthase 2	Homo sapiens	125-141
14753029-1	2003	INTRODUCTION: Nimesulid (Mesulid) is a non-steroid anti-inflammatory drug (NSAID), acting by the selective inhibition of the Cyclooxygenase-2 (COX-2) isoenzyme.	nimesulide	14-23	prostaglandin-endoperoxide synthase 2	Homo sapiens	143-148
14753029-1	2003	INTRODUCTION: Nimesulid (Mesulid) is a non-steroid anti-inflammatory drug (NSAID), acting by the selective inhibition of the Cyclooxygenase-2 (COX-2) isoenzyme.	nimesulide	25-32	prostaglandin-endoperoxide synthase 2	Homo sapiens	125-141
14753029-1	2003	INTRODUCTION: Nimesulid (Mesulid) is a non-steroid anti-inflammatory drug (NSAID), acting by the selective inhibition of the Cyclooxygenase-2 (COX-2) isoenzyme.	nimesulide	25-32	prostaglandin-endoperoxide synthase 2	Homo sapiens	143-148
14572603-7	2003	Interestingly, the cyclooxygenase (COX-) 2-selective inhibitor nimesulide (NS) and celecoxib (CXB) showed different responses than those of other inhibitors.	nimesulide	63-73	cytochrome c oxidase II, mitochondrial	Mus musculus	19-42
14572603-7	2003	Interestingly, the cyclooxygenase (COX-) 2-selective inhibitor nimesulide (NS) and celecoxib (CXB) showed different responses than those of other inhibitors.	nimesulide	75-77	cytochrome c oxidase II, mitochondrial	Mus musculus	19-42
14531950-0	2003	Nimesulide inhibits tumor growth in mice implanted hepatoma: overexpression of Bax over Bcl-2.	nimesulide	0-10	BCL2-associated X protein	Mus musculus	79-82
14730095-4	2003	Indomethacin (IND), an inhibitor preferentially acting on COX-1, as well as nimesulide (NIM) and celecoxib (CECOX), i.e. preferential and selective inhibitor of COX-2, respectively, administered icv almost completely blocked the antinociceptive effect of ACETA in Randall-Selitto method.	nimesulide	76-86	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	161-166
14531950-0	2003	Nimesulide inhibits tumor growth in mice implanted hepatoma: overexpression of Bax over Bcl-2.	nimesulide	0-10	B cell leukemia/lymphoma 2	Mus musculus	88-93
14531950-5	2003	Nimesulide also decreased cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) and Bcl-2 expression, while increased the level of Bax protein.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	26-42
14531950-5	2003	Nimesulide also decreased cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) and Bcl-2 expression, while increased the level of Bax protein.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	44-49
14531950-5	2003	Nimesulide also decreased cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) and Bcl-2 expression, while increased the level of Bax protein.	nimesulide	0-10	B cell leukemia/lymphoma 2	Mus musculus	80-85
14531950-5	2003	Nimesulide also decreased cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) and Bcl-2 expression, while increased the level of Bax protein.	nimesulide	0-10	BCL2-associated X protein	Mus musculus	127-130
14531950-6	2003	CONCLUSION: Nimesulide suppresses tumor growth and induces apoptosis by inhibiting COX-2 and PGE2 expression, which may be related to overexpression of Bax over Bcl-2.	nimesulide	12-22	prostaglandin-endoperoxide synthase 2	Mus musculus	83-88
14531950-6	2003	CONCLUSION: Nimesulide suppresses tumor growth and induces apoptosis by inhibiting COX-2 and PGE2 expression, which may be related to overexpression of Bax over Bcl-2.	nimesulide	12-22	BCL2-associated X protein	Mus musculus	152-155
14531950-6	2003	CONCLUSION: Nimesulide suppresses tumor growth and induces apoptosis by inhibiting COX-2 and PGE2 expression, which may be related to overexpression of Bax over Bcl-2.	nimesulide	12-22	B cell leukemia/lymphoma 2	Mus musculus	161-166
12946449-2	2003	For this purpose, the effects of selective COX-2 inhibitors, NS-398 and nimesulide, on the expression of COX-2, PGE2 release and respiratory burst, degranulation and cytokine release in activated neutrophils were examined.	nimesulide	72-82	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-48
12946449-2	2003	For this purpose, the effects of selective COX-2 inhibitors, NS-398 and nimesulide, on the expression of COX-2, PGE2 release and respiratory burst, degranulation and cytokine release in activated neutrophils were examined.	nimesulide	72-82	prostaglandin-endoperoxide synthase 2	Homo sapiens	105-110
12969784-1	2003	The present study was conducted to examine the effects of selective cyclooxygenase (COX)-2 inhibitors, nimesulide and etodolac, on early stages of tongue carcinogenesis due to 4-nitroquinoline 1-oxide(4-NQO).	nimesulide	103-113	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	68-90
14512150-3	2003	In the present study, we examined the possibility that the neuroprotective effects of the cyclooxygenase-2 inhibitor nimesulide would depend upon reduction of oxidative stress following cerebral ischemia.	nimesulide	117-127	prostaglandin-endoperoxide synthase 2	Homo sapiens	90-106
14512150-7	2003	Few Fluoro-Jade B positive cells were seen in CA1 region of hippocampus in ischemic animals treated with nimesulide compared with vehicle.	nimesulide	105-115	carbonic anhydrase 1	Homo sapiens	46-49
12970750-8	2003	Not only TNF-induced cell death but also apoptosis triggered by the CD95 and TRAIL receptors was enhanced by nimesulide.	nimesulide	109-119	tumor necrosis factor	Homo sapiens	9-12
12970750-8	2003	Not only TNF-induced cell death but also apoptosis triggered by the CD95 and TRAIL receptors was enhanced by nimesulide.	nimesulide	109-119	Fas cell surface death receptor	Homo sapiens	68-72
12970750-4	2003	Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E(2) (PGE(2)) production, only in H21 cells.	nimesulide	67-77	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-44
12970750-4	2003	Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E(2) (PGE(2)) production, only in H21 cells.	nimesulide	67-77	tumor necrosis factor	Homo sapiens	88-91
14511336-4	2003	Co-administration of SR140333, a selective substance P receptor (neurokinin-1) antagonist, or nimesulide, a cyclooxygenase-2-selective inhibitor, augmented the acute effects of morphine, prevented morphine tolerance and reversed established tolerance.	nimesulide	94-104	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	108-124
12970750-4	2003	Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E(2) (PGE(2)) production, only in H21 cells.	nimesulide	67-77	tumor necrosis factor	Homo sapiens	107-110
12970750-4	2003	Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E(2) (PGE(2)) production, only in H21 cells.	nimesulide	67-77	tumor necrosis factor	Homo sapiens	107-110
12970750-4	2003	Here we demonstrate that the selective COX-2 inhibitors NS-398 and nimesulide increased TNF sensitivity of TNF-resistant HeLa H21 and TNF-sensitive HeLa D98 cells, although this cytokine induced significant COX-2 activity, as judged by prostaglandin E(2) (PGE(2)) production, only in H21 cells.	nimesulide	67-77	prostaglandin-endoperoxide synthase 2	Homo sapiens	207-212
12970750-5	2003	TNF did also not induce PGE(2) production in MCF-7/casp-3 cells stably expressing COX-2; however, nimesulide strongly enhanced TNF-induced apoptosis in these cells.	nimesulide	98-108	tumor necrosis factor	Homo sapiens	127-130
14511336-6	2003	Co-exposure with the peptide CGRP receptor antagonist CGRP8-37, SR140333 or nimesulide prevented the morphine-induced increase in the expression of CGRP immunoreactivity.	nimesulide	76-86	calcitonin-related polypeptide alpha	Rattus norvegicus	29-33
14567645-4	2003	Induction of apoptosis in A549 cells by nimesulide (nonaerosolized or aerosolized) in combination with doxorubicin was evaluated by established techniques such as caspase-3 estimation and terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining.	nimesulide	40-50	DNA nucleotidylexotransferase	Homo sapiens	188-225
14567645-8	2003	The specific caspase-3 activity in A549 cells treated with nimesulide (40 microg/ml) and doxorubicin (0.25 microg/ml) in combination was 3 and 5 times higher than doxorubicin and nimesulide, respectively.	nimesulide	59-69	caspase 3	Homo sapiens	13-22
14567645-1	2003	PURPOSE: To evaluate the in vitro effects of an aerosolized cyclooxygenase-2 (COX-2) inhibitor, nimesulide, on the cytotoxicity and apoptotic response of doxorubicin against the human lung adenocarcinoma cell line A549.	nimesulide	96-106	prostaglandin-endoperoxide synthase 2	Homo sapiens	60-76
14567645-1	2003	PURPOSE: To evaluate the in vitro effects of an aerosolized cyclooxygenase-2 (COX-2) inhibitor, nimesulide, on the cytotoxicity and apoptotic response of doxorubicin against the human lung adenocarcinoma cell line A549.	nimesulide	96-106	prostaglandin-endoperoxide synthase 2	Homo sapiens	78-83
14567645-8	2003	The specific caspase-3 activity in A549 cells treated with nimesulide (40 microg/ml) and doxorubicin (0.25 microg/ml) in combination was 3 and 5 times higher than doxorubicin and nimesulide, respectively.	nimesulide	179-189	caspase 3	Homo sapiens	13-22
14567645-11	2003	CONCLUSION: Our results indicate that aerosolized nimesulide significantly enhances doxorubicin activity against A549 cells, and the enhanced cytotoxicity was probably mediated via a COX-2-independent mechanism.	nimesulide	50-60	prostaglandin-endoperoxide synthase 2	Homo sapiens	183-188
12821125-4	2003	PGE(2) production was inhibited by the COX-2 inhibitor nimesulide.	nimesulide	55-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	39-44
12917209-0	2003	The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.	nimesulide	81-91	prostaglandin-endoperoxide synthase 2	Homo sapiens	4-20
12917209-0	2003	The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.	nimesulide	81-91	androgen receptor	Homo sapiens	100-117
12917209-0	2003	The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.	nimesulide	81-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	144-149
12917209-3	2003	We found that two cyclooxygenase 2-specific NSAIDs, celecoxib and nimesulide, dramatically reduced the expression of androgen-inducible genes, such as prostate-specific antigen, hK2, and the FK506-binding protein 51 (FKBP51).	nimesulide	66-76	prostaglandin-endoperoxide synthase 2	Homo sapiens	18-34
12917209-3	2003	We found that two cyclooxygenase 2-specific NSAIDs, celecoxib and nimesulide, dramatically reduced the expression of androgen-inducible genes, such as prostate-specific antigen, hK2, and the FK506-binding protein 51 (FKBP51).	nimesulide	66-76	RBPJ pseudogene 3	Homo sapiens	178-181
14567460-0	2003	Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines.	nimesulide	87-97	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	69-74
14567460-4	2003	AIMS: The aim of our study was to characterize the effects of two COX-2 selective inhibitors, NS-398 and nimesulide, on colorectal cancer cell proliferation, and to describe the molecular mechanisms involved.	nimesulide	105-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	66-71
14567460-14	2003	CONCLUSION: NS-398 and nimesulide inhibit colorectal cell proliferation through induction of p21Cip1 and p27Kip1.	nimesulide	23-33	cyclin dependent kinase inhibitor 1A	Homo sapiens	93-100
14567460-14	2003	CONCLUSION: NS-398 and nimesulide inhibit colorectal cell proliferation through induction of p21Cip1 and p27Kip1.	nimesulide	23-33	cyclin dependent kinase inhibitor 1B	Homo sapiens	105-112
22900315-1	2003	Antiradical activity of nimesulide, a commonly used COX-2 specific inhibitor, was estimated in vitro by 1, 1 diphenyl-2-picrylhydrazyl (DPPH) assay, nitroblue tetrazolium reduction assay and lipid peroxidation assay, respectively.	nimesulide	24-34	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	52-57
22900315-6	2003	Nimesulide pretreatment was found to protect the tissue from enhanced levels of lipid peroxidation, and also stimulated the levels of glutathione-S-transferase (GST) in liver and glutathione reductase in kidneys.	nimesulide	0-10	hematopoietic prostaglandin D synthase	Rattus norvegicus	134-159
22900315-6	2003	Nimesulide pretreatment was found to protect the tissue from enhanced levels of lipid peroxidation, and also stimulated the levels of glutathione-S-transferase (GST) in liver and glutathione reductase in kidneys.	nimesulide	0-10	hematopoietic prostaglandin D synthase	Rattus norvegicus	161-164
22900315-8	2003	Although, in our study, nimesulide proved to be an inducer of GST (a marker for chemoprevention) and a scavenger of superoxide anions at higher concentrations (> 250 microM), but the relevance of suppression of SOD enzyme activity, which may contribute to the drug"s toxic effects cannot be ignored.	nimesulide	24-34	hematopoietic prostaglandin D synthase	Rattus norvegicus	62-65
12946449-9	2003	FMLP- or OZ-induced PGE2 release was abolished by the addition of NS-398 or nimesulide; nevertheless, even a high concentration of COX-2 inhibitor did not change FMLP- or OZ-induced expression of COX-2 at message and protein levels.	nimesulide	76-86	formyl peptide receptor 1	Homo sapiens	0-4
12946449-11	2003	These studies showed that selective COX-2 inhibitors, NS-398 and nimesulide, suppressed PGE2 and proinflammatory cytokine release in activated neutrophils.	nimesulide	65-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	36-41
14566678-4	2003	To avoid gastrointestinal side effects of regular NSAIDs, we also showed the chemopreventive effect of nimesulide, a selective inhibitor of the second isoform of COX, COX-2, which does not affect COX-l house-keeping activity in gastrointestinal mucosa on the same model.	nimesulide	103-113	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	167-172
14592556-4	2003	Pretreatment with COX-1 and COX-3 inhibitors (aspirin at a low dose of 1 mg kg(-1), SC 560 and acetaminophen, 0.3-3 mg kg(-1)) slightly augmented thrombolysis by ACE-I, while COX-2 inhibitors (nimesulide and coxibs at doses <1 mg kg(-1) and aspirin at a high dose of 50 mg kg(-1)) or a kinin B2 receptor antagonist (icatibant) abolished it.	nimesulide	193-203	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	18-23
12844343-6	2003	The abundance of DSCR1 and TCTE1L mRNA was attenuated when myometrial contraction was inhibited by Nimesulide (n=6), a specific prostaglandin H synthase 2 inhibitor.	nimesulide	99-109	calcipressin-1	Ovis aries	17-22
12844343-6	2003	The abundance of DSCR1 and TCTE1L mRNA was attenuated when myometrial contraction was inhibited by Nimesulide (n=6), a specific prostaglandin H synthase 2 inhibitor.	nimesulide	99-109	dynein light chain Tctex-type 3	Ovis aries	27-33
12844343-6	2003	The abundance of DSCR1 and TCTE1L mRNA was attenuated when myometrial contraction was inhibited by Nimesulide (n=6), a specific prostaglandin H synthase 2 inhibitor.	nimesulide	99-109	prostaglandin G/H synthase 2	Ovis aries	128-154
12844343-10	2003	Upregulation of DSCR1 and TCTE1L in both betamethasone-induced premature labor and spontaneous term labor and inhibition of their expression by Nimesulide suggest a functional role of these two genes in myometrial activation associated with onset of labor.	nimesulide	144-154	calcipressin-1	Ovis aries	16-21
14518559-3	2003	Nimesulide, a preferential COX-2 inhibitor was evaluated for its efficacy against experimental colitis in two different models (acetic acid- and LTB4-induced IBD) in rats.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	27-32
12807536-1	2003	BACKGROUND: The cyclooxygenase-2 inhibitor nimesulide is able to reduce kainate-induced oxidative stress in vivo.	nimesulide	43-53	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	16-32
14592556-4	2003	Pretreatment with COX-1 and COX-3 inhibitors (aspirin at a low dose of 1 mg kg(-1), SC 560 and acetaminophen, 0.3-3 mg kg(-1)) slightly augmented thrombolysis by ACE-I, while COX-2 inhibitors (nimesulide and coxibs at doses <1 mg kg(-1) and aspirin at a high dose of 50 mg kg(-1)) or a kinin B2 receptor antagonist (icatibant) abolished it.	nimesulide	193-203	cytochrome c oxidase III, mitochondrial	Rattus norvegicus	28-33
12618123-7	2003	Moreover the COX-2 selective inhibitor nimesulide attenuated kindling development.	nimesulide	39-49	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	13-18
12717830-1	2003	AIM: To evaluate the potential role of Nimesulide, a selective COX-2 inhibitor, in proliferation and apoptosis of gastric adenocarcinoma cells SGC7901.	nimesulide	39-49	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	63-68
12717830-8	2003	Meanwhile, Nimesulide could up-regulate the expression of P27(kip1) protein.	nimesulide	11-21	cyclin dependent kinase inhibitor 1B	Homo sapiens	58-66
12717830-10	2003	The up-regulation of P27(kip1) gene may contribute to the accumulation of these cells in the G(0)/G(1) phase following treatment with Nimesulide.	nimesulide	134-144	cyclin dependent kinase inhibitor 1B	Homo sapiens	21-29
12717833-8	2003	Expression levels of c-jun and p53 were found to be elevated for the tumors from mice treated with nimesulide and 5-FU comparing to those with either of them, but a reduced PGE(2) level was observed only for the treatment with nimesulide.	nimesulide	99-109	jun proto-oncogene	Mus musculus	21-26
12717833-8	2003	Expression levels of c-jun and p53 were found to be elevated for the tumors from mice treated with nimesulide and 5-FU comparing to those with either of them, but a reduced PGE(2) level was observed only for the treatment with nimesulide.	nimesulide	99-109	transformation related protein 53, pseudogene	Mus musculus	31-34
12717833-8	2003	Expression levels of c-jun and p53 were found to be elevated for the tumors from mice treated with nimesulide and 5-FU comparing to those with either of them, but a reduced PGE(2) level was observed only for the treatment with nimesulide.	nimesulide	227-237	jun proto-oncogene	Mus musculus	21-26
12717833-8	2003	Expression levels of c-jun and p53 were found to be elevated for the tumors from mice treated with nimesulide and 5-FU comparing to those with either of them, but a reduced PGE(2) level was observed only for the treatment with nimesulide.	nimesulide	227-237	transformation related protein 53, pseudogene	Mus musculus	31-34
12569549-0	2003	A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters.	nimesulide	30-40	prostaglandin G/H synthase 2	Mesocricetus auratus	2-18
12586733-3	2003	We found that prophylactic administration of nimesulide, a preferential COX-2 inhibitor, in the feed resulted in a significant delay in the onset of ALS type motor impairment.	nimesulide	45-55	cytochrome c oxidase II, mitochondrial	Mus musculus	72-77
12725321-4	2003	Furthermore, nimesulid, a cyclooxygenase-2 selective inhibitor, also suppressed colonic aberrant crypt foci/tumors as well as sulindac.	nimesulide	13-22	prostaglandin-endoperoxide synthase 2	Mus musculus	26-42
12725321-5	2003	Administration of nimesulid caused apoptosis indices to be significantly higher along with cyclooxygenase-2 expression being significantly lower than in controls.	nimesulide	18-27	prostaglandin-endoperoxide synthase 2	Mus musculus	91-107
12643859-6	2003	Indomethacin, resveratrol (selective COX-1 blocker), and COX-2 antagonists, nimesulide, NS-398, DuP-697, and L-752860, attenuated the additional inhibitory effects of gut manipulation following laparotomy in a dose-dependent manner.	nimesulide	76-86	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	57-62
12751821-5	2003	The cyclooxygenase-2-selective inhibitors nimesulide and SC-58125 did not inhibit fatty acid amide hydrolase activity at either pH.	nimesulide	42-52	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	4-20
14506907-5	2003	Nimesulide is a preferential COX-2 inhibitor widely used to treat pain.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	29-34
12493569-1	2003	Nimesulide, a selective inhibitor of cyclooxygenase-2, has been reported to cause less gastric damage, compared to other NSAIDs.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	37-53
14598890-7	2003	Our findings indicate that nimesulide may inhibit cancer metastasis through inhibition of pro-MMP-9 and MMP-9 inductions.	nimesulide	27-37	matrix metallopeptidase 9	Rattus norvegicus	94-99
14598890-7	2003	Our findings indicate that nimesulide may inhibit cancer metastasis through inhibition of pro-MMP-9 and MMP-9 inductions.	nimesulide	27-37	matrix metallopeptidase 9	Rattus norvegicus	104-109
14506908-3	2003	The CFA model was then further studied for the effects of treatment with the NSAID, nimesulide (a preferential cyclo-oxygenase [COX]-2 inhibitor).	nimesulide	84-94	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	128-134
14506908-7	2003	CONCLUSION: This study demonstrates that CSF biomarker profiles, as detected by SELDI technology, can consistently and reproducibly differentiate inflammatory from neuropathic pain, and reflect the analgesic action produced by the preferential COX-2 inhibitor, nimesulide.	nimesulide	261-271	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	244-249
14506909-3	2003	Nimesulide, a selective inhibitor of COX-2, has been shown to relieve pain rapidly in arthritis.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-42
14506909-18	2003	CONCLUSIONS: Nimesulide, a COX-2 selective inhibitor, has a rapid onset of action in the blood compartment, with early inhibition of PGE2 generation, an index of COX-2 activity.	nimesulide	13-23	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	27-32
14506909-18	2003	CONCLUSIONS: Nimesulide, a COX-2 selective inhibitor, has a rapid onset of action in the blood compartment, with early inhibition of PGE2 generation, an index of COX-2 activity.	nimesulide	13-23	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	162-167
12408728-0	2002	Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors.	nimesulide	62-72	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	133-138
12593597-1	2003	BACKGROUND: The purpose of the present study was to evaluate the effect of a relatively selective cyclooxygenase (COX)-2 inhibitor (nimesulide) and non-selective COX-1/COX-2 inhibitor (naproxen) used as an adjunct to non-surgical (scaling and root planing [SRP]) periodontal therapy in chronic periodontitis patients on the gingival tissue (GT) levels of prostaglandin (PG)E2 and PGF2alpha.	nimesulide	132-142	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	114-120
12593597-13	2003	CONCLUSIONS: Nimesulides, relatively selective COX-2 inhibitors, may have additional inhibitory effects on GT PGF2alpha levels in the first week following non-surgical periodontal treatment.	nimesulide	13-24	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	47-52
12429575-10	2002	Aspirin, indomethacin and nimesulide inhibited COX-1 activity, without altering LO activity.	nimesulide	26-36	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	47-52
12507282-0	2003	A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression.	nimesulide	19-29	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	2-7
12507282-0	2003	A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression.	nimesulide	19-29	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	140-145
12507282-0	2003	A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression.	nimesulide	19-29	nitric oxide synthase 2	Rattus norvegicus	150-154
12507282-6	2003	Feeding of nimesulide significantly decreased polyamine content and PCNA-labeling index in tongue carcinoma.	nimesulide	11-21	proliferating cell nuclear antigen	Rattus norvegicus	68-72
12507282-8	2003	In addition, nimesulide feeding reduced COX-2 and iNOS expression in the tongue dysplasia and neoplasms.	nimesulide	13-23	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	40-45
12507282-8	2003	In addition, nimesulide feeding reduced COX-2 and iNOS expression in the tongue dysplasia and neoplasms.	nimesulide	13-23	nitric oxide synthase 2	Rattus norvegicus	50-54
12507282-9	2003	These results suggest that 400 ppm nimesulide in diet, when given during the promotion phase, exerts chemopreventive ability against 4-NQO-induced tongue tumorigenesis through inhibition of cell proliferation activity in conjunction with modification of COX-2 and iNOS expression of the target lesions.	nimesulide	35-45	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	254-259
12507282-9	2003	These results suggest that 400 ppm nimesulide in diet, when given during the promotion phase, exerts chemopreventive ability against 4-NQO-induced tongue tumorigenesis through inhibition of cell proliferation activity in conjunction with modification of COX-2 and iNOS expression of the target lesions.	nimesulide	35-45	nitric oxide synthase 2	Rattus norvegicus	264-268
12499915-0	2003	The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-30
12499915-0	2003	The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	112-117
12499915-2	2003	This study was designed to investigate the effects of the COX-2 inhibitor nimesulide on the growth of human pancreatic cancer cells.	nimesulide	74-84	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-63
12499915-13	2003	CONCLUSION: The selective COX-2 inhibitor nimesulide is antimitogenic in pancreatic cancer cells, which is independent of COX-2 expression.	nimesulide	42-52	prostaglandin-endoperoxide synthase 2	Homo sapiens	26-31
12499915-13	2003	CONCLUSION: The selective COX-2 inhibitor nimesulide is antimitogenic in pancreatic cancer cells, which is independent of COX-2 expression.	nimesulide	42-52	prostaglandin-endoperoxide synthase 2	Homo sapiens	122-127
12439336-0	2002	Colocalization of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon adenocarcinoma COLO 205 cells.	nimesulide	45-55	BCL2 associated X, apoptosis regulator	Homo sapiens	18-21
12439336-0	2002	Colocalization of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon adenocarcinoma COLO 205 cells.	nimesulide	45-55	BH3 interacting domain death agonist	Homo sapiens	27-30
12439336-0	2002	Colocalization of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon adenocarcinoma COLO 205 cells.	nimesulide	45-55	voltage dependent anion channel 1	Homo sapiens	35-41
12439336-2	2002	In the present study the effect of nimesulide (NIM), a specific COX-2 inhibitor, on apoptosis and interactions between BCL-2 family death promoters BAX and BID and BAX and VDAC-1 were examined in human colon adenocarcinoma COLO 205 cells.	nimesulide	35-45	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	64-69
12439336-2	2002	In the present study the effect of nimesulide (NIM), a specific COX-2 inhibitor, on apoptosis and interactions between BCL-2 family death promoters BAX and BID and BAX and VDAC-1 were examined in human colon adenocarcinoma COLO 205 cells.	nimesulide	47-50	BCL2 associated X, apoptosis regulator	Homo sapiens	148-151
12439336-2	2002	In the present study the effect of nimesulide (NIM), a specific COX-2 inhibitor, on apoptosis and interactions between BCL-2 family death promoters BAX and BID and BAX and VDAC-1 were examined in human colon adenocarcinoma COLO 205 cells.	nimesulide	47-50	BH3 interacting domain death agonist	Homo sapiens	156-159
12208318-3	2002	In this double-blind study, we evaluated the effects of a preferential inhibitor of the inducible isoform of cyclo-oxygenase-2, nimesulide, on the spinal nociceptive flexion reflex (RIII reflex) before and after administration of an NO donor in healthy volunteers.	nimesulide	128-138	prostaglandin-endoperoxide synthase 2	Homo sapiens	109-126
12410334-0	2002	Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats.	nimesulide	34-44	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-30
12410334-3	2002	The present study examines the temporal and spatial profiles of COX-2 expression following diffuse traumatic brain injury (TBI) in rats, and the effects of the COX-2 inhibitor nimesulide on cognitive and motor outcomes.	nimesulide	176-186	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	160-165
12410334-9	2002	Administration of the COX-2 inhibitor nimesulide resulted in a significant and substantial improvement in cognitive function compared to vehicle-treated controls, while motor deficits after injury was only improved at 24 h after injury.	nimesulide	38-48	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27
12411468-4	2002	The vasoconstriction elicited by COX-2 inhibition was greater when NO production was inhibited because glomerular filtration rate decreased by >25% when nimesulide was administered to dogs with a reduced NO synthesis.	nimesulide	156-166	prostaglandin-endoperoxide synthase 2	Canis lupus familiaris	33-38
12398903-2	2002	The present study evaluated the pharmacological effects of the selective cyclooxygenase-2 inhibitor nimesulide on delayed neuronal death of hippocampal CA1 neurons following transient global cerebral ischemia in gerbils.	nimesulide	100-110	prostaglandin-endoperoxide synthase 2	Homo sapiens	73-89
12398903-2	2002	The present study evaluated the pharmacological effects of the selective cyclooxygenase-2 inhibitor nimesulide on delayed neuronal death of hippocampal CA1 neurons following transient global cerebral ischemia in gerbils.	nimesulide	100-110	carbonic anhydrase 1	Homo sapiens	152-155
12398903-5	2002	Treatment with a single dose of nimesulide given 30 min before ischemia also resulted in a significant increase in the number of healthy neurons in the hippocampal CA1 sector 7 days after ischemia.	nimesulide	32-42	carbonic anhydrase 1	Homo sapiens	164-167
12398903-6	2002	Of interest is the finding that nimesulide rescued CA1 pyramidal neurons from ischemic death even when treatment was delayed until 24 h after ischemia (34+/-9% protection).	nimesulide	32-42	carbonic anhydrase 1	Homo sapiens	51-54
12398903-7	2002	Neuroprotective effect of nimesulide is still evident 30 days after the ischemic episode, providing the first experimental evidence that cyclooxygenase-2 inhibitors confer a long-lasting neuroprotection.	nimesulide	26-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	137-153
12189188-10	2002	Nimesulide, a COX-2 selective inhibitor used as positive control, showed similar suppressive effects on the development of ACFs in AOM-treated rats and polyps in Apc gene knockout mice.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19
12189188-10	2002	Nimesulide, a COX-2 selective inhibitor used as positive control, showed similar suppressive effects on the development of ACFs in AOM-treated rats and polyps in Apc gene knockout mice.	nimesulide	0-10	APC regulator of WNT signaling pathway	Rattus norvegicus	162-165
12166615-1	2002	We previously found that the cyclooxygenase (COX)-2 preferential inhibitor nimesulide protects rodents" chondrocytes against apoptotic death in vitro.	nimesulide	75-85	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	29-51
12570019-4	2002	Nimesulide, a preferential inhibitor of cyclooxygenase-2 (0.05, 0.5 or 1 mg/kg, subcutaneously) completely abolished the hypothermia, resulting in an acceleration of the fever phase.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	40-56
12570019-6	2002	Nimesulide (0.5 mg/kg) partially prevented serum TNF-alpha elevation.	nimesulide	0-10	tumor necrosis factor	Rattus norvegicus	49-58
12570019-10	2002	Both these drugs also reduced elevated TNF-alpha levels, a fact which may, at least partly, explain the antihypothermic effect of nimesulide.	nimesulide	130-140	tumor necrosis factor	Rattus norvegicus	39-48
12126971-4	2002	Acetylsalicylic acid, indomethacin, nimesulide and rofecoxib were all effective in eliminating the increase in endothelin ET(B) receptor-mediated contraction induced by interleukin-1 beta, but only indomethacin and rofecoxib significantly reduced the spontaneous development of this reaction in cultured arteries.	nimesulide	36-46	interleukin 1 beta	Homo sapiens	169-187
12166616-6	2002	During treatment with nimesulide, in addition to clinical improvement and less pain, serum levels of MMP-3, MMP-8 and COMP fell indicating a beneficial effect on cartilage catabolism.	nimesulide	22-32	cartilage oligomeric matrix protein	Homo sapiens	118-122
12166616-2	2002	The aim of this pilot clinical study was to examine the effects of a nonsteroidal anti-inflammatory drug, nimesulide, on the synthesis of matrix metalloproteinases (MMPs) which are important enzymes in cartilage proteolysis.	nimesulide	106-116	matrix metallopeptidase 1	Homo sapiens	165-169
12166616-6	2002	During treatment with nimesulide, in addition to clinical improvement and less pain, serum levels of MMP-3, MMP-8 and COMP fell indicating a beneficial effect on cartilage catabolism.	nimesulide	22-32	matrix metallopeptidase 3	Homo sapiens	101-106
12166616-6	2002	During treatment with nimesulide, in addition to clinical improvement and less pain, serum levels of MMP-3, MMP-8 and COMP fell indicating a beneficial effect on cartilage catabolism.	nimesulide	22-32	matrix metallopeptidase 8	Homo sapiens	108-113
12452063-3	2002	The current study was designed to evaluate the potential role of Nimesulide, a selective COX-2 inhibitor, on the PGE2 level, proliferation and apoptosis of gastric adenocarcinoma cell line SGC7901.	nimesulide	65-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	89-94
12065685-10	2002	Administration of VEGF neutralizing antibody (2.5 microg ip twice a week) and cyclooxygenase-2 selective inhibitor (nimesulide, 30 mg/L) also hampered Ang II proangiogenic effect.	nimesulide	116-126	prostaglandin-endoperoxide synthase 2	Mus musculus	78-94
12065685-10	2002	Administration of VEGF neutralizing antibody (2.5 microg ip twice a week) and cyclooxygenase-2 selective inhibitor (nimesulide, 30 mg/L) also hampered Ang II proangiogenic effect.	nimesulide	116-126	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	151-157
12021934-0	2002	COX-2 inhibitor (nimesulide) induced acute liver failure.	nimesulide	17-27	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5
11961048-4	2002	Conversely, chronic treatment of the hCOX-2 transgenics with the preferential COX-2 inhibitor nimesulide reversed the hCOX-2-mediated decrease of cortical p18(INK4) mRNA expression in the brain.	nimesulide	94-104	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-43
11961048-4	2002	Conversely, chronic treatment of the hCOX-2 transgenics with the preferential COX-2 inhibitor nimesulide reversed the hCOX-2-mediated decrease of cortical p18(INK4) mRNA expression in the brain.	nimesulide	94-104	cytochrome c oxidase II, mitochondrial	Mus musculus	38-43
11961048-4	2002	Conversely, chronic treatment of the hCOX-2 transgenics with the preferential COX-2 inhibitor nimesulide reversed the hCOX-2-mediated decrease of cortical p18(INK4) mRNA expression in the brain.	nimesulide	94-104	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	118-124
11961048-4	2002	Conversely, chronic treatment of the hCOX-2 transgenics with the preferential COX-2 inhibitor nimesulide reversed the hCOX-2-mediated decrease of cortical p18(INK4) mRNA expression in the brain.	nimesulide	94-104	cyclin dependent kinase inhibitor 2C	Mus musculus	155-158
11961048-6	2002	Moreover, treatment of wild-type primary cortico-hippocampal neuron cultures with the COX-2 preferential inhibitor nimesulide significantly attenuated glutamate-mediated apoptotic damage, which coincided with inhibition of glutamate-mediated pRb phosphorylation.	nimesulide	115-125	cytochrome c oxidase II, mitochondrial	Mus musculus	86-91
12046075-2	2002	We sought to investigate the effect of the selective COX-2 inhibitor, Nimesulide on proliferation and apoptosis of SMMC-7721 human hepatoma cells.	nimesulide	70-80	prostaglandin-endoperoxide synthase 2	Homo sapiens	53-58
12046075-9	2002	CONCLUSION: The selective COX-2 inhibitor, Nimesulide can inhibit the proliferation of SMMC-7721 cells and increase apoptosis rate and apoptosis index of SMMC-7721 cells.	nimesulide	43-53	prostaglandin-endoperoxide synthase 2	Homo sapiens	26-31
11810182-3	2002	Chronic treatment of mice with the selective COX-2 inhibitor nimesulide reduced the hCOX-2-mediated induction of hippocampal C1qB mRNA expression.	nimesulide	61-71	cytochrome c oxidase II, mitochondrial	Mus musculus	45-50
11940691-2	2002	Clinical and laboratory experience with nimesulide, an NSAID with preferential cyclooxygenase-2 inhibition, suggests that it may be a good candidate for AD therapy.	nimesulide	40-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	79-95
11915030-6	2002	The exposure to lipopolysaccharide (LPS) or epidermal growth factor (EGF) determined an increase of PG and NO production in both cell lines and this increase was strongly reduced by COX-2 inhibitors such as celecoxib (CLX) and nimesulide (NIME).	nimesulide	227-237	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	182-187
11915030-6	2002	The exposure to lipopolysaccharide (LPS) or epidermal growth factor (EGF) determined an increase of PG and NO production in both cell lines and this increase was strongly reduced by COX-2 inhibitors such as celecoxib (CLX) and nimesulide (NIME).	nimesulide	239-243	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	182-187
11915030-8	2002	CLX and NIME also inhibited cell proliferation, but only in MDR1 cells.	nimesulide	8-12	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
11950021-10	2002	ACECLO, DICLO, INDO, NIM significantly inhibited basal and IL-1beta stimulated IL-6 production; CELE and IBUP only inhibited IL-1beta stimulated IL-6 production; and ROFE and PIROX had no significant effects.	nimesulide	21-24	interleukin 1 beta	Homo sapiens	59-67
11950021-10	2002	ACECLO, DICLO, INDO, NIM significantly inhibited basal and IL-1beta stimulated IL-6 production; CELE and IBUP only inhibited IL-1beta stimulated IL-6 production; and ROFE and PIROX had no significant effects.	nimesulide	21-24	interleukin 6	Homo sapiens	79-83
12126060-4	2002	The enhanced angiogenesis by bFGF was inhibited by indomethacin or selective COX-2 inhibitors, NS398, nimesulide, and JTE-522.	nimesulide	102-112	fibroblast growth factor 2	Rattus norvegicus	29-33
11810182-3	2002	Chronic treatment of mice with the selective COX-2 inhibitor nimesulide reduced the hCOX-2-mediated induction of hippocampal C1qB mRNA expression.	nimesulide	61-71	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	84-90
11810182-3	2002	Chronic treatment of mice with the selective COX-2 inhibitor nimesulide reduced the hCOX-2-mediated induction of hippocampal C1qB mRNA expression.	nimesulide	61-71	complement component 1, q subcomponent, beta polypeptide	Mus musculus	125-129
11872629-0	2002	Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide.	nimesulide	192-202	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	24-40
11840453-0	2002	Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-43
11840453-0	2002	Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.	nimesulide	0-10	peroxisome proliferator activated receptor alpha	Homo sapiens	66-108
11840453-0	2002	Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	122-138
11840453-1	2002	OBJECTIVE: To characterize the inhibitory effects of therapeutic concentrations of the nonsteroidal antiinflammatory drug nimesulide (NIM) on peroxisome proliferator-activated receptor (PPAR)-induced cyclooxygenase 2 (COX-2) gene expression in human synovial fibroblasts (HSFs) from patients with osteoarthritis (OA) and to define the intracellular mechanisms mediating the response.	nimesulide	122-132	peroxisome proliferator activated receptor alpha	Homo sapiens	142-184
11840453-1	2002	OBJECTIVE: To characterize the inhibitory effects of therapeutic concentrations of the nonsteroidal antiinflammatory drug nimesulide (NIM) on peroxisome proliferator-activated receptor (PPAR)-induced cyclooxygenase 2 (COX-2) gene expression in human synovial fibroblasts (HSFs) from patients with osteoarthritis (OA) and to define the intracellular mechanisms mediating the response.	nimesulide	122-132	peroxisome proliferator activated receptor alpha	Homo sapiens	186-190
11840453-1	2002	OBJECTIVE: To characterize the inhibitory effects of therapeutic concentrations of the nonsteroidal antiinflammatory drug nimesulide (NIM) on peroxisome proliferator-activated receptor (PPAR)-induced cyclooxygenase 2 (COX-2) gene expression in human synovial fibroblasts (HSFs) from patients with osteoarthritis (OA) and to define the intracellular mechanisms mediating the response.	nimesulide	122-132	prostaglandin-endoperoxide synthase 2	Homo sapiens	200-216
11840453-1	2002	OBJECTIVE: To characterize the inhibitory effects of therapeutic concentrations of the nonsteroidal antiinflammatory drug nimesulide (NIM) on peroxisome proliferator-activated receptor (PPAR)-induced cyclooxygenase 2 (COX-2) gene expression in human synovial fibroblasts (HSFs) from patients with osteoarthritis (OA) and to define the intracellular mechanisms mediating the response.	nimesulide	122-132	prostaglandin-endoperoxide synthase 2	Homo sapiens	218-223
11872629-1	2002	Expression of cyclooxygenase (COX)-2 protein during rat hepatocarcinogenesis associated with fatty change, fibrosis, cirrhosis and oxidative DNA damage, caused by a choline-deficient, L-amino acid-defined (CDAA) diet were investigated in F344 male rats, along with the chemopreventive efficacy of the specific COX-2 inhibitor, nimesulide (NIM).	nimesulide	327-337	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-36
11872629-1	2002	Expression of cyclooxygenase (COX)-2 protein during rat hepatocarcinogenesis associated with fatty change, fibrosis, cirrhosis and oxidative DNA damage, caused by a choline-deficient, L-amino acid-defined (CDAA) diet were investigated in F344 male rats, along with the chemopreventive efficacy of the specific COX-2 inhibitor, nimesulide (NIM).	nimesulide	339-342	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-36
12137558-5	2002	An example is nimesulide, a selective cyclo-oxygenase-2 inhibitor widely used for the treatment of inflammatory and pain conditions, which has been recently associated with rare but serious and unpredictable adverse reactions in the liver (increases in serum aminotransferase activities, hepatocellular necrosis, and/or intrahepatic cholestasis).	nimesulide	14-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	38-55
12664612-0	2002	Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, against PhIP-induced mammary carcinogenesis.	nimesulide	27-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	51-67
12664612-0	2002	Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, against PhIP-induced mammary carcinogenesis.	nimesulide	27-37	pleckstrin homology domain interacting protein	Homo sapiens	87-91
12086401-2	2002	Our previous studies indicated that nimesulide and celecoxib, selective COX-2 inhibitors, show inhibitory effects of intestinal carcinogenesis in azoxymethane-treated rats and mice and in Min mice models.	nimesulide	36-46	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	72-77
12086401-3	2002	We recently found that nimesulide suppressed PhIP-induced breast cancer in female SD rats in which COX-2 protein was overexpressed.	nimesulide	23-33	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	99-104
12378813-0	2002	[Nimesulide (Aulin)--the selective COX-2 inhibitor in the treatment of ENT diseases].	nimesulide	1-11	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	35-40
12382025-1	2002	Tumorsuppressive effects of a selective inhibitor of cyclooxygenase-2 (COX-2) nimesulide (NIM) activity and pineal hormone melatonin (MEL) and their combination in two chemopreventive studies of mammary carcinogenesis were evaluated.	nimesulide	78-88	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	71-76
12378813-0	2002	[Nimesulide (Aulin)--the selective COX-2 inhibitor in the treatment of ENT diseases].	nimesulide	13-18	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	35-40
11825322-5	2001	However, the older drugs etodolac, nimesulide and meloxicam, made before COX-2 was discovered, are also COX-1-sparing and have good GI safety and therapeutic activities.	nimesulide	35-45	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	73-78
11688989-7	2001	Also, a COX-2 inhibitor, niflumic acid, inhibited the PG-LXR/LTB(4)DH eicosanoid oxidoreductase (EOR) by 80% while other COX-2 inhibitors such as nimesulide and NS-398 did not inhibit this enzyme.	nimesulide	146-156	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	8-13
11825322-5	2001	However, the older drugs etodolac, nimesulide and meloxicam, made before COX-2 was discovered, are also COX-1-sparing and have good GI safety and therapeutic activities.	nimesulide	35-45	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	104-109
11673754-6	2001	Amelioration of the clinical symptoms by use of nimesulide indicates that COX-2 may play an important pathogenetic role in hyperprostaglandin E syndrome/antenatal Bartter syndrome.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
11820457-8	2001	In TNBS-induced acute inflammation of the colon, nimesulide reduced the formation of inflammatory edema, probably by a mechanism related to inhibition of PGE2 production by COX-2 pathway.	nimesulide	49-59	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	173-178
11553512-5	2001	Furthermore, Ca(o)(2+)- and PLA-mediated PGE(2) production was abolished in the presence of NS-398 or nimesulide, two different COX-2-selective inhibitors.	nimesulide	102-112	prostaglandin-endoperoxide synthase 2	Homo sapiens	128-133
11695069-0	2001	Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis.	nimesulide	75-85	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	59-64
11811354-5	2001	Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	nimesulide	222-232	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	0-16
11811354-5	2001	Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	nimesulide	222-232	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	18-23
11838318-9	2001	Nimesulide (2 mg/kg), naproxen (10 mg/kg) and rofecoxib (2 mg/kg) significantly reversed LPS-mediated despair behavior.	nimesulide	0-10	toll-like receptor 4	Mus musculus	89-92
11487718-3	2001	In the present study subcellular BAX translocations in human colon adenocarcinoma COLO 205 cells exposed to various anticancer drugs [camptothecin (CPT), etoposide (ETO), staurosporine (STP), 2-chloro-2"-deoxyadenosine (2CdA) and nimesulide (NIM)] was examined.	nimesulide	230-240	BCL2 associated X, apoptosis regulator	Homo sapiens	33-36
11570615-6	2001	Reaction rates for COX-2 inhibitors were 21.3% for nimesulide, 17.3% for meloxicam, 33.3% for celecoxib, and 3.0% for rofecoxib.	nimesulide	51-61	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	19-24
11487718-3	2001	In the present study subcellular BAX translocations in human colon adenocarcinoma COLO 205 cells exposed to various anticancer drugs [camptothecin (CPT), etoposide (ETO), staurosporine (STP), 2-chloro-2"-deoxyadenosine (2CdA) and nimesulide (NIM)] was examined.	nimesulide	242-245	BCL2 associated X, apoptosis regulator	Homo sapiens	33-36
11840344-6	2001	RESULTS: The increase in uPA, MMP-9 and MMP-1 levels detected in corneal organ cultures treated with 100 nM cPAF was blocked by 5 microM NS398 and 10 microM nimesulide, concentrations at which these inhibitors selectively inhibit COX-2 activity.	nimesulide	157-167	plasminogen activator, urokinase	Homo sapiens	25-28
11840344-6	2001	RESULTS: The increase in uPA, MMP-9 and MMP-1 levels detected in corneal organ cultures treated with 100 nM cPAF was blocked by 5 microM NS398 and 10 microM nimesulide, concentrations at which these inhibitors selectively inhibit COX-2 activity.	nimesulide	157-167	matrix metallopeptidase 9	Homo sapiens	30-35
11673754-0	2001	Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.	nimesulide	149-159	prostaglandin-endoperoxide synthase 2	Homo sapiens	21-37
11673754-0	2001	Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.	nimesulide	149-159	prostaglandin-endoperoxide synthase 2	Homo sapiens	122-138
11673754-4	2001	In this study administration of the cyclooxygenase-2 (COX-2) specific inhibitor nimesulide to patients with hyperprostaglandin E syndrome/antenatal Bartter syndrome blocked renal prostaglandin E(2) formation and relieved the key parameters hyperprostaglandinuria, secondary hyperaldosteronism, and hypercalciuria.	nimesulide	80-90	prostaglandin-endoperoxide synthase 2	Homo sapiens	36-52
11673754-4	2001	In this study administration of the cyclooxygenase-2 (COX-2) specific inhibitor nimesulide to patients with hyperprostaglandin E syndrome/antenatal Bartter syndrome blocked renal prostaglandin E(2) formation and relieved the key parameters hyperprostaglandinuria, secondary hyperaldosteronism, and hypercalciuria.	nimesulide	80-90	prostaglandin-endoperoxide synthase 2	Homo sapiens	54-59
11840344-6	2001	RESULTS: The increase in uPA, MMP-9 and MMP-1 levels detected in corneal organ cultures treated with 100 nM cPAF was blocked by 5 microM NS398 and 10 microM nimesulide, concentrations at which these inhibitors selectively inhibit COX-2 activity.	nimesulide	157-167	matrix metallopeptidase 1	Homo sapiens	40-45
11840344-6	2001	RESULTS: The increase in uPA, MMP-9 and MMP-1 levels detected in corneal organ cultures treated with 100 nM cPAF was blocked by 5 microM NS398 and 10 microM nimesulide, concentrations at which these inhibitors selectively inhibit COX-2 activity.	nimesulide	157-167	prostaglandin-endoperoxide synthase 2	Homo sapiens	230-235
11473974-0	2001	Prevention of postoperative adhesion formation in rat uterine horn model by nimesulide: a selective COX-2 inhibitor.	nimesulide	76-86	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	100-105
11473974-3	2001	A rat model was used to investigate the efficacy of nimesulide, a selective cyclooxygenase-2 inhibitor, in the prevention of adhesion formation.	nimesulide	52-62	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	76-92
11518028-5	2001	Imperatorin and isoimperatorin exhibited strong-to-medium inhibition on cyclooxygenase-1- and cyclooxygenase-2-catalysed prostaglandin E2 release, with inhibition percentages similar to those of the reference drugs, indometacin and nimesulide, respectively.	nimesulide	232-242	prostaglandin-endoperoxide synthase 1	Mus musculus	72-88
11518028-5	2001	Imperatorin and isoimperatorin exhibited strong-to-medium inhibition on cyclooxygenase-1- and cyclooxygenase-2-catalysed prostaglandin E2 release, with inhibition percentages similar to those of the reference drugs, indometacin and nimesulide, respectively.	nimesulide	232-242	prostaglandin-endoperoxide synthase 2	Mus musculus	94-110
11475788-2	2001	She would take nimesulide, a selective cyclo-oxygenase-2 inhibitor, used in a variety of inflammatory, pain and fever states.	nimesulide	15-25	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-56
11549211-2	2001	Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cyclo-oxygenase 2 and has been associated with a total of 13 reported cases of severe liver injury including our case.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	91-108
11990080-4	2001	Indomethacin (IND), an inhibitor preferentially acting on COX-1, as well as nimesulide (NIM) and celecoxib (CECOX), i.e. respectively preferential and selective inhibitors of COX-2, markedly decreased the antinociceptive activity of ACETA in Randall-Selitto test.	nimesulide	76-86	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	175-180
11408855-1	2001	OBJECTIVE: Our goal was to test the hypothesis that the previously demonstrated progesterone-independent prolongation of pregnancy in rats treated with cervical application of the cyclooxygenase 2 inhibitor nimesulide is the result of inhibition of cervical ripening.	nimesulide	207-217	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	180-196
11408855-12	2001	CONCLUSIONS: Treatment with cervical application of the cyclooxygenase 2 inhibitor nimesulide prevents the physiologic process of cervical ripening in late pregnancy.	nimesulide	83-93	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	56-72
11085996-9	2001	The biosynthesis was inhibited by indomethacin, whereas the selective COX-2 inhibitor nimesulide was ineffective.	nimesulide	86-96	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	70-75
11292587-3	2001	We used the choledocho-venous fistula (CVF) rat model for these studies and inhibited COX-2 by feeding the animals nimesulide, a selective inhibitor of COX-2 activity.	nimesulide	115-125	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	86-91
11292587-3	2001	We used the choledocho-venous fistula (CVF) rat model for these studies and inhibited COX-2 by feeding the animals nimesulide, a selective inhibitor of COX-2 activity.	nimesulide	115-125	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	152-157
11292587-8	2001	Hepatic Bcl-2 protein expression was fourfold lower in the livers from nimesulide-treated CVF rats.	nimesulide	71-81	BCL2, apoptosis regulator	Rattus norvegicus	8-13
11393589-3	2001	We examined the effect of the cyclooxygenase-2 inhibitor, nimesulide (N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide), on kainate-induced seizures and delayed neurotoxicity.	nimesulide	58-68	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	30-46
11248083-4	2001	To address this hypothesis, we used dosing with nimesulide, which inhibited COX-2 ex vivo, depressed urinary 2,3 dinor 6-keto PGF(1alpha) by approximately 60% but had no effect on thromboxane formation by platelets, which only express COX-1.	nimesulide	48-58	cytochrome c oxidase II, mitochondrial	Mus musculus	76-81
11248083-4	2001	To address this hypothesis, we used dosing with nimesulide, which inhibited COX-2 ex vivo, depressed urinary 2,3 dinor 6-keto PGF(1alpha) by approximately 60% but had no effect on thromboxane formation by platelets, which only express COX-1.	nimesulide	48-58	cytochrome c oxidase I, mitochondrial	Mus musculus	235-240
11455321-2	2001	The use of nimesulide, a COX-2 selective NSAID, has been recently proposed due to its capacity to selectively inhibit the enzyme expressed in the myometrium and endometrium.	nimesulide	11-21	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	25-30
11455321-9	2001	The occurrence of chronic renal failure in strict relationship with maternal nimesulide assumption in this case is strongly suggestive for a pharmacological damage, either direct or mediated by renin angiotensin inhibition, and possibly modulated by genetic factors, likely to account for the different outcome of similarly treated patients.	nimesulide	77-87	renin	Homo sapiens	194-199
11503270-4	2001	Selective COX-2 inhibitors i.e. meloxicam, nimesulid, etodolac or highly selective COX-2 inhibitors i.e. celecoxib, rofecoxib have antiinflammatory and analgesic properties with less or no gastrointestinal or other NSAIDs-typical adverse effects.	nimesulide	43-52	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	10-15
11399097-0	2001	Nimesulide reduces interleukin-1beta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts.	nimesulide	0-10	interleukin 1 beta	Homo sapiens	19-36
11399097-0	2001	Nimesulide reduces interleukin-1beta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	45-61
11399097-1	2001	OBJECTIVE: To characterize the effects of nimesulide (NIM) on basal and induced cyclo-oxygenase-2 (COX-2) gene expression in human synovial fibroblasts (HSF) and to define the intracellular mechanisms that mediate the changes in COX-2 expression and synthesis in response to the drug.	nimesulide	42-52	interleukin 6	Homo sapiens	153-156
11264253-11	2001	Surprisingly, the structurally related COX-2 inhibitors, NS 398 and nimesulide, significantly reduced both neurogenic and SP-induced oedema (70% and 42% for neurogenic oedema, respectively; 49% and 46% for SP-induced oedema, respectively).	nimesulide	68-78	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	39-44
11171823-0	2001	Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.	nimesulide	105-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29
11171823-2	2001	AIMS: We compared the biochemical and gastrointestinal effects of nimesulide, a potent and selective COX-2 inhibitor, with naproxen which exhibits no selectivity.	nimesulide	66-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	101-106
11171823-13	2001	INTERPRETATION: Nimesulide has preferential selectivity for COX-2 over COX-1 in vivo at full therapeutic doses and induces less gastrointestinal damage than that seen with naproxen in the short term.	nimesulide	16-26	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	60-65
11171823-13	2001	INTERPRETATION: Nimesulide has preferential selectivity for COX-2 over COX-1 in vivo at full therapeutic doses and induces less gastrointestinal damage than that seen with naproxen in the short term.	nimesulide	16-26	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	71-76
11348485-0	2001	Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog.	nimesulide	78-88	prostaglandin-endoperoxide synthase 2	Canis lupus familiaris	47-63
11263679-0	2001	A reduction of tumor necrosis factor-alpha in paw exudate of lipopolysaccharide treated rats by nimesulide.	nimesulide	96-106	tumor necrosis factor	Rattus norvegicus	15-42
11263679-2	2001	In our previous study we found that nimesulide, a COX-2 selective inhibitor, prevents the lipopolysaccharide-induced elevation in plasma TNF-alpha in rats.	nimesulide	36-46	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	50-55
11263679-2	2001	In our previous study we found that nimesulide, a COX-2 selective inhibitor, prevents the lipopolysaccharide-induced elevation in plasma TNF-alpha in rats.	nimesulide	36-46	tumor necrosis factor	Rattus norvegicus	137-146
11263679-3	2001	The present study was undertaken to elucidate the effect of nimesulide on TNF-alpha levels in the paw exudate of rats pretreated with lipopolysaccharide (LPS).	nimesulide	60-70	tumor necrosis factor	Rattus norvegicus	74-83
11160644-3	2001	Using the ratio of IC(50) values (COX-1/COX-2), the selectivity ratio for the inhibition of COX-2 by etoricoxib in the human whole blood assay was 106, compared with values of 35, 30, 7.6, 7.3, 2.4, and 2.0 for rofecoxib, valdecoxib, celecoxib, nimesulide, etodolac, and meloxicam, respectively.	nimesulide	245-255	prostaglandin-endoperoxide synthase 2	Homo sapiens	92-97
11245450-0	2001	Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.	nimesulide	161-171	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	24-40
11348485-10	2001	In vitro nimesulide inhibitory potencies for cyclooxygenase (COX)-1 and COX-2 isoenzymes were determined using a whole blood assay.	nimesulide	9-19	cytochrome c oxidase subunit I	Canis lupus familiaris	45-67
11348485-10	2001	In vitro nimesulide inhibitory potencies for cyclooxygenase (COX)-1 and COX-2 isoenzymes were determined using a whole blood assay.	nimesulide	9-19	cytochrome c oxidase subunit II	Canis lupus familiaris	72-77
11348485-12	2001	The inhibitory concentration (IC50) for inhibition of COX-2 and COX-1 were 1.6 +/- 0.4 microM (0.49 +/- 0.12 microg/mL) and 20.3 +/- 2.8 microM (6.3 +/- 0.86 microg/mL) giving a nimesulide COX-1/COX-2 ratio of 12.99 +/- 3.41.	nimesulide	178-188	cytochrome c oxidase subunit II	Canis lupus familiaris	54-59
11348485-12	2001	The inhibitory concentration (IC50) for inhibition of COX-2 and COX-1 were 1.6 +/- 0.4 microM (0.49 +/- 0.12 microg/mL) and 20.3 +/- 2.8 microM (6.3 +/- 0.86 microg/mL) giving a nimesulide COX-1/COX-2 ratio of 12.99 +/- 3.41.	nimesulide	178-188	cytochrome c oxidase subunit I	Canis lupus familiaris	64-69
11348486-13	2001	It was concluded from the comparison of in vivo and in vitro IC50, that nimesulide is a potent NSAID for which some Cox-1 inhibition is required to obtain clinically relevant efficacy.	nimesulide	72-82	cytochrome c oxidase subunit I	Canis lupus familiaris	116-121
11156565-12	2001	The selective COX-2 inhibitor, nimesulide, but not the COX-1 inhibitor valeryl salicylate, significantly attenuated SLIGRL-NH(2)-induced smooth muscle relaxation and PGE(2) release.	nimesulide	31-41	cytochrome c oxidase II, mitochondrial	Mus musculus	14-19
11208767-7	2001	COX-2 inhibition (nimesulide, 5 microg.	nimesulide	18-28	cytochrome c oxidase subunit II	Canis lupus familiaris	0-5
11296542-0	2001	Introduction to "nimesulide: beyond COX-2".	nimesulide	17-27	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	36-41
11296543-8	2001	Furthermore, the histamine-receptor-independent stimulation of gastric acid output by 5-MeF was greatly inhibited by nimesulide, which also suggests that nimesulide was acting on the parietal cell signaling pathway at a non-histamine-receptor site.	nimesulide	154-164	E74-like factor 4 (ets domain transcription factor)	Mus musculus	88-91
11296546-0	2001	Differential regulation of interleukin-1 beta-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts.	nimesulide	90-100	interleukin 1 beta	Homo sapiens	27-45
11296546-0	2001	Differential regulation of interleukin-1 beta-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts.	nimesulide	90-100	prostaglandin-endoperoxide synthase 2	Homo sapiens	54-70
11296546-2	2001	Nimesulide or NS-398 inhibited IL-1 beta-induced PGE2 production at all concentrations tested, and in addition they suppressed IL-1 beta-induced COX-2 mRNA expression and protein synthesis.	nimesulide	0-10	interleukin 1 beta	Homo sapiens	31-40
11296546-2	2001	Nimesulide or NS-398 inhibited IL-1 beta-induced PGE2 production at all concentrations tested, and in addition they suppressed IL-1 beta-induced COX-2 mRNA expression and protein synthesis.	nimesulide	0-10	interleukin 1 beta	Homo sapiens	127-136
11296546-2	2001	Nimesulide or NS-398 inhibited IL-1 beta-induced PGE2 production at all concentrations tested, and in addition they suppressed IL-1 beta-induced COX-2 mRNA expression and protein synthesis.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	145-150
11296547-4	2001	Pre-treatment of the cultures with nimesulide, a preferential cyclooxygenase (COX)-2 inhibitor, or with ibuprofen, a non-selective COX-1/COX-2 inhibitor, protected the chondrocytes against the staurosporine-mediated nuclear damage and cell death in a concentration-dependent manner (10(-12) to 10(-6) M).	nimesulide	35-45	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	62-84
10996026-8	2000	All the other mNSAIDs, including nimesulide (NIM-03), fluosulide (CGP28238), FK3311 and NS398, also rescued THP-1 from Leu-OME mediated killing, although to a lesser degree.	nimesulide	33-43	GLI family zinc finger 2	Homo sapiens	108-113
11073841-8	2000	In addition, inhibition of cyclooxygenase-2 by nimesulide significantly reduced kallikrein-induced effects.	nimesulide	47-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-43
11073841-8	2000	In addition, inhibition of cyclooxygenase-2 by nimesulide significantly reduced kallikrein-induced effects.	nimesulide	47-57	kallikrein related peptidase 4	Homo sapiens	80-90
11094215-0	2000	Severe oligohydramnios induced by cyclooxygenase-2 inhibitor nimesulide.	nimesulide	61-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	34-50
10996026-8	2000	All the other mNSAIDs, including nimesulide (NIM-03), fluosulide (CGP28238), FK3311 and NS398, also rescued THP-1 from Leu-OME mediated killing, although to a lesser degree.	nimesulide	45-51	GLI family zinc finger 2	Homo sapiens	108-113
10783320-0	2000	The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats.	nimesulide	20-30	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-9
11020910-2	2000	BACKGROUND/AIMS: In this study, it was aimed to examine the effect of nimesulide, a selective inhibitor of cox-2 enzyme, to the gastric mucosa and to correlate its effect with aspirin.	nimesulide	70-80	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	107-112
10851109-0	2000	Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen.	nimesulide	81-91	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	42-47
10851109-16	2000	CONCLUSIONS: The results confirmed that the COX-2-selective inhibitor nimesulide is an effective and well-tolerated agent for use in general practices to treat acute low back pain.	nimesulide	70-80	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-49
11011115-0	2000	Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.	nimesulide	19-29	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	43-59
11011115-2	2000	Nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2), is a good candidate as a chemopreventive agent with low toxicity.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	37-53
11011115-2	2000	Nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2), is a good candidate as a chemopreventive agent with low toxicity.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	55-60
11011115-11	2000	The results therefore provide evidence that the selective COX-2 inhibitor, nimesulide, possesses chemopreventive activity against PhIP-induced mammary carcinogenesis in rats.	nimesulide	75-85	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	58-63
10964725-2	2000	Acetylsalycilic acid, nimesulide, or SQ22536 was used as respective antagonist of COX-1, COX-2, or adenylate cyclase using aortic rings precontracted with phenylephrine and exposed to cumulative concentrations of acetylcholine (ACh).	nimesulide	22-32	cytochrome c oxidase subunit I	Oryctolagus cuniculus	82-87
10961715-7	2000	In conclusion, COX-2-COX-1 selectivity was demonstrated in vivo with the drugs aceclofenac, nabumetone, meloxicam, nimesulide, and paracetamol.	nimesulide	115-125	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	15-20
10961715-7	2000	In conclusion, COX-2-COX-1 selectivity was demonstrated in vivo with the drugs aceclofenac, nabumetone, meloxicam, nimesulide, and paracetamol.	nimesulide	115-125	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	21-26
10961716-0	2000	Interaction between NSAIDs and steroid in rat stomach: safety of nimesulide as a preferential COX-2 inhibitor in the stomach.	nimesulide	65-75	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	94-99
10961716-6	2000	These results suggest that the ulcerogenic potential of preferential a COX-1 inhibitor increases following concomitant administration with a steroid, whereas, nimesulide, a preferential COX-2 inhibitor, is nonulcerogenic, even when administered concomitantly with a steroid, and is therefore a clinically useful antiinflammatory agent.	nimesulide	159-169	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	186-191
10821793-7	2000	bFGF-stimulated angiogenesis was inhibited by indomethacin or selective COX-2 inhibitors, NS-398, nimesulide, and JTE-522.	nimesulide	98-108	fibroblast growth factor 2	Rattus norvegicus	0-4
10833474-6	2000	Par-4 levels were increased in cells treated with COX inhibitors such as NS-398, nimesulide, SC-58125, and sulindac sulfide.	nimesulide	81-91	pro-apoptotic WT1 regulator	Homo sapiens	0-5
10783320-4	2000	The aim of this study was to test the effect of nimesulide, a preferential COX-2 inhibitor, on the DSS-induced 8-oxodGuo increase.	nimesulide	48-58	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	75-80
10811136-10	2000	We show here that the expression of cyclooxygenase 2 is increased in LNM35 and that a specific cyclooxygenase 2 inhibitor, nimesulide, can inhibit the invasion of LNM35 in vitro through Matrigel containing basement membrane components.	nimesulide	123-133	prostaglandin-endoperoxide synthase 2	Homo sapiens	36-52
10811136-10	2000	We show here that the expression of cyclooxygenase 2 is increased in LNM35 and that a specific cyclooxygenase 2 inhibitor, nimesulide, can inhibit the invasion of LNM35 in vitro through Matrigel containing basement membrane components.	nimesulide	123-133	prostaglandin-endoperoxide synthase 2	Homo sapiens	95-111
10783320-9	2000	These effects may explain at least partly the well-documented protective action towards colon cancer by preferential COX-2 inhibitors, either xenobiotics such as nimesulide or natural nutrients.	nimesulide	162-172	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	117-122
10785514-7	2000	The COX-2-selective inhibitors NS-398 and nimesulide and the TXA(2) receptor antagonist BMS 180,291 inhibited TNF-alpha- and Ang II-mediated increases in DNA content and cell number by approximately 95%.	nimesulide	42-52	prostaglandin-endoperoxide synthase 2	Homo sapiens	4-9
10815926-2	2000	Our study shows that a cyclooxygenase (COX)-2 inhibitor, nimesulide, can inhibit proliferation of non-small cell lung cancer cell lines in vitro in a dose-dependent manner, in part by inducing apoptosis even at clinically achievable low concentrations.	nimesulide	57-67	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	23-45
10785514-7	2000	The COX-2-selective inhibitors NS-398 and nimesulide and the TXA(2) receptor antagonist BMS 180,291 inhibited TNF-alpha- and Ang II-mediated increases in DNA content and cell number by approximately 95%.	nimesulide	42-52	tumor necrosis factor	Homo sapiens	110-119
10785514-7	2000	The COX-2-selective inhibitors NS-398 and nimesulide and the TXA(2) receptor antagonist BMS 180,291 inhibited TNF-alpha- and Ang II-mediated increases in DNA content and cell number by approximately 95%.	nimesulide	42-52	angiotensinogen	Homo sapiens	125-131
10780769-10	2000	The COX 2:COX 1 selectivity ratio (COX 2 IC50/COX I IC50) was <0.0001 for nimesulide, 0.001 for NS398, 0.03 for flurbiprofen and 1.9 for indomethacin.	nimesulide	77-87	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	4-9
10780769-12	2000	The relative cyclo-oxygenase 2 selectivity of N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulphonamide and nimesulide may have implications for the treatment of asthma and other inflammatory pulmonary diseases.	nimesulide	104-114	prostaglandin-endoperoxide synthase 2	Homo sapiens	13-30
10780769-10	2000	The COX 2:COX 1 selectivity ratio (COX 2 IC50/COX I IC50) was <0.0001 for nimesulide, 0.001 for NS398, 0.03 for flurbiprofen and 1.9 for indomethacin.	nimesulide	77-87	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	10-15
10780769-10	2000	The COX 2:COX 1 selectivity ratio (COX 2 IC50/COX I IC50) was <0.0001 for nimesulide, 0.001 for NS398, 0.03 for flurbiprofen and 1.9 for indomethacin.	nimesulide	77-87	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	35-40
10741939-9	2000	The decrease in the extent of colitis induced by nimesulide was accompanied by a significant decrease in mucosal MPO and NOS activities.	nimesulide	49-59	myeloperoxidase	Rattus norvegicus	113-116
10729362-6	2000	Two inhibitors of cyclooxygenase-2, N-[4-nitro-2-phenoxyphenyl]-methanesulfonamide (nimesulide) and 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid (indomethacin), inhibited the formation of mineralized nodules by ST2 cells.	nimesulide	84-94	prostaglandin-endoperoxide synthase 2	Mus musculus	18-34
10708736-5	2000	After 24 h of kainate administration, the drastic decrease in hippocampal glutathione content and the significant increase in lipid peroxidation were attenuated in nimesulide-treated rats, suggesting that the induction of cyclooxygenase-2 is involved in kainate-mediated free radicals formation.	nimesulide	164-174	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	222-238
10721503-0	2000	Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).	nimesulide	56-66	prostaglandin-endoperoxide synthase 2	Homo sapiens	110-147
10721503-0	2000	Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).	nimesulide	56-66	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	149-154
10721503-1	2000	Molecular models of the complex between the selective COX-2 inhibitor nimesulide and the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 have been built using a combination of homology modelling, conformational searching and automated docking techniques.	nimesulide	70-80	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	54-59
10721503-1	2000	Molecular models of the complex between the selective COX-2 inhibitor nimesulide and the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 have been built using a combination of homology modelling, conformational searching and automated docking techniques.	nimesulide	70-80	prostaglandin-endoperoxide synthase 2	Homo sapiens	125-162
10721503-3	2000	It is found that nimesulide exploits the extra space made available by the replacement at position 523 of an isoleucine residue in COX-1 by a valine in COX-2 and establishes electrostatic interactions with both Arg-106 and Arg-499 (Arg-120 and Arg-513 in PGHS-1 numbering).	nimesulide	17-27	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	131-136
10721503-3	2000	It is found that nimesulide exploits the extra space made available by the replacement at position 523 of an isoleucine residue in COX-1 by a valine in COX-2 and establishes electrostatic interactions with both Arg-106 and Arg-499 (Arg-120 and Arg-513 in PGHS-1 numbering).	nimesulide	17-27	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	152-157
10721503-3	2000	It is found that nimesulide exploits the extra space made available by the replacement at position 523 of an isoleucine residue in COX-1 by a valine in COX-2 and establishes electrostatic interactions with both Arg-106 and Arg-499 (Arg-120 and Arg-513 in PGHS-1 numbering).	nimesulide	17-27	prostaglandin-endoperoxide synthase 1	Homo sapiens	255-261
11216473-2	2000	We found that the COX-2 selective inhibitor, nimesulide, reduces azoxymethane (AOM)-induced aberrant crypt foci (ACF) in rats and colon carcinogenesis in mice, as well as formation of intestinal polyps in Min mice.	nimesulide	45-55	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	18-23
11153163-11	2000	Nimesulide and meloxicam selectively block COX-2 and are recommended to patients at risk or treated with diuretics.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48
11249549-0	2000	Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	50-55
11249549-4	2000	The main novel pharmacological actions obtained using nimesulide in vivo at therapeutic doses, or in vitro at concentrations within the therapeutic range of free (unbound) drug, include: a preferential inhibition of prostaglandin synthesis via COX-2, and reductions in cytokine action/release, histamine release, the release of enzymes that degrade cartilage, and the release of superoxide anions and other toxic substances from neutrophils.	nimesulide	54-64	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	244-249
11521058-3	2000	The effect of pentoxifylline (PXF), nimesulide (NIM), indomethacin (INDO) and dexamethasone (DEX) on the regulation of PGE2 and TNF-alpha production was tested.	nimesulide	48-51	tumor necrosis factor	Rattus norvegicus	128-137
11521058-5	2000	The COX inhibitors (NIM and INDO) and DEX were found to inhibit the LPS-induced elevation in PGE2 production, while PXF lacked such an inhibitory effect.	nimesulide	20-23	coproporphyrinogen oxidase	Rattus norvegicus	4-7
10636620-0	2000	Inhibition of cyclooxygenase 2 by nimesulide decreases prostaglandin E2 formation but does not alter brain edema or clinical recovery after closed head injury in rats.	nimesulide	34-44	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-30
10741939-10	2000	Nimesulide and SC-236 decreased the enhanced colonic eicosanoid generation in acetic acid and iodoacetamide-induced colitis, and, in iodoacetamide-treated rats, nimesulide also decreased the elevated serum TNF-alpha and IL-1beta levels.	nimesulide	0-10	tumor necrosis factor	Rattus norvegicus	206-215
10741939-10	2000	Nimesulide and SC-236 decreased the enhanced colonic eicosanoid generation in acetic acid and iodoacetamide-induced colitis, and, in iodoacetamide-treated rats, nimesulide also decreased the elevated serum TNF-alpha and IL-1beta levels.	nimesulide	0-10	interleukin 1 beta	Rattus norvegicus	220-228
10741939-10	2000	Nimesulide and SC-236 decreased the enhanced colonic eicosanoid generation in acetic acid and iodoacetamide-induced colitis, and, in iodoacetamide-treated rats, nimesulide also decreased the elevated serum TNF-alpha and IL-1beta levels.	nimesulide	161-171	tumor necrosis factor	Rattus norvegicus	206-215
10741939-10	2000	Nimesulide and SC-236 decreased the enhanced colonic eicosanoid generation in acetic acid and iodoacetamide-induced colitis, and, in iodoacetamide-treated rats, nimesulide also decreased the elevated serum TNF-alpha and IL-1beta levels.	nimesulide	161-171	interleukin 1 beta	Rattus norvegicus	220-228
11195195-1	2000	Nimesulide (Aulin) refers to the class of sulphonanilides, which is unique among the non-steroidal antiinflammatory drugs (NSAIDs), being also the first drug on the market of pharmaceuticals, which preferentially inhibits the enzyme cyclooxygenase-2 (COX-2).	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	233-249
11195195-1	2000	Nimesulide (Aulin) refers to the class of sulphonanilides, which is unique among the non-steroidal antiinflammatory drugs (NSAIDs), being also the first drug on the market of pharmaceuticals, which preferentially inhibits the enzyme cyclooxygenase-2 (COX-2).	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	251-256
11195195-1	2000	Nimesulide (Aulin) refers to the class of sulphonanilides, which is unique among the non-steroidal antiinflammatory drugs (NSAIDs), being also the first drug on the market of pharmaceuticals, which preferentially inhibits the enzyme cyclooxygenase-2 (COX-2).	nimesulide	12-17	prostaglandin-endoperoxide synthase 2	Homo sapiens	233-249
11195195-1	2000	Nimesulide (Aulin) refers to the class of sulphonanilides, which is unique among the non-steroidal antiinflammatory drugs (NSAIDs), being also the first drug on the market of pharmaceuticals, which preferentially inhibits the enzyme cyclooxygenase-2 (COX-2).	nimesulide	12-17	prostaglandin-endoperoxide synthase 2	Homo sapiens	251-256
11195195-3	2000	Many newly found factors, together with the preferential inhibition of COX-2, are also contributing to the therapeutic effects of Nimesulide.	nimesulide	130-140	prostaglandin-endoperoxide synthase 2	Homo sapiens	71-76
10590224-2	1999	Recently, we found similar inhibitory effects with a selective cyclooxygenase (COX)-2 inhibitor, nimesulide.	nimesulide	97-107	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	63-85
10391112-4	1999	Finally, the latest published clinical data of new selective and highly selective inhibitors of COX-2 (meloxicam, nimesulide, etodolac, celecoxib and MK966) are discussed.	nimesulide	114-124	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	96-101
10419480-6	1999	Indomethacin-treated PGHS-1 and nimesulide-treated PGHS-2 rapidly formed narrow singlet EPR (25-26 G in PGHS-1; 21 G in PGHS-2), and the same line shapes persisted throughout the reactions.	nimesulide	32-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	51-57
10419480-6	1999	Indomethacin-treated PGHS-1 and nimesulide-treated PGHS-2 rapidly formed narrow singlet EPR (25-26 G in PGHS-1; 21 G in PGHS-2), and the same line shapes persisted throughout the reactions.	nimesulide	32-42	prostaglandin-endoperoxide synthase 1	Homo sapiens	104-110
10419480-6	1999	Indomethacin-treated PGHS-1 and nimesulide-treated PGHS-2 rapidly formed narrow singlet EPR (25-26 G in PGHS-1; 21 G in PGHS-2), and the same line shapes persisted throughout the reactions.	nimesulide	32-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-126
10419480-8	1999	For nimesulide-treated PGHS-2, radical formed in concert with Intermediate II, but later persisted while Intermediate II relaxed.	nimesulide	4-14	prostaglandin-endoperoxide synthase 2	Homo sapiens	23-29
10669115-11	1999	Moreover, two inhibitors of phosphodiesterase type IV (RO 20-1724 and nimesulide) reduced the elastase release only in the absence of ADA (RO 20-1724: percent inhibition in absence or presence of ADA = 20.2 +/- 15.0 and 4.4 +/- 5.1 respectively; nimesulide: percent inhibition in absence or presence of ADA = 22.2 +/- 19.6 and 0.8 +/- 3.0 respectively).	nimesulide	70-80	adenosine deaminase	Homo sapiens	196-199
10669115-11	1999	Moreover, two inhibitors of phosphodiesterase type IV (RO 20-1724 and nimesulide) reduced the elastase release only in the absence of ADA (RO 20-1724: percent inhibition in absence or presence of ADA = 20.2 +/- 15.0 and 4.4 +/- 5.1 respectively; nimesulide: percent inhibition in absence or presence of ADA = 22.2 +/- 19.6 and 0.8 +/- 3.0 respectively).	nimesulide	70-80	adenosine deaminase	Homo sapiens	196-199
10669115-12	1999	Similarly, RO 20-1724 and nimesulide increased intracellular cAMP levels only in absence of ADA (RO 20-1724: percent cAMP increment in absence or presence of ADA = 215.4 +/- 97.5 and 47.3 +/- 53.3 respectively; nimesulide: percent cAMP increment in absence or presence of ADA = 177.7 +/- 19.0 and 19.5 +/- 29.3 respectively).	nimesulide	26-36	adenosine deaminase	Homo sapiens	158-161
10669115-12	1999	Similarly, RO 20-1724 and nimesulide increased intracellular cAMP levels only in absence of ADA (RO 20-1724: percent cAMP increment in absence or presence of ADA = 215.4 +/- 97.5 and 47.3 +/- 53.3 respectively; nimesulide: percent cAMP increment in absence or presence of ADA = 177.7 +/- 19.0 and 19.5 +/- 29.3 respectively).	nimesulide	26-36	adenosine deaminase	Homo sapiens	158-161
10609620-2	1999	In this study, we tested whether nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, might be a valid alternative for patients with histories of adverse reaction to ASA or NSAIDs.	nimesulide	33-43	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-73
10609620-2	1999	In this study, we tested whether nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, might be a valid alternative for patients with histories of adverse reaction to ASA or NSAIDs.	nimesulide	33-43	prostaglandin-endoperoxide synthase 2	Homo sapiens	75-80
10567084-1	1999	We previously reported the effect of a cyclooxygenase (COX)-2 inhibitor, nimesulide, on experimental allergic neuritis (EAN) in both the induction and effector phases, in contrast to the usual COX inhibitor, which was effective only when administered in the induction phase.	nimesulide	73-83	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	39-61
10591596-11	1999	Experiment 3: On GD16, pregnant dams received either 100 mg/kg nimesulide (a specific PGHS-2 inhibitor) or vehicle (saline) subcutaneously, 2 hr before treatment with either 6 g/kg alcohol (given intragastrically) or isocaloric sucrose.	nimesulide	63-73	prostaglandin-endoperoxide synthase 2	Mus musculus	86-92
10731303-1	1999	BACKGROUND: Nimesulide is a relatively new non-steroidal anti-inflammatory drug that is gaining popularity in many countries because it is a selective cyclooxygenase 2 inhibitor.	nimesulide	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	151-167
10638109-1	1999	The aim of the study was to assess the efficacy, tolerability and chondroprotection afforded by nimesulide, a selective cyclooxygenase-2 inhibitor and piroxicam in a randomised, double blind, controlled clinical trial in 90 patients suffering from osteoarthritis of the knee joint.	nimesulide	96-106	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-136
10924891-0	1999	Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive effect of nimesulide.	nimesulide	103-113	5'-nucleotidase, cytosolic II	Homo sapiens	58-61
10924891-1	1999	The involvement of the nitric oxide-cyclic GMP pathway in the peripheral antinociception induced by the COX-2 preferential inhibitor nimesulide was assessed by using the formalin test in the rat.	nimesulide	133-143	5'-nucleotidase, cytosolic II	Homo sapiens	43-46
10924891-1	1999	The involvement of the nitric oxide-cyclic GMP pathway in the peripheral antinociception induced by the COX-2 preferential inhibitor nimesulide was assessed by using the formalin test in the rat.	nimesulide	133-143	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	104-109
10924891-5	1999	Moreover, the antinociceptive effect of local nimesulide was potentiated by the coadministration of 3-morpholino-sydnonimine-HCl (SIN-1, a nitric oxide donor).	nimesulide	46-56	MAPK associated protein 1	Homo sapiens	130-135
10924891-6	1999	It is concluded that nimesulide produces antinociception by a peripheral mechanism of action requiring activation of the nitric oxide-cyclic GMP pathway at the local level.	nimesulide	21-31	5'-nucleotidase, cytosolic II	Homo sapiens	141-144
10455298-0	1999	Calcium antagonistic properties of the cyclooxygenase-2 inhibitor nimesulide in human myometrial myocytes.	nimesulide	66-76	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
10455298-1	1999	The non-steroidal anti-inflammatory drug nimesulide is a selective inhibitor of cyclooxygenase-2 which relaxes spontaneously contracting human myometrium in vivo and is potentially a useful tocolytic drug.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	80-96
10218990-13	1999	TSP1 in the myometrium decreased when myometrial contraction was inhibited by nimesulide.	nimesulide	78-88	THBS1	Ovis aries	0-4
10431478-0	1999	Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.	nimesulide	11-21	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	41-46
10431478-0	1999	Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.	nimesulide	11-21	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	51-56
10369399-3	1999	Nimesulide (4-nitro-2-phenoxymethanesulphonanilide) is a chemically unique anti-inflammatory agent in that it has a higher pKa (6.5) than conventional acidic NSAIDs and it is one of the newer class of NSAIDs that are selective for cyclooxygenase-2.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	231-247
10369401-4	1999	Nimesulide appears to exploit this enlarged binding site for establishing a number of favourable contacts with the enzyme that lead to selective inhibition of COX-2.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	159-164
10369401-0	1999	Molecular model of the interaction between nimesulide and human cyclooxygenase-2.	nimesulide	43-53	prostaglandin-endoperoxide synthase 2	Homo sapiens	64-80
10369401-7	1999	Docking studies were then undertaken with many different nimesulide conformers, a family of which could establish very favourable interactions with the NSAID binding site of human COX-2 by exploiting the extra space made available by the isoleucine/valine replacement.	nimesulide	57-67	prostaglandin-endoperoxide synthase 2	Homo sapiens	180-185
10369402-1	1999	In man, nimesulide selectively inhibits cyclooxygenase-2 (COX-2) with little effect on haemostatic function or gastric prostaglandin formation.	nimesulide	8-18	prostaglandin-endoperoxide synthase 2	Homo sapiens	40-56
10369402-1	1999	In man, nimesulide selectively inhibits cyclooxygenase-2 (COX-2) with little effect on haemostatic function or gastric prostaglandin formation.	nimesulide	8-18	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-63
10369402-5	1999	During the treatment period, both nimesulide and naproxen significantly inhibited COX-2-dependent PGE2 synthesis in the whole blood; however, naproxen had a lesser effect than nimesulide.	nimesulide	34-44	prostaglandin-endoperoxide synthase 2	Homo sapiens	82-87
10369404-2	1999	The abilities of nimesulide to inhibit COX-2 preferentially and to exert other novel anti-inflammatory actions are consistent with good efficacy and safety.	nimesulide	17-27	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	39-44
10205009-7	1999	At higher doses, indomethacin (> or =1 mg kg(-1)) and nimesulide (30 mg kg(-1)), but not SC-58125 (up to 10 mg kg(-1)), significantly inhibited COX-1 activity (as measured by whole blood thromboxane synthesis).	nimesulide	57-67	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	147-152
10335911-9	1999	DISCUSSION: Together with the new insights into the possible consequences of renal cyclooxygenase-2 (COX-2) inhibition, the reported cases should draw the attention of doctors and patients to the importance of recognizing any possible signs of renal impairment during nimesulide therapy, although only extensive epidemiological data can define the real impact of its renal toxicity.	nimesulide	268-278	prostaglandin-endoperoxide synthase 2	Homo sapiens	83-99
10335911-9	1999	DISCUSSION: Together with the new insights into the possible consequences of renal cyclooxygenase-2 (COX-2) inhibition, the reported cases should draw the attention of doctors and patients to the importance of recognizing any possible signs of renal impairment during nimesulide therapy, although only extensive epidemiological data can define the real impact of its renal toxicity.	nimesulide	268-278	prostaglandin-endoperoxide synthase 2	Homo sapiens	101-106
10205009-10	1999	Similarly, reduction of leukocyte infiltration was only observed with the doses of indomethacin and nimesulide that caused significant suppression of COX-1 activity.	nimesulide	100-110	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	150-155
10342040-1	1999	OBJECTIVES: The aim of this study was to investigate the effects of two nonsteroidal anti-inflammatory drugs (NSAIDs), nimesulide and sodium diclofenac, on the production of proteoglycans (PG), prostaglandin E2 (PGE2) and cytokines (IL-6 and IL-8) by human articular chondrocytes in vitro.	nimesulide	119-129	interleukin 6	Homo sapiens	233-237
10342040-1	1999	OBJECTIVES: The aim of this study was to investigate the effects of two nonsteroidal anti-inflammatory drugs (NSAIDs), nimesulide and sodium diclofenac, on the production of proteoglycans (PG), prostaglandin E2 (PGE2) and cytokines (IL-6 and IL-8) by human articular chondrocytes in vitro.	nimesulide	119-129	C-X-C motif chemokine ligand 8	Homo sapiens	242-246
10342040-12	1999	Nimesulide inhibited PGE2 production by unstimulated (IC50 = 6 ng/ml) and IL-1 beta-stimulated (IC50 = 6.9 ng/ml) chondrocytes.	nimesulide	0-10	interleukin 1 beta	Homo sapiens	74-83
10342040-14	1999	Furthermore, both nimesulide and diclofenac at therapeutic concentrations significantly decreased spontaneous and IL-1 beta-stimulated IL-6 production by human chondrocytes, but did not modify IL-8 production.	nimesulide	18-28	interleukin 1 beta	Homo sapiens	114-123
10342040-14	1999	Furthermore, both nimesulide and diclofenac at therapeutic concentrations significantly decreased spontaneous and IL-1 beta-stimulated IL-6 production by human chondrocytes, but did not modify IL-8 production.	nimesulide	18-28	interleukin 6	Homo sapiens	135-139
10342040-15	1999	CONCLUSION: From the results of this study we conclude that nimesulide and diclofenac at therapeutic concentrations are potent inhibitors of PGE2 and IL-6 production while they do not modify proteoglycan or IL-8 production.	nimesulide	60-70	interleukin 6	Homo sapiens	150-154
10072704-1	1999	Nimesulide, a selective COX-2 inhibitor, exerts potent anti-inflammatory and analgesic effects when administered orally, rectally or topically.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	24-29
10774758-2	1999	Her mother ingested therapeutic doses of nimesulide, a non-steroidal anti-inflammatory (cyclo-oxygenase-2 inhibitor) drug, during the last 2 weeks of pregnancy.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	88-105
10503963-3	1999	A COX-2 inhibitor, nimesulide, lowered the intrapleural level of 6-keto-PGF1alpha and inhibited hyperplasia of the pleural matrix, suggesting that COX-2 expressed in mesothelial cells may play a role in the synthesis of extracellular matrix through formation of PGI2.	nimesulide	19-29	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	2-7
9920026-0	1999	Enhancement of phosphorylation and transcriptional activity of the glucocorticoid receptor in human synovial fibroblasts by nimesulide, a preferential cyclooxygenase 2 inhibitor.	nimesulide	124-134	nuclear receptor subfamily 3 group C member 1	Homo sapiens	67-90
9920026-0	1999	Enhancement of phosphorylation and transcriptional activity of the glucocorticoid receptor in human synovial fibroblasts by nimesulide, a preferential cyclooxygenase 2 inhibitor.	nimesulide	124-134	prostaglandin-endoperoxide synthase 2	Homo sapiens	151-167
9920026-1	1999	OBJECTIVE: To examine the effect of 2 nonsteroidal antiinflammatory drugs (NSAIDs), nimesulide (NIM), a preferential cyclooxygenase 2 (COX-2) inhibitor, and naproxen (NAP), on the functional parameters and transcriptional activity of the glucocorticoid receptor (GR) system in cultured human synovial fibroblasts (HSF).	nimesulide	84-94	prostaglandin-endoperoxide synthase 2	Homo sapiens	135-140
9920026-1	1999	OBJECTIVE: To examine the effect of 2 nonsteroidal antiinflammatory drugs (NSAIDs), nimesulide (NIM), a preferential cyclooxygenase 2 (COX-2) inhibitor, and naproxen (NAP), on the functional parameters and transcriptional activity of the glucocorticoid receptor (GR) system in cultured human synovial fibroblasts (HSF).	nimesulide	96-99	prostaglandin-endoperoxide synthase 2	Homo sapiens	135-140
10503963-3	1999	A COX-2 inhibitor, nimesulide, lowered the intrapleural level of 6-keto-PGF1alpha and inhibited hyperplasia of the pleural matrix, suggesting that COX-2 expressed in mesothelial cells may play a role in the synthesis of extracellular matrix through formation of PGI2.	nimesulide	19-29	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	147-152
9829404-9	1998	Nimesulide had the next highest selectivity for COX2 (38-fold), and tolfenamic acid and meclofenamic acid had 15-fold selectivity for COX2.	nimesulide	0-10	cytochrome c oxidase subunit II	Canis lupus familiaris	48-52
10377818-6	1999	The inhibitor of COX-2, nimesulide, was effective on experimental allergic neuritis, even if given after the onset of clinical signs.	nimesulide	24-34	prostaglandin-endoperoxide synthase 2	Homo sapiens	17-22
9925294-0	1998	Structural basis for selective inhibition of COX-2 by nimesulide.	nimesulide	54-64	prostaglandin-endoperoxide synthase 2	Homo sapiens	45-50
28976651-5	1998	With purified COX-1, inhibition was absent with nimesulide, weak with acemetacin (inhibitory concentration of 50% [IC50 ] 85 mmol/L), and potent with indomethacin (IC50 0.6 mmol/L).	nimesulide	48-58	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	14-19
9855006-0	1998	Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice.	nimesulide	23-33	prostaglandin-endoperoxide synthase 2	Mus musculus	60-76
9855006-1	1998	The effects of nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2) on azoxymethane (AOM)-induced colon carcinogenesis were investigated in mice.	nimesulide	15-25	prostaglandin-endoperoxide synthase 2	Mus musculus	70-75
28976651-6	1998	Inhibition of purified COX-2 occurred with nimesulide and indomethacin (IC50 values 90 and 4.1 mmol/L, respectively) but not acemetacin.	nimesulide	43-53	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	23-28
9808683-0	1998	Selective cyclooxygenase-2 inhibition by nimesulide in man.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	10-26
28976651-7	1998	All results with nimesulide are consistent with a preferential block of COX-2 that contributes to relatively little gastric damage in patients.	nimesulide	17-27	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	72-77
9808683-4	1998	We examined the activity of nimesulide, a Cox-2 selective nonsteroidal antiinflammatory drug, in vitro against purified enzymes and in vivo in man.	nimesulide	28-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	42-47
9760036-5	1998	In contrast, at 3 h after carrageenin injection, cyclooxygenase 2 inhibitors significantly inhibited all inflammatory parameters however suppression with piroxicam and aspirin was greater, and more pronounced than at 6 h. NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform.	nimesulide	233-243	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	49-65
9808683-8	1998	Nimesulide was highly selective against ovine Cox-2, so that at concentrations attained in vivo, it had no effect on Cox-1 but completely suppressed Cox-2.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	149-154
9812177-1	1998	Nimesulide is a selective COX-2 inhibitor used in a variety of inflammatory, pain and fever states.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	26-31
9831330-3	1998	Standard non-steroidal anti-inflammatory drugs can be considered nonselective; compounds such as meloxicam and nimesulide can be classified as COX-2 preferential; and compounds such as SC 58125 and L-754,337 are selective for COX-2.	nimesulide	111-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	143-148
9679967-0	1998	Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.	nimesulide	27-37	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	51-67
9824808-0	1998	In vivo administration of nimesulide, a selective PGHS-2 inhibitor, increases in vitro myometrial sensitivity to prostaglandins while lowering sensitivity to oxytocin.	nimesulide	26-36	prostaglandin G/H synthase 2	Ovis aries	50-56
9679967-1	1998	The chemopreventive potential of a selective cyclooxygenase-2 inhibitor, nimesulide (NIM), against the development of rat superficial urinary bladder carcinomas after initiation with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) was examined.	nimesulide	73-83	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	45-61
9718266-4	1998	However, the lipopolysaccharide-induced enhancement of writhing reaction and an increment of 6-keto-prostaglandin F1alpha level were diminished by the administration of cyclooxygenase-2-selective inhibitors, such as NS-398, nimesulide, or L-745337, to a level similar to the mice that did not receive lipopolysaccharide.	nimesulide	224-234	prostaglandin-endoperoxide synthase 2	Mus musculus	169-185
9645681-10	1998	In myometrium after nimesulide infusion, OTR and Hsp 70 mRNA decreased significantly (P < 0.05) compared with vehicle infused animals, but the decrease in Hsp 90 and ER mRNA fell outside the level of significance.	nimesulide	20-30	oxytocin receptor	Ovis aries	41-44
9645681-10	1998	In myometrium after nimesulide infusion, OTR and Hsp 70 mRNA decreased significantly (P < 0.05) compared with vehicle infused animals, but the decrease in Hsp 90 and ER mRNA fell outside the level of significance.	nimesulide	20-30	heat shock cognate 71 kDa protein	Ovis aries	49-55
9645681-11	1998	In the endometrium, nimesulide produced a decrease in ER and OTR mRNA (P < 0.05) compared with vehicle infused animals, but the changes in Hsp 90 and 70 mRNA fell outside the level of significance.	nimesulide	20-30	oxytocin receptor	Ovis aries	61-64
9645681-12	1998	Nimesulide reversed the up-regulation of PGHS-2 mRNA that occurred in myometrium, endometrium, and placenta during vehicle infusion (P < 0.05).	nimesulide	0-10	prostaglandin G/H synthase 2	Ovis aries	41-47
9718267-0	1998	Effects of the selective cyclooxygenase-2 inhibitor nimesulide on vascular contractions in endothelium-denuded rat aorta.	nimesulide	52-62	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	25-41
9718267-8	1998	It is concluded that the cyclooxygenase inhibitors nimesulide or indomethacin reduce vascular responsiveness to alpha-adrenoceptor agonists in endothelium-denuded rat aorta, presumably by preventing the formation of vasoconstrictor prostaglandins in aortic smooth muscle by cyclooxygenase-2.	nimesulide	51-61	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	274-290
9773153-35	1998	CONCLUSIONS: COX-2-COX-1 selectivity was demonstrated "in vivo" in aceclofenac, meloxicam, nabumetone, nimesulide and paracetamol.	nimesulide	103-113	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18
9653772-2	1998	In vitro, indomethacin inhibited PGH synthase (PGHS)-1 and PGHS-2 almost equally, while NS-398 and nimesulide inhibited only PGHS-2.	nimesulide	99-109	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	125-131
9532613-1	1998	Nimesulide, a selective cyclooxygenase-2-inhibiting nonsteroidal anti-inflammatory drug, has been found to be a potent anti-inflammatory and analgesic drug, when administered orally, rectally or topically.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-40
9712237-0	1998	Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat.	nimesulide	31-41	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	55-71
9773153-35	1998	CONCLUSIONS: COX-2-COX-1 selectivity was demonstrated "in vivo" in aceclofenac, meloxicam, nabumetone, nimesulide and paracetamol.	nimesulide	103-113	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	19-24
9604145-9	1998	These results suggest that inhibition by nimesulide of PGE2 release from macrophages, namely inflammatory cells, would be neither due to inhibition of COX-2 mRNA expression nor COX-2 induction, but to the selective inhibition of COX-2 activity itself.	nimesulide	41-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	151-156
9604145-9	1998	These results suggest that inhibition by nimesulide of PGE2 release from macrophages, namely inflammatory cells, would be neither due to inhibition of COX-2 mRNA expression nor COX-2 induction, but to the selective inhibition of COX-2 activity itself.	nimesulide	41-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	177-182
9604145-9	1998	These results suggest that inhibition by nimesulide of PGE2 release from macrophages, namely inflammatory cells, would be neither due to inhibition of COX-2 mRNA expression nor COX-2 induction, but to the selective inhibition of COX-2 activity itself.	nimesulide	41-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	177-182
9820127-0	1998	Dual effects of nimesulide, a COX-2 inhibitor, in human platelets.	nimesulide	16-26	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	30-35
9820127-2	1998	Since nimesulide is considered to be a selective inhibitor of COX-2, it has not been studied in detail in relation to its mechanistic effects on platelets, which express COX-1.	nimesulide	6-16	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	62-67
9839538-0	1998	Nimesulide prevents lipopolysaccharide-induced elevation in plasma tumor necrosis factor-alpha in rats.	nimesulide	0-10	tumor necrosis factor	Rattus norvegicus	67-94
9839538-1	1998	The present study was undertaken to test the hypothesis of possible inhibitory effect of nimesulide (4-nitro-2-phenoxymethane-sulfoxide) on plasma TNF-alpha level.	nimesulide	89-99	tumor necrosis factor	Rattus norvegicus	147-156
9839538-7	1998	It appears that the anti-inflammatory properties of nimesulide may in part be attributed to its inhibitory effect on TNF-alpha production.	nimesulide	52-62	tumor necrosis factor	Rattus norvegicus	117-126
9885412-1	1998	Nimesulide is a newer non-steroidal anti-inflammatory drug (NSAID) with selective cyclo-oxygenase (COX)-2 blocking property and has demonstrated a potent analgesic and anti-inflammatory activity on oral and rectal administration.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	82-105
9444611-5	1997	Differently, meloxicam, nimesulide and diclofenac were approximately 10- to 20-fold more potent in inhibiting the cyclooxygenase activity of monocyte PGHS-2 than platelet PGHS-1.	nimesulide	24-34	prostaglandin-endoperoxide synthase 2	Homo sapiens	150-156
9444611-5	1997	Differently, meloxicam, nimesulide and diclofenac were approximately 10- to 20-fold more potent in inhibiting the cyclooxygenase activity of monocyte PGHS-2 than platelet PGHS-1.	nimesulide	24-34	prostaglandin-endoperoxide synthase 1	Homo sapiens	171-177
9473726-0	1997	Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice.	nimesulide	47-57	prostaglandin-endoperoxide synthase 2	Mus musculus	71-87
9473726-3	1997	Nimesulide, a selective inhibitor of COX-2, is much less ulcerogenic.	nimesulide	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	37-42
9427063-0	1997	In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.	nimesulide	90-100	prostaglandin-endoperoxide synthase 2	Homo sapiens	59-75
9427063-5	1997	In several in vitro assays using either purified COX-2 and COX-1 preparations or cell preparations (both from animal and human origins) expressing COX-1 or COX-2, ten out of eleven different groups have demonstrated that nimesulide selectively inhibits COX-2.	nimesulide	221-231	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	49-54
9427063-5	1997	In several in vitro assays using either purified COX-2 and COX-1 preparations or cell preparations (both from animal and human origins) expressing COX-1 or COX-2, ten out of eleven different groups have demonstrated that nimesulide selectively inhibits COX-2.	nimesulide	221-231	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	59-64
9427063-5	1997	In several in vitro assays using either purified COX-2 and COX-1 preparations or cell preparations (both from animal and human origins) expressing COX-1 or COX-2, ten out of eleven different groups have demonstrated that nimesulide selectively inhibits COX-2.	nimesulide	221-231	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	147-152
9427063-5	1997	In several in vitro assays using either purified COX-2 and COX-1 preparations or cell preparations (both from animal and human origins) expressing COX-1 or COX-2, ten out of eleven different groups have demonstrated that nimesulide selectively inhibits COX-2.	nimesulide	221-231	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	156-161
9427063-5	1997	In several in vitro assays using either purified COX-2 and COX-1 preparations or cell preparations (both from animal and human origins) expressing COX-1 or COX-2, ten out of eleven different groups have demonstrated that nimesulide selectively inhibits COX-2.	nimesulide	221-231	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	156-161
9427063-7	1997	Moreover, an in vivo whole blood assay performed on healthy volunteers demonstrated a significant fall in COX-2 PGE2 production without any effect on COX-1 TXB2 production in subjects treated with nimesulide (100 mg b.i.d.	nimesulide	197-207	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	106-111
9427063-10	1997	Nimesulide can thus be considered a relatively selective COX-2 inhibitor.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
9152412-5	1997	The COX-2 inhibitors NS-398 and nimesulide only slightly inhibited PGE2 production, whereas the COX-1/COX-2 inhibitors indomethacin, piroxicam and tenoxicam strongly inhibited PGE2 production.	nimesulide	32-42	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	4-9
9353161-5	1997	The fMLP-induced response of LPS-primed neutrophils was susceptible to suppression by the methane-sulphonanilide anti-inflammatory drug nimesulide and RO 20-1724, which selectively inhibit cAMP-catabolizing phosphodiesterase type IV.	nimesulide	136-146	formyl peptide receptor 1	Homo sapiens	4-8
9253957-5	1997	These results suggest that the marked antipyretic action of nimesulide is primarily mediated through the selective inhibition of the activity of brain cyclooxygenase-2 induced under febrile conditions.	nimesulide	60-70	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	151-167
9154324-20	1997	Classical non-steroidal anti-inflammatory drugs (NSAIDs) inhibited both enzymes with varying potencies but only the three compounds previously shown to be selective COX-2 inhibitors (SC-58125, NS-398 and nimesulide) showed higher potency towards the COX of PMA-treated HUV-EC-C. 8.	nimesulide	204-214	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	165-170
9351500-10	1997	In contrast, selective COX-2 inhibitors, such as NS-398 and nimesulide (10 mg kg[-1], s.c.), had no effect on any of the responses induced by TC and did not cause gross damage in the mucosa.	nimesulide	60-70	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	23-28
9475035-17	1997	Recently drugs such as nimesulide and meloxicam with selective action on COX-2 have been discovered and introduced into medicine.	nimesulide	23-33	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	73-78
9257931-10	1997	IL-1beta alone (1-50 u ml(-1) induced PGE2 formation without significant nitrite formation, a response which was inhibited by the COX-2 specific inhibitor nimesulide.	nimesulide	155-165	interleukin 1 beta	Homo sapiens	0-8
9257931-10	1997	IL-1beta alone (1-50 u ml(-1) induced PGE2 formation without significant nitrite formation, a response which was inhibited by the COX-2 specific inhibitor nimesulide.	nimesulide	155-165	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	130-135
9272300-0	1997	Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.	nimesulide	12-22	interleukin 6	Homo sapiens	79-83
9272300-0	1997	Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.	nimesulide	12-22	serpin family E member 1	Homo sapiens	101-106
9272300-1	1997	OBJECTIVES: To evaluate the effect of therapeutic and pharmacologic concentrations of two non-steroidal anti-inflammatory drugs (NSAIDs), nimesulide and naproxen, on the synthesis of urokinase (uPA), plasminogen activator inhibitor (PAI-1) and interleukin-6 (IL-6) in human synovial fibroblasts isolated from osteoarthritis (OA) patients.	nimesulide	138-148	proline rich acidic protein 1	Homo sapiens	194-197
9272300-3	1997	RESULTS: Nimesulide and naproxen induced a dose-dependent decrease in uPA synthesis.	nimesulide	9-19	proline rich acidic protein 1	Homo sapiens	70-73
9179403-14	1997	Pretreatment with the conventional non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin and ibuprofen, and the selective COX-2 inhibitors, NS-398 and nimesulide, completely blocked IL-1 beta-induced PGE2 release and COX activity.	nimesulide	158-168	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	129-134
9179403-14	1997	Pretreatment with the conventional non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin and ibuprofen, and the selective COX-2 inhibitors, NS-398 and nimesulide, completely blocked IL-1 beta-induced PGE2 release and COX activity.	nimesulide	158-168	interleukin 1 beta	Homo sapiens	189-198
15989631-4	1997	Only meloxicam and (albeit to a lesser extent) nimesulide could be described as selective for COX-2.	nimesulide	47-57	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	94-99
9353169-1	1997	Effects of the selective cyclooxygenase-2 (COX-2) inhibitors such as NS-398 and nimesulide on duodenal HCO3- secretory and ulcerogenic responses to mucosal acidification were examined in rats, in comparison with indomethacin, a nonselective COX inhibitor.	nimesulide	80-90	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	43-48
9048568-4	1997	Addition of a cyclooxygenase inhibitor, nimesulide, similarly resulted in a narrow PGHS-2 radical.	nimesulide	40-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	83-89
9048568-9	1997	Addition of nimesulide to ASA-treated PGHS-2 inhibited the lipoxygenase and resulted in a narrow radical EPR like that seen in PGHS-2 treated with TNM or nimesulide alone.	nimesulide	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	38-44
9048568-9	1997	Addition of nimesulide to ASA-treated PGHS-2 inhibited the lipoxygenase and resulted in a narrow radical EPR like that seen in PGHS-2 treated with TNM or nimesulide alone.	nimesulide	12-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	127-133
17694360-4	1997	However, the PGHS-2 selective inhibitors nimesulide, flosulide and NS398 showed a much greater inhibition of human PGHS-2.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	13-19
17694360-4	1997	However, the PGHS-2 selective inhibitors nimesulide, flosulide and NS398 showed a much greater inhibition of human PGHS-2.	nimesulide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	115-121
9014225-2	1996	Non-steroidal anti-inflammatory drugs (NSAIDs) (nimesulide, indomethacin and ibuprofen) strongly inhibited LPS-stimulated PGE2 production without any effect on COX-2 protein expression, suggesting that NSAIDs are active in inhibiting the ability of COX-2 to convert arachidonic acid (AA) endogenously released in response to LPS stimulation.	nimesulide	48-58	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	249-254
9014217-0	1996	Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats.	nimesulide	11-21	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	38-54
8737748-9	1996	Diflunisal and nimesulide were > 4-fold selective for PGHS-2, and NS-398 was > 30-fold selective for PGHS-2.	nimesulide	15-25	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-63
9014217-2	1996	Nimesulide, a preferential inhibitor of COX-2, reduced pleural PGE2 production and was almost as active as indomethacin and 10 times more active than ibuprofen.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	40-45
8852524-5	1996	In particular, nimesulide is selective for COX-2 and displays additional properties in terms of its effects on inflammatory mediator synthesis and release.	nimesulide	15-25	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48
7506191-0	1993	Nimesulide as a downregulator of the activity of the neutrophil myeloperoxidase pathway.	nimesulide	0-10	myeloperoxidase	Homo sapiens	64-79
8595067-3	1995	Nimesulide (CAS 51803-78-2) has been shown to inhibit with high selectivity COX-2 without affecting COX-1 activity, so explaining the previous observations about the selectivity of the anti-prostaglandin effect of the drug.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	76-81
8595067-6	1995	So we evaluated the time dependency of the effect of nimesulide on COX-1 and COX-2.	nimesulide	53-63	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	67-72
8595067-6	1995	So we evaluated the time dependency of the effect of nimesulide on COX-1 and COX-2.	nimesulide	53-63	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	77-82
8595067-8	1995	Nimesulide inhibited COX-2 activity in a concentration-dependent manner.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	21-26
8595067-11	1995	In conclusion nimesulide"s selective inhibitory effect on COX-2 is time-dependent whereas its weak effect on COX-1 is not time-dependent.	nimesulide	14-24	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	58-63
8595067-13	1995	Nimesulide shares with other sulfanilide-like drugs the time dependence of its selective effect on COX-2.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-104
8595070-2	1995	Recent studies indicate that nimesulide not only inhibits prostaglandin synthesis in certain cell types, but also has pleiotropic effects on neutrophil functions, including the respiratory burst, integrin-mediated adherence and synthesis of platelet-activating factor (PAF).	nimesulide	29-39	PCNA clamp associated factor	Homo sapiens	241-267
8595070-2	1995	Recent studies indicate that nimesulide not only inhibits prostaglandin synthesis in certain cell types, but also has pleiotropic effects on neutrophil functions, including the respiratory burst, integrin-mediated adherence and synthesis of platelet-activating factor (PAF).	nimesulide	29-39	PCNA clamp associated factor	Homo sapiens	269-272
8595070-3	1995	In the present study, the effect of nimesulide on PAF synthesis was compared with its effect on the production of leukotriene B4 (LTB4).	nimesulide	36-46	PCNA clamp associated factor	Homo sapiens	50-53
8595070-6	1995	These results indicate an inhibition by nimesulide of a common step in the release of these lipid mediators, i.e. the activation of phospholipase A2, possibly by elevating intracellular cAMP.	nimesulide	40-50	phospholipase A2 group IB	Homo sapiens	132-148
8595070-8	1995	Furthermore, the inhibitory effects of nimesulide on PAF and LTB4 production could largely be prevented by addition of H89, an inhibitor of cAMP-dependent protein kinase (PK-A).	nimesulide	39-49	PCNA clamp associated factor	Homo sapiens	53-56
8595070-9	1995	It is concluded that an increase in intracellular cAMP is instrumental in the observed effects of nimesulide on the release of PAF and LTB4 by activated neutrophils and that limited availability of arachidonic acid, also the substrate for the cyclooxygenase pathway, may very well contribute to the effects of nimesulide on prostaglandin synthesis observed in other cell types.	nimesulide	98-108	PCNA clamp associated factor	Homo sapiens	127-130
7736703-6	1995	In the present work, we found that sulphanilamide and some sulphanilamide-related anti-inflammatory drugs such as dapsone, nimesulide and sulphapyridine reduce the availability of HOCl in the extracellular microenvironment of activated neutrophils and prevent the inactivation of alpha 1-antitrypsin by these cells in a dose-dependent manner.	nimesulide	123-133	serpin family A member 1	Homo sapiens	280-299
7736703-10	1995	Therefore, sulphanilamide-related drugs, i.e. dapsone, nimesulide and sulphapyridine, have the potential to reduce the bioavailability of neutrophil-derived HOCl and, in turn, to favour the alpha 1-antitrypsin-dependent control of neutrophil elastolytic activity.	nimesulide	55-65	serpin family A member 1	Homo sapiens	190-209
7505332-8	1993	NIM and OH-NIM potentiated, whereas ASA and INDO reversed, the inhibitory effect of adenylate cyclase agonists, such as prostaglandin E1 and forskolin.	nimesulide	0-3	small nucleolar RNA, H/ACA box 73A	Homo sapiens	134-150
8385794-7	1993	The MPO-dependent autoactivation of latent metalloenzymes by PMN, with consequent A1PI inactivation, was inhibited by the nonsteroidal anti-inflammatory drug nimesulide (NMS).	nimesulide	158-168	myeloperoxidase	Homo sapiens	4-7
8385794-7	1993	The MPO-dependent autoactivation of latent metalloenzymes by PMN, with consequent A1PI inactivation, was inhibited by the nonsteroidal anti-inflammatory drug nimesulide (NMS).	nimesulide	170-173	myeloperoxidase	Homo sapiens	4-7
8601574-0	1996	Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.	nimesulide	72-82	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	109-125
8601574-3	1996	Nimesulide is a selective inhibitor of cyclooxygenase 2 and has been shown to have a more potent anti-inflammatory action than piroxicam, but be less ulcerogenic and, therefore, a potentially more useful chemopreventive agent.	nimesulide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	39-55
8601574-8	1996	These results suggest that nimesulide, a selective cyclooxygenase 2 inhibitor, warrants attention as a candidate for chemopreventive agent with low toxicity, active against colon carcinogenesis.	nimesulide	27-37	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	51-67
8900441-8	1996	The selective PGHS-2 inhibitors NS-398, nimesulide and SC-58125 suppressed the inflammatory reaction and caused a marked decrease in the level of PGE2 but not in those of TXB2 and 6-keto-PGF 1 alpha.	nimesulide	40-50	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	14-20
8595066-3	1995	Nimesulide (CAS 51803-78-2) differentially inhibited prostanoid synthesis in these human tissues as well as with in vitro enzyme assays, and was less potent than indometacin (CAS 53-86-1) on COX-1.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	191-196
8595066-12	1995	With the in vitro assay, nimesulide (0.01 to 100 mumol/l) did not inhibit PGE formation by COX-1 but caused a concentration-related inhibition of PGE formation by COX-2 (4-60%).	nimesulide	25-35	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	163-168
7824814-6	1994	Using TNF alpha-treated endothelium, neutrophil transmigration was inhibited by the methane sulfonanilide anti-inflammatory drug nimesulide.	nimesulide	129-139	tumor necrosis factor	Homo sapiens	6-15
7824814-7	1994	Moreover, neutrophil adherence to TNF alpha-treated endothelial monolayers, cultured in microtiter wells, was markedly reduced by nimesulide.	nimesulide	130-140	tumor necrosis factor	Homo sapiens	34-43
7824814-10	1994	The data suggest that nimesulide reduces neutrophil transendothelial migration primarily by limiting the cell anchorage to the TNF alpha-activated endothelium.	nimesulide	22-32	tumor necrosis factor	Homo sapiens	127-136
8240466-7	1993	Nimesulide (1-50 mumol/l showed a dose-dependent inhibitory activity on superoxide anion and chemiluminescence production from PMNs stimulated with the oligopeptide fMLP, the ionophore A23187, and the phorbol ester PMA.	nimesulide	0-10	formyl peptide receptor 1	Homo sapiens	165-169
8240466-9	1993	Studies with the fluorescent calcium chelating dye FURA 2/AM showed that nimesulide was able to reduce free cytosolic calcium increase produced by fMLP and the ionophore ionomycin.	nimesulide	73-83	formyl peptide receptor 1	Homo sapiens	147-151
8240466-10	1993	The preincubation of cells with the specific adenosine receptor antagonist theophylline was able to significantly reverse the inhibitory activity of nimesulide, either on free radical production and enzyme release, and on free cytosolic calcium increase sustained by fMLP and the ionophores.	nimesulide	149-159	formyl peptide receptor 1	Homo sapiens	267-271
7506191-6	1993	Nimesulide also inactivated hypochlorous acid directly and protected alpha 1-antitrypsin from the neutrophil-mediated oxidation.	nimesulide	0-10	serpin family A member 1	Homo sapiens	69-88
7506191-7	1993	Thus, neutrophil elastolytic activity may be attenuated by nimesulide-spared alpha 1-antitrypsin.	nimesulide	59-69	serpin family A member 1	Homo sapiens	77-96
7506191-8	1993	The prevention of oxidative inactivation of alpha 1-antitrypsin by nimesulide strictly correlates with the drug"s ability to suppress the extracellular availability of hypochlorous acid.	nimesulide	67-77	serpin family A member 1	Homo sapiens	44-63
7506195-0	1993	Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils.	nimesulide	0-10	PCNA clamp associated factor	Homo sapiens	20-46
7506195-6	1993	Since both these responses are mediated through activation of the integrin CD11b/CD18 on the neutrophil surface, we conclude that nimesulide interferes with the signal transduction leading to this activation.	nimesulide	130-140	integrin subunit alpha M	Homo sapiens	75-80
7506195-6	1993	Since both these responses are mediated through activation of the integrin CD11b/CD18 on the neutrophil surface, we conclude that nimesulide interferes with the signal transduction leading to this activation.	nimesulide	130-140	integrin subunit beta 2	Homo sapiens	81-85
7506195-7	1993	We also observed a strong inhibition of platelet-activating factor (PAF) synthesis by activated neutrophils in the presence of nimesulide.	nimesulide	127-137	PCNA clamp associated factor	Homo sapiens	40-66
7506195-7	1993	We also observed a strong inhibition of platelet-activating factor (PAF) synthesis by activated neutrophils in the presence of nimesulide.	nimesulide	127-137	PCNA clamp associated factor	Homo sapiens	68-71
7506199-2	1993	Within the range of therapeutic concentrations, nimesulide was 99% bound to serum involving a nonsaturated process (NKA = 91).	nimesulide	48-58	tachykinin precursor 1	Homo sapiens	116-119
7506199-3	1993	This binding was almost identical to binding of nimesulide to serum albumin (NKA = 95).	nimesulide	48-58	albumin	Homo sapiens	62-75
7506199-3	1993	This binding was almost identical to binding of nimesulide to serum albumin (NKA = 95).	nimesulide	48-58	tachykinin precursor 1	Homo sapiens	77-80
7506199-12	1993	The present study also demonstrated 2 distinct nimesulide binding sites (site I and site II) on serum albumin (10 mumol/L) with different affinities: site II KA = 3.57 x 10(5) L/mol and site I KA = 1.24 x 10(5) L/mol.	nimesulide	47-57	albumin	Homo sapiens	96-109
1340506-3	1992	The oral administration of nimesulide lowered the phagocyte ability to generate O2- in response to both FMLP (percent inhibition = 67.62) and OPZ (percent inhibition = 36.75).	nimesulide	27-37	formyl peptide receptor 1	Homo sapiens	104-108
35537317-6	2022	The COX-2 inhibitor nimesulide was then administered during abstinence prior to an EtOH reinstatement or sucrose preference or to measure PGE2 content.	nimesulide	20-30	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	4-9
2170285-1	1990	The anti-inflammatory drug nimesulide was found to effectively reduce the availability of hypochlorous acid, the most potent chlorinated oxidant generated by the myeloperoxidase system of activated neutrophils.	nimesulide	27-37	myeloperoxidase	Homo sapiens	162-177
33793830-7	2021	In addition, we show that phosphatidylinositol 3-kinase gamma is associated with hepatic damage induced by nimesulide, because it altered liver function and increased the protein immunostaining of cyclooxygenase 2 and nuclear factor kappa B in the liver tissue of nimesulide-treated animals.	nimesulide	107-117	prostaglandin-endoperoxide synthase 2	Mus musculus	197-213
33793830-7	2021	In addition, we show that phosphatidylinositol 3-kinase gamma is associated with hepatic damage induced by nimesulide, because it altered liver function and increased the protein immunostaining of cyclooxygenase 2 and nuclear factor kappa B in the liver tissue of nimesulide-treated animals.	nimesulide	264-274	prostaglandin-endoperoxide synthase 2	Mus musculus	197-213
34634192-2	2022	Since the anti-inflammatory agent nimesulide selectively inhibited B0AT1 in vitro, we hypothesized that nimesulide exhibits in vivo potential to restrict neutral amino acid absorption, and therefore, may improve insulin sensitivity.	nimesulide	34-44	solute carrier family 6 (neurotransmitter transporter), member 19	Mus musculus	67-72
34634192-2	2022	Since the anti-inflammatory agent nimesulide selectively inhibited B0AT1 in vitro, we hypothesized that nimesulide exhibits in vivo potential to restrict neutral amino acid absorption, and therefore, may improve insulin sensitivity.	nimesulide	104-114	solute carrier family 6 (neurotransmitter transporter), member 19	Mus musculus	67-72
34634192-7	2022	Nimesulide treatment improved insulin sensitivity and glycemic control, increased GLP-1, decreased liver lipids, and improved FGF-21 in serum.	nimesulide	0-10	glucagon	Mus musculus	82-87
34634192-7	2022	Nimesulide treatment improved insulin sensitivity and glycemic control, increased GLP-1, decreased liver lipids, and improved FGF-21 in serum.	nimesulide	0-10	fibroblast growth factor 21	Mus musculus	126-132
34844599-14	2021	Finally, Progesterone, Flutamide, Nimesulide, Methotrexate and Temozolomide were identified to target these hub genes and might be targeted therapies for Chronic chagasic cardiomyopathy.	nimesulide	34-44	ELAV like RNA binding protein 2	Homo sapiens	108-111
34077833-0	2021	New nimesulide derivatives with amide/sulfonamide moieties: Selective COX-2 inhibition and antitumor effects.	nimesulide	4-14	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	70-75
34077833-2	2021	Experimental analyses showed that among seventeen compounds, N8 and N10 have remarkable potency and selectivity for the COX-2 enzyme over COX-1 at very low doses as compared to nimesulide.	nimesulide	177-187	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	120-125
34077833-2	2021	Experimental analyses showed that among seventeen compounds, N8 and N10 have remarkable potency and selectivity for the COX-2 enzyme over COX-1 at very low doses as compared to nimesulide.	nimesulide	177-187	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	138-143
34354940-0	2021	Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?	nimesulide	4-14	KRAS proto-oncogene, GTPase	Homo sapiens	81-85
34354940-0	2021	Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?	nimesulide	4-14	phosphatase and tensin homolog	Homo sapiens	86-90
34354940-4	2021	Nimesulide is a selective COX-2 inhibitor that has shown anticancer effects in neoplastic pancreatic cells.	nimesulide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	26-31
1974545-3	1990	H-7, an established protein kinase C inhibitor, and nimesulide, a new putative inhibitor of this enzyme, blunted both superoxide anion production and beta-2 adrenoceptor desensitization.	nimesulide	52-62	adrenoceptor beta 2	Homo sapiens	150-169
34575442-4	2021	In this study, nimesulide, a cyclooxygenase (COX)-2 selective inhibitor, was conjugated with hyaluronic acid (HA), and the HA-nimesulide conjugates were expected to increase the solubility and biocompatibility for alleviating the DES in the benzalkonium chloride (BAC)-induced goblet cell-loss dry eye model.	nimesulide	15-25	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	29-51
35129118-0	2022	Fast crystal growth of amorphous nimesulide: implication of surface effects.	nimesulide	33-43	Fas activated serine/threonine kinase	Homo sapiens	0-4
35129118-5	2022	Fast surface crystal growth of NIME can persist up to Tg + 57 C with a weak jump in its growth rates at 30-40 C. In addition, surface crystal growth and GC growth of NIME exhibit an almost identical temperature dependence, supporting the view that GC growth is indeed a surface-facilitated process.	nimesulide	31-35	Fas activated serine/threonine kinase	Homo sapiens	0-4
35129118-5	2022	Fast surface crystal growth of NIME can persist up to Tg + 57 C with a weak jump in its growth rates at 30-40 C. In addition, surface crystal growth and GC growth of NIME exhibit an almost identical temperature dependence, supporting the view that GC growth is indeed a surface-facilitated process.	nimesulide	166-170	Fas activated serine/threonine kinase	Homo sapiens	0-4
35129118-6	2022	Moreover, the bubble-induced fast crystal growth of NIME is observed in the interior of its supercooled liquid with approximately the same growth kinetics as surface crystal growth.	nimesulide	52-56	Fas activated serine/threonine kinase	Homo sapiens	29-33
2820212-3	1987	In fact, chemiluminescence and superoxide anion generation by polymorphonuclear leukocytes (PMN) stimulated with zymosan particles or with the synthetic peptide FMLP are inhibited by nimesulide and its 4-OH metabolite in a dose dependent fashion without affecting cell viability.	nimesulide	183-193	formyl peptide receptor 1	Homo sapiens	161-165
34980783-1	2022	Our previous studies identified that nimesulide analogs which bear a methoxy substituent at the para-position of the phenyl ring could be potential radiotracer candidates for detecting disorders related to cyclooxygenase-2 (COX-2) expression and activity in vivo using positron emission tomography (PET) in the brain.	nimesulide	37-47	prostaglandin-endoperoxide synthase 2	Mus musculus	206-222
34980783-1	2022	Our previous studies identified that nimesulide analogs which bear a methoxy substituent at the para-position of the phenyl ring could be potential radiotracer candidates for detecting disorders related to cyclooxygenase-2 (COX-2) expression and activity in vivo using positron emission tomography (PET) in the brain.	nimesulide	37-47	prostaglandin-endoperoxide synthase 2	Mus musculus	224-229
33675915-11	2021	EEPA (50 and 100 mg/kg) and nimesulide (25 mg/kg) reduced mRNA levels of MMP-9 mRNA, but not of TIMP-1 in gingival tissue of periodontitis-induced mice.	nimesulide	28-38	matrix metallopeptidase 9	Mus musculus	73-78
33675915-11	2021	EEPA (50 and 100 mg/kg) and nimesulide (25 mg/kg) reduced mRNA levels of MMP-9 mRNA, but not of TIMP-1 in gingival tissue of periodontitis-induced mice.	nimesulide	28-38	tissue inhibitor of metalloproteinase 1	Mus musculus	96-102
33617802-6	2021	These data indicate that the inhibition effects of Nav1.5 and Kv11.1 by meloxicam, nimesulide, piroxicam, and diclofenac might contribute to their potential cardiac risk.	nimesulide	83-93	sodium voltage-gated channel alpha subunit 5	Homo sapiens	51-57
33617802-6	2021	These data indicate that the inhibition effects of Nav1.5 and Kv11.1 by meloxicam, nimesulide, piroxicam, and diclofenac might contribute to their potential cardiac risk.	nimesulide	83-93	potassium voltage-gated channel subfamily A member 1	Homo sapiens	62-66
34052431-3	2021	METHODS: SHR were exposed to ouabain or vehicle and treated or not with the selective COX-2 inhibitor nimesulide for 5 weeks.	nimesulide	102-112	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	86-91
33244799-3	2021	Enzyme inhibition studies revealed that most of the compounds showed a moderate-to-strong inhibitory activity (IC50  = 0.18-0.34 muM) against the COX-2 enzyme as compared with celecoxib (IC50  = 0.12 muM), ibuprofen (IC50  = 5.33 muM), and nimesulide (IC50  = 1.68 muM).	nimesulide	240-250	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	146-151